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G-protein coupled receptor kinases (GRKs) are key regulators of GPCR 
signalling, and the search continues for potent and selective GRK inhibitors, for 
example, for the treatment of congestive heart failure. Compound101 
(cmpd101), a GRK inhibitor, was developed by the Takeda Pharmaceuticals 
Company, and it exhibits some selectivity for the GRK2/3 subfamily. In this 
thesis, a number of novel cmpd101 analogues were investigated to determine 
their abilities to inhibit agonist-induced arrestin-3 recruitment to the µ opioid 
receptor (MOPr) and δ opioid receptor (DOPr) (as a proxy of GRK-induced 
phosphorylation of the receptor). In addition, the selectivity of cmpd101 and 
novel analogues towards different GRK isoforms was investigated following 
cellular overexpression of the GRK isoforms. To further explore the general 
selectivity of these novel analogues, their effects on agonist-induced Gi 
activation and MOPr internalisation were also explored. In DAMGO-stimulated 
cells, novel compounds BU14016, BU16005 and BU16007 showed significantly 
greater inhibition of arrestin-3 recruitment to MOPr than compound101, whilst 
compounds BU14013, BU14014 showed significantly less inhibition. In contrast, 
in cells treated with the lower efficacy MOPr agonist morphine, compound101 
did not inhibit arrestin-3 recruitment, whilst only compounds BU16005 and 
BU14016 had any inhibitory capacity against morphine. Thus, the inhibitory 
effect of the novel analogues on GRK phosphorylation and following arrestin-3 
recruitment to MOPr is apparently agonist-dependent. Interestingly, the novel 
analogues were not effective at reducing SNC80- or DADLE-induced arrestin-3 
recruitment to DOPr. Thus, the effects of the novel analogues may also be 
GPCR subtype-dependent. Moreover, GRK isoform-overexpression studies 
with subsequent arrestin-3 recruitment measurements, suggested that the novel 
analogues show little or no selectivity between the isoforms, although this 
reflects the key role of GRK2 in promoting initial phosphorylation of MOPr. 
Overall, this thesis provides new evidence regarding the selectivity of cmpd101 
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1.1 G protein-coupled receptors (GPCRs) 
G protein-coupled receptors (GPCRs) are the largest protein family in mammals, 
comprising more than 800 receptors in the human genome (Fredriksson et al. 2003). 
GPCRs are localised on the plasma membrane of cells and they generally transduce 
external stimuli to the cell. They play a vital role in regulating many intracellular 
signalling pathways, which regulate many physiological functions including vision, 
smell, inflammatory response, neurotransmission and cellular differentiation and 
growth (Lefkowitz 2000). Therefore, any disturbance in GPCR signalling pathways 
has the potential to lead to diseases such as cancer, diabetes, inflammation, cardiac 
dysfunction and neuronal damage (Hu, Mai & Chen 2017). Also, GPCRs are 
pharmacologically important because around 30% of clinically used drugs target 
GPCRs (Hauser et al. 2017).  
 
1.1.1 Classification of GPCRs 
GPCRs are classified into six families based on sequence homology and similarity 
in function (Alexander et al. 2017; Hu, Mai & Chen 2017). The class A receptors, 
also known as the rhodopsin-like family, are the largest family of GPCRs including, 
light receptors, hormones, neurotransmitters, and includes the opioid receptors. 
Class B GPCRs, also called the secretin receptor family, includes 15 members, such 
as the secretin, glucagon and glucagon-like peptide1 receptor (Karageorgos et al. 
2018). Class B is characterised by a long N-terminus with around 120 residues, 
which mostly interact with large peptide endogenous ligands (Hu, Mai & Chen 2017). 
Class C GPCRs includes metabotropic glutamate family, GABAB receptors and 
calcium-sensing receptors. Class C has a large N-terminus with about 600 residues 
(Hu, Mai & Chen 2017). Class C receptors are dimers with the ligand-binding pocket 
located on the extracellular Venus flytrap domain. Class D GPCRs includes fungal 
mating pheromone receptors, while class E includes cAMP receptors (Fredriksson 
et al. 2003). Class F GPCRs include frizzled/smoothened receptors, which consist 
of 10 frizzleds that are activated by Wnt signal, and smoothened, which regulates 
the hedgehog signal that plays an important role in embryonic development 




1.1.2 Structure of GPCRs 
GPCRs have a conserved structure which consists of seven transmembrane α-
helices (7TM) connected by three alternating intracellular (ICL1-3) and three 
extracellular (ECL1-3) loops followed by a cytoplasmic carboxyl-terminus tail (Figure 
1.1) (Katritch, Cherezov & Stevens 2012). The extracellular region (ECL) includes 
an extracellular N-terminus, which varies in length between GPCR families (Katritch, 
Cherezov & Stevens 2012; Latek et al. 2012). The intercellular regions interact with 
G proteins, G protein-coupled receptor kinases (GRKs), arrestins and other 
downstream effectors (Latek et al. 2012). 
 
1.1.3 GPCR Signalling 
GPCRs transduce signal from the extracellular to the intracellular regions. Different 
efficacy ligands can modulate GPCRs signalling. The ligands of GPCR fall into these 
basic categories: a full agonist that induces a maximal signal response, a partial 
agonist that produces a submaximal signal response, an antagonist, which occupies 
the receptor binding site and does not produce a response, and an inverse agonist, 







Table 1.1 Classification of GPCRs 
Family  Representative examples 
Class A Rhodopsin-like family • Light receptors 
• Hormones 
• Neurotransmitters 
• Opioid receptors 
Class B Secretin receptor • Secretin 
• Glucagon 
• Glucagon-like peptide1 
Class C  • Metabotropic glutamate family 
• GABAB receptors 
• Calcium sensing receptors 
Class D  • Fungal mating pheromone receptors 
Class E  • cAMP receptors 












Figure 1.1 General structure of GPCRs 
A) Schematic representation of the main features of GPCR structure. GPCR structure consists of seven transmembrane (TM1-TM7) domains 
connected by three intracellular (ICL1-ICL3) and three extracellular (ECL1-ECL3) loops, an extracellular N-terminus and intracellular C-terminus. B) 
The crystal structure of angiotensin II type 1 receptor (AT1R) (pink), an example of GPCR, bound to an agonist (purple) showing the arrangement 
of the seven transmembrane domains. Crystal structure of AT1R was taken from Wingler and Lefkowitz (2020). 
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Activation of GPCRs by an agonist is followed by the movement of transmembrane 
helices 5 and 6 (Gurevich, V. V. & Gurevich 2019), which creates a cavity on the 
cytoplasmic side of the receptor, which, in turn, becomes the docking site for G 
proteins, G protein-coupled receptor kinases (GRKs), and arrestins (Gurevich, V. V. 
& Gurevich 2019; Hilger, Masureel & Kobilka 2018). The heterotrimeric G proteins 
consist of Gα, Gβ and Gγ subunits. G proteins are divided, based on the homology 
of Gα, into four major families: Gs, Gi/o, Gq/11 and G12/13 (Downes & Gautam 1999).  
 
Upon receptor activation, binding of G protein to the activated receptor resulting in 
the release of GDP and binding of GTP (Figure 1.2). Consequently, Gα subunit 
dissociates from the βγ dimer, where each subunit can bind to their effectors (Figure 
1.2). The free GPCR can bind to another G protein and go through the same cycle, 
which leads to amplification of the signal. This ongoing activation must be controlled 
to ensure the cells are not over-activated and to maintain homeostasis; therefore, 
the signal needs to be turned off in due course. This occurs in two-step mechanism: 
phosphorylation of the serine/threonine (Ser/Thr) residues on the C-terminal and/or 
intracellular loop of the activated receptor by G protein-coupled receptor kinases 
(GRKs) that enhance the binding affinity of arrestins. Binding of arrestin to the 
activated receptor block G protein interaction with the receptor subjects it to 





Figure 1.2 General schematic of GPCR signalling  
Upon activation of a GPCR by an agonist, 1) the agonist-activated receptor couples to G proteins; 
2) Coupling to G proteins triggers the exchange of GDP for GTP followed by the dissociation of 
Gα and Gβγ subunits. Each subunit can activate downstream effectors; 3) The activated receptor 
is phosphorylated by GRKs which triggers the binding of arrestins; 4) Arrestin binding leads to 





1.1.4 Biased Agonism and Barcode Phosphorylation  
Classically, GPCRs are considered on-off states that switch between two 
conformations, active and inactive (Gurevich, V. V. & Gurevich 2020). Based on this 
binary theory , agonists were believed to increase the signal by shifting the 
equilibrium towards the active conformation, where inverse agonists reduce basal 
activity by shifting the equilibrium towards the inactive conformation (Rang 2006). 
The neutral antagonists bind to the receptor without disturbing the equilibrium. 
Previously, it was thought that ligands could activate GPCR and initiate signalling 
pathways equally mediated by arrestins and G proteins. Since the discovery of 
ligands that can selectively activate particular pathways, the former theory cannot 
explain this phenomenon. Accumulating studies have shown that some ligands can 
preferentially activate particular pathways and block others (Rankovic, Brust & Bohn 
2016). Therefore, the phenomenon of biased agonism or functional selectivity has 
been suggested. Biased agonism has been an active area of research because it 
can overcome some adverse effects of balance agonist such as respiratory 
depression produced by morphine (Kelly 2013). 
 
A few years ago, two studies suggested the barcode phosphorylation based on the 
findings of the phosphorylation of β2AR and M3-muscarinic acetylcholine receptor 
(Butcher et al. 2011; Nobles et al. 2011; Yang et al. 2017). The authors found that 
that β2AR was phosphorylated by different GRKs, which led to different cellular 
functions (Nobles et al. 2011). Similarly the M3-muscarinic acetylcholine receptor 
was shown to be differently phosphorylated in different cells (Butcher et al. 2011). 
These findings suggested that phosphorylation of a GPCR is dictating the cellular 
functions (Yang et al. 2017). There are only seven members of the GRK kinase 
family that phosphorylate hundreds of GPCRs. Previously, studies suggested that 
GRKs have no receptor specificity (Kohout & Lefkowitz 2003). However, some 
GRKs contribute differently in GPCR signalling. For instance, DOPr internalisation 
in HEK293 cells is governed by two different pathways: GRK2-dependent and 
GRK2-independent, with each mechanism having a different outcome (Zhang et al. 
2008). In GRK2-dependent internalisation, this pathway is governed by arrestins 2 
and 3 and results in DOPr recycling (Zhang et al. 2008). On the other hand, GRK2-
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independent internalisation is mediated by arrestin-3 and causes DOPr degradation 
(Zhang et al. 2008). 
 
1.2 Opioid Receptors 
Opioid receptors are GPCRs that belong to the class A family of GPCRs. There are 
four subtypes of opioids receptors: mu (MOPr), delta (DOPr), kappa (KOPr), and 
opioid-related nociception receptors (Corder et al. 2018). In this thesis, I will mainly 
focus on MOPr and DOPr as examples of GPCRs, as they are the most important 
targets for pain therapy, in particular, morphine at MOPr (Williams et al. 2013).  
 
Opioids are the best choice for treating acute being less effective in chronic pain. 
Morphine, oxycodone, fentanyl, methadone and other opioids are widely used in 
pain management. Morphine mainly exerts its analgesic activity through the 
activation of MOPr. However, acute use of morphine leads to the development of 
undesired side effects, such as respiratory depression, and prolonged use leads to 
development of tolerance, dependence and addiction (Bailey & Connor 2005; 
Waldhoer, Bartlett & Whistler 2004).  
 
1.2.1 Opioid Receptor Signalling 
Opioid receptors are widely expressed pre- and post-synaptically in the central and 
peripheral nervous system. Opioid receptors are also expressed in non-neuronal 
tissues. The highest levels of MOPr are in the thalamus, periaqueductal gray, locus 
coeruleus (LC), rostral ventromedial medulla (RVM), and dorsal horn of the spinal 
cord (Pasternak & Pan 2013). Traditionally, MOPr signals from the plasma 
membrane although recent studies have suggested that internalised receptors can 
signal from endosomes (Stoeber et al. 2018). Activation of MOPr leads to multiple 
physiological effects, such as analgesia, euphoria, respiratory depression and 
reduction on gastric motility (Toubia & Khalife 2019).  
 
Activation of MOPr in the midbrain stimulates descending inhibitory impulses 
through inhibition of GABA to the periaqueductal gray, which activates descending 
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inhibitory neurons. Those neurons stimulate enkephalin-containing neurons that are 
connected directly to the dorsal horn in the spinal cord. Consequently, this leads to 
a reduction of the nociceptive transmission from the periphery to the thalamus 
(James & Williams 2020). 
 
MOPr agonists induce euphoric actions through the mesolimbic system by 
decreasing GABA inhibition, resulting in excess release of dopamine, which is 
responsible for euphoric actions. 
 
Activation of MOPr, like other GPCRs, by an agonist leads to conformational 
changes that allow the intracellular regions to adopt an open conformation to couple 
to G proteins (Figure 1.3) (Huang et al. 2015; Kelly, Bailey & Henderson 2008). The 
main G protein subtype that MOPr couples to is Gi/o (Carter & Medzihradsky 1993). 
Activation of MOPr through G proteins promotes the opening of G protein-coupled 
inwardly rectifying potassium (GIRK) channels resulting in decreasing neuronal 
excitability (Ikeda, K et al. 2000; Nagi & Pineyro 2014). Also, MOPr inhibits voltage-
gated calcium channels which leads to hyperpolarisation of the cell, in turn inhibiting 
action potential and decreasing the release of neurotransmitter (Schroeder et al. 
1991; Seward, Hammond & Henderson 1991). In addition, activation of Gi/o inhibits 
adenylyl cyclase (AC) and thereby reduces cyclic adenosine monophosphate 
(cAMP) levels (Carter & Medzihradsky 1993; Levine & Taiwo 1989). Moreover, 
MOPr can also signal through ERK, PKC and JNK pathways (Figure 1.3) (Belcheva 
et al. 1998; Gutstein et al. 1997; Kam, Chan & Wong 2004). 
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Table 1.2 Location and function of MOPr and DOPr 
 




Mu (MOPr) Thalamus, periaqueductal gray, 
locus coeruleus (LC), rostral 
ventromedial medulla (RVM), and 
dorsal horn of the spinal cord 
 
Analgesia, gastrointestinal 










Delta (DOPr) Cortex, olfactory bulb, thalamus, 
amygdala, caudate putamen, 




Dynorphin A, enkephalins, 
β-endorphin 









Figure 1.3 MOPr signalling 
Activation of MOPr by an extracellular agonist results in coupling to Gi/o that leads to a decrease 
in the influx of calcium (Ca+2) and increases potassium (K+) efflux and decreases cAMP levels 
through inhibition of adenylyl cyclase (AC) leading to decrease of neuronal excitability and signal 
transduction. MOPr is phosphorylated by GRK, which leads to the recruitment of arrestin that 
can initiate arrestin-dependent signalling and receptor internalisation. Other kinases also can 
regulate MOPr, such as PKC, ERK and JNK 
 
1.2.2 Regulation of Opioid Receptor Signalling 
Phosphorylation of proteins is one of the most important and frequent post-
translational modifications. The most common cellular kinases that regulate GPCR 
phosphorylation are GRKs, protein kinase C (PKC), and possibly Ca2+/calmodulin-
dependent protein kinase II (CaMKII), proto-oncogene tyrosine-protein kinase (Src) 
(Chen, YJ et al. 2013; Just et al. 2013; Lowe et al. 2015). 
 
Around 20 phosphorylation sites in MOPr have been predicted (Williams et al. 
2013). The main kinases that phosphorylate particular MOPr residues are GRKs 
and studies also reported that MOPr can be phosphorylated by other kinases such 
as PKC, Src, CAMKII, ERK and JNK (Figure 1.4) (Dang, Napier & Christie 2009; 
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Koch, T et al. 1997; Melief et al. 2010; Schmidt et al. 2000). The important residues 
for MOPr phosphorylation are a cluster of serine and threonine within 
370TREHPSTANT379 motif in the C-terminal (Doll et al. 2011; Just et al. 2013).  
 
It is established that distinct agonists differentially phosphorylate MOPr (Williams et 
al. 2013). Studies have shown that high efficacy opioids such as DAMGO and 
etonitazene initially induce phosphorylation of Ser375 followed by Thr370, Thr376 and 
Thr379 (Just et al. 2013). This phosphorylation is mediated by GRK2/3 and 
subsequent recruitment of arrestin (Groer et al. 2011; Just et al. 2013; Miess et al. 
2018). Treatment with morphine only induces phosphorylation of Thr375 and weak 
phosphorylation of Thr370, Thr376 and Thr379 (Miess et al. 2018) where this 
phosphorylation is mainly mediated in part by GRK5 (Doll et al. 2012).  
 
Receptor desensitisation, which is defined as a reduction in the signal transduction 
of the opioid receptor after stimulation with agonist (Allouche, Noble & Marie 2014), 
is a common event observed after prolonged agonist treatment and is readily 
observed with the opioid receptors. After prolonged treatment with an opioid agonist, 
the receptor undergoes desensitisation, which involves initial receptor 
phosphorylation and arrestin recruitment. In locus coeruleus neurons, mutation of 
serine and threonine residues of the receptor (Thr354, Ser355, Ser356, Thr357, Ser363, 
Thr370, Ser375, Thr376, Thr379 and Thr383) greatly reduces acute desensitisation 
brought on by exposure to Met-enkephalin (ME) (Arttamangkul et al. 2019; Kliewer 
et al. 2019). Bailey, Llorente, et al. (2009) reported that ME and morphine-induced 
desensitisation of MOPr enhanced upon activation of PKC in locus coeruleus 
neurons. In AtT20 cells,   mutation of all Ser/Thr at C-terminus of MOPr to alanine 
abolished ME-induced MOPr desensitisation but that induced by morphine (Yousuf 
et al. 2015). Morphine-induced desensitisation is only reduced by inhibition of PKC 
(Yousuf et al. 2015). Studies found that PKC is involved in morphine-induced 
desensitisation (Ingram & Traynor 2009; Levitt & Williams 2012; Yousuf et al. 2015).  
 
There are two types of desensitisation of GPCR signalling. Homologous 
desensitisation, which is mainly mediated by GRKs, is recognised as an active 
receptor conformation. In homologous desensitisation, the agonist-activated 
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receptor undergoes desensitisation. On the other hand, in heterologous 
desensitisation, the second messenger-dependent kinases (PKA or PKC) 
phosphorylate non-activated receptor, which leads to desensitisation of the non-





Figure 1.4 MOPr phosphorylation sites 
A schematic illustration of rat MOPr phosphorylation residues. The residues probably 
phosphorylated by particular kinases are colour-coded; in red are residues phosphorylated by G 
protein-coupled receptors (GRKs), in grey are residues phosphorylated by protein kinase C 
(PKC), in yellow are residues possibly phosphorylated by proto-oncogene tyrosine-protein 
kinase (SRC), in pink are residues phosphorylated by Ca2+/calmodulin kinase II (CaMKII), and 
white represents putative phosphorylation residues. (Adapted from Lemos Duarte and Devi 
(2020). 
 
Binding of arrestins to phosphorylated GPCR results in blocking the G protein 
signalling, consequently, desensitising the receptor and terminating the signalling.  
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Opioid therapy remains the first choice for managing severe pain, but it is limited by 
developing tolerance over time. Tolerance to opioids is defined as the loss of 
receptor responsiveness following prolong administration of agonist (Williams et al. 
2013). Despite all efforts to study the mechanism of developing tolerance, the exact 
mechanism has not been determined. Although the relationship between tolerance 
and desensitisation has been observed; its exact mechanism still unclear. It has 
been shown that the receptor phosphorylation might play a role in opioid tolerance. 
Studies have been shown that all 11 phosphorylation residues on the C-terminus of 
MOPr were involved in tolerance (Arttamangkul et al. 2019). Mutation of 
375STANT379 to alanine eliminated tolerance and only reduced desensitisation 
(Arttamangkul et al. 2019). Knock-in mice with mutation of Ser375 displayed 
desensitisation to ME and showed tolerance to morphine, but did not develop 
tolerance to fentanyl treatment (Kliewer et al. 2019). These findings show the 
complexity of the mechanism of tolerance and they also suggest that these 




DOPr plays a role in nociception, gastro-intestinal motility, olfaction and mood 
(Allouche, Noble & Marie 2014). DOPr is highly expressed in the olfactory tract, 
striatum, caudate, putamen, cerebral cortex, amygdala and dorsal horn (Table 1.2) 
(Allouche, Noble & Marie 2014; Le Merrer et al. 2009). 
 
One advantage of DOPr agonists over MOPr agonists is that they are less likely 
prone to abuse (Brandt et al. 2001; Negus et al. 1998; Stevenson et al. 2005). Also, 
they do not cause side effects such as constipation or respiratory depression which 
are the main side effects caused by MOPr agonists (Vicente-Sanchez et al. 2018). 
Also, DOPr agonists are highly effective in chronic pain, but are weak in acute pain 
compared to MOPr agonists (Gallantine & Meert 2005; Vicente-Sanchez et al. 
2018). However, DOPr agonists such as SNC80 have been shown to trigger 
convulsions, a major issue in the development of DOPr agonists as medicines 




DOPr is phosphorylated at Thr361 and Ser363 in an agonist-induced manner (Kouhen 
et al. 2000), which is mediated by GRK2/3 (Qiu, Loh & Law 2007). Phosphorylation 
of DOPr at Ser344 is mediated by PKC in an agonist-independent manner (Xiang et 
al. 2001).  
 
Studies have reported that different DOPr agonists preferentially recruit distinct 
arrestin isoform (Vicente-Sanchez et al. 2018). For instance, DPDPE, a higher 
efficacy peptide DOPr agonist, recruited arrestin-3 in the phosphorylation-
dependent internalisation of DOPr in mouse embryonic fibroblasts (Qiu, Loh & Law 
2007). On the other hand, etorphine-induced DOPr internalisation in SK‐N‐BE cells 
was mediated by arrestin-2 (Bowman et al. 2015). In addition, SNC80, a high 
efficacy DOPr agonist, preferentially recruited arrestin-2 resulting in DOPr 
desensitisation and acute tolerance (Vicente-Sanchez et al. 2018). In arrestin-2 
knockout mice, an increased in SNC80 potency was observed and decreased in 
acute tolerance (Pradhan et al. 2016). On the other hand, the lower efficacy DOPr 
agonists ARM390 or JNJ20788560 recruited arrestin-3 resulting in receptor 
resensitisation (Pradhan et al. 2016). In arrestin-3 knock-in mice, it was observed 
that receptor resensitisation was impaired and increased acute tolerance upon 
stimulation with ARM390 or JNJ20788560 (Pradhan et al. 2016). 
 
1.3 Arrestins 
Arrestins are 48 kDa proteins and were discovered as proteins that bind to the 
phosphorylated rhodopsin (Kuhn, Hall & Wilden 1984). After that, arrestin subtypes 
were discovered and advancements in molecular studies revealed their structures 
and how they bind to GPCRs. Since the discovery of the role of arrestins in agonist-
induced internalisation of β2AR, many more studies have shown that arrestins 
regulate trafficking of GPCRs and non-GPCRs substrates such as ERK1/2, AKT 
and JNK3 (Gurevich, V. V. & Gurevich 2019; Moore, Milano & Benovic 2007; 
Shenoy & Lefkowitz 2011). 
There are only four arrestins which are divided into two groups: visual and non-
visual arrestins (Tian, Kang & Benovic 2014). Visual-specific arrestins are arrestin-
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1 (rod arrestin) and arrestin-4 (cone arrestin). The widely expressed nonvisual 
arrestins are arrestin-2 (β-arresin1) and arrestin-3 (β-arrestin2) (Latek et al. 2012; 
Premont & Gainetdinov 2007). With the advancement in molecular structural studies 
using X-ray crystallography, arrestins structures have been reported. Arrestins have 
two main domains: the N-domain and C-domain, each consisting of antiparallel β-
sheets which are joined by small flexible loops (Figure 1.5) (Tian, Kang & Benovic 
2014). The N-domain and C-domain are connected by a small hinge region (Latek 
et al. 2012; Tian, Kang & Benovic 2014). The carboxyl-terminus of arrestins involves 
in maintaining the basal state of arrestins (Shukla & Dwivedi-Agnihotri 2020).  
 
Arrestins are cytoplasmic proteins that play a critical role in regulating GPCRs 
signalling. Classically, the primary role of arrestins is thought to be the prevention 
of G protein binding to GPCRs, which leads to termination of G protein-mediated 
GPCRs signalling (Shukla & Dwivedi-Agnihotri 2020). In recent years, the role of 
arrestins has expanded and their importance in regulating downstream signalling of 
GPCRs demonstrated (Shukla & Dwivedi-Agnihotri 2020). For instance, arrestins 
can modulate ubiquitination and degradation by interacting with E3 ubiquitin ligases 
(Shenoy & Lefkowitz 2011; Shukla & Dwivedi-Agnihotri 2020). Also, arrestins have 
been shown to regulate GPCR internalisation. The overexpression of arrestins was 
found to enhance the agonist-induced internalisation of β2AR (Kang, DS, Tian & 
Benovic 2014). Later, studies have shown that arrestins interact with clathrin and 
clathrin adapter protein-2 (AP2), key proteins involved in the assembly of clathrin-
coated pits (CCPs) and which facilitate receptor trafficking (Kang, DS, Tian & 
Benovic 2014; Shukla & Dwivedi-Agnihotri 2020).  
 
Recent structural studies revealed that arrestins and G proteins bind to the same 
interhelical cavity on the cytoplasmic tail of the receptor (Figure 1.5) (Gurevich, V. 
V. & Gurevich 2019; Kang, Y et al. 2015; Rasmussen et al. 2011; Zhou et al. 2017). 
Thus, binding of arrestins to the phosphorylated receptor precludes the binding of 
G protein, resulting in termination of G protein signalling. Arrestins bind to the 
phosphorylated receptor with a high affinity that is gained from binding tightly to the 






Figure 1.5 Structure of Arrestin 
A ribbon structure of arrestin-2 showing the N-domain, C-domain, polar core, and the biding sites 
for GPCR, clathrin and adaptin. Taken from Kang, DS, Tian and Benovic (2014). 
 
Non-visual arrestins bind to clathrin, a major component of clathrin-coated pits 
(CCPs) and clathrin-adaptor AP2, which regulate clathrin assembly and are a target 
receptor for CCPs (Kang, DS, Tian & Benovic 2014). The binding site in arrestins is 
a clathrin binding box, which is located in the c-terminal region of arrestins (Figure 
1.5) (Kang, DS, Tian & Benovic 2014). The arrestin C-terminus becomes accessible 
for clathrin after binding to the phosphorylated receptor (Kang, DS, Tian & Benovic 
2014). 
 
Cahill et al. (2017) used a chimeric β2V2R construct, which consists of β2AR with C-
terminal tail exchanged with the vasopressin type 2 receptor (V2R) C-terminal tail, 
to study the distinct conformations of receptor-arrestin complexes. This construct 
has the advantage of β2AR, a class A GPCR which weakly and transiently binds to 
arrestins, and V2R, a class B GPCR which tightly binds to arrestins (Cahill et al. 
2017). It was found that the GPCR/arrestin-2 complex had two conformations: tail 
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conformation and core conformation. In tail conformation, arrestin-2 bound to the 
phosphorylated C-terminal of the receptor and this was involved in the 
internalisation of GPCR, while it did not block G protein binding to the receptor. In 
the core conformation, arrestin-2 made another interaction with the receptor 
transmembrane core that prevented G protein signalling and subsequently 
desensitisation of the receptor.  
 
Several studies have reported cryo-EM and X-ray crystal structures of GPCR in 
complex with arrestin (Huang et al. 2020; Kang, Y et al. 2015; Lee et al. 2020; Staus 
et al. 2020; Yin et al. 2019). All these crystal structures provide mechanistic insights 
into the interaction of arrestin with the receptor. Briefly, the phosphorylated C-
terminus of the receptor displaced the C-terminus of arrestin. The C-terminal end of 
helix8 of the receptor projects towards the N-terminal end of the arrestin. The 
receptor core engages the arrestin finger loop and the arrestin C-terminal domain 
C-edge loops diffuse through the lipid bilayer (Yoo, Bhardwaj & Benovic 2020). 
 
1.4 G Protein-Coupled Receptor Kinases (GRKs) 
The G protein-coupled receptor kinases (GRKs) are a family of seven kinases that 
phosphorylate serine and threonine residues normally in the third intracellular loop 
and/or carboxyl tail of activated GPCRs (Ferguson 2001; Guccione et al. 2016). This 
phosphorylation promotes the binding of arrestins, which leads to the uncoupling of 
G proteins from the receptor (Smith & Rajagopal 2016). The binding of arrestins 
leads to desensitisation of the G protein-mediated response and internalisation of 
the receptor (Hanyaloglu & von Zastrow 2008).  
 
1.4.1 Classification of GRKs 
The GRKs are grouped into three subfamilies; GRK1, GRK2 and GRK4 (Table 1.3) 
(Pierce, Premont & Lefkowitz 2002). The GRK1 subfamily consists of GRK1 and 
GRK7, and they are found almost exclusively in the retina (Homan & Tesmer 2015; 
Premont & Gainetdinov 2007; Thal et al. 2011). The GRK2 subfamily is composed 
of GRK2 and GRK3, both of which are widely distributed (Premont & Gainetdinov 
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2007; Thal et al. 2011). The GRK4 subfamily consists of GRK4, GRK5 and GRK6, 
whereas GRK5 and GRK6 are widely distributed. GRK4 is mainly expressed in the 
testis (Premont & Gainetdinov 2007). GRKs are also expressed differently in 
different cell types. For example, GRK6 and GRK3 expression levels in the heart 
are low compared to GRK2 and GRK5 expression levels.  
 
1.4.2 Structure of GRKs 
The crystal structures of bovine GRK2 with Gα (Tesmer, VM et al. 2005) and Gβγ 
subunits (Lodowski et al. 2003) have been published as have the crystal structure 
of GRK2 with inhibitors such as balanol, compound101 (cmpd101), RNA aptamer 
paroxetine, CCG26584 and GSK180736A, have been reported (Homan et al. 2015; 
Homan et al. 2014; Tesmer, JJ et al. 2010; Tesmer, VM et al. 2012; Thal et al. 2012; 
Thal et al. 2011). All GRK isoforms share the general structure which consists of a 
conserved central catalytic domain (about 270 amino acids), which is shared with 
other AGC kinases such as PKA, PKC, an N-terminal domain (185 amino acids) 
and a C-terminal domain (100-230 amino acids) (Figures 1.6 and 1.7) (Penela et al. 
2010; Pitcher, Freedman & Lefkowitz 1998). 
 
The kinase domain consists of a small lobe (N) and a large lobe (C) (Figure 1.7). 
The small lobe is formed by six-stranded antiparallel β-sheets and three α-helices 
(αB, αC and αK) while the large lobe is composed of α-helices and four antiparallel 
β-strands. The ATP binding site, which is shared by about 500 different kinases, is 
located on the interface of the two lobes (Guccione et al. 2016; Lodowski et al. 2003; 
Thal et al. 2011). The ATP binding site of the kinase is composed of the adenine, 
ribose, triphosphate and hydrophobic subsites (Thal et al. 2011). The N-terminal 
domain anchors the kinase to the intracellular membrane which contains the 
regulator of G protein signalling homology (RH) domain (Dhami et al. 2002; Penela 
et al. 2010; Sallese, Mariggiò, et al. 2000). The C-terminal domain consists of a 
seven-stranded antiparallel β-barrel with a C-terminal helix on one end. In GRK2/3 
isoforms, the C-terminal contains the pleckstrin homology (PH), which is unique to 
GRK2/3. The PH domain is the binding site for phosphatidylinositol 4, 5, 
biphosphate (PIP2), which binds directly to GRK and facilitates the membrane 
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association of GRK and Gβγ subunits (Sallese, Iacovelli, et al. 2000). The binding of 
Gβγ leads to an increase in the phosphorylation of GPCR and recruitment of GRK 
(Lodowski et al. 2003; Penela et al. 2010). 
 














GRK7 Retina (cones) 553 62 
GRK2 
GRK2 Ubiquitous 689 79 






GRK5 Ubiquitous 590 68 
GRK6 Ubiquitous 576 66 
References: Gurevich, Vsevolod V., Gurevich and Tesmer (2016); Santulli, Trimarco and 
Iaccarino (2013). 
GRKs are soluble proteins; thus, their C-termini contain a particular element to able 
them to target the membrane. GRK1 and GRK7 are prenylated at their C-termini 
where GRK2 and GRK3 C-termini are composed of pleckstrin homology, which 
interacts with phosphatidylinositol 4, 5-biphosphate (PIP 2) and free Gβγ subunits 
(Koch, WJ et al. 1993). This interaction facilitates the translocation of GRK2/3 from 
the cytoplasm to the plasma membrane to be able to phosphorylate agonist-
activated GPCR (Gurevich, Vsevolod V., Gurevich & Tesmer 2016). However, 
GRK5 does not have a pleckstrin domain in its C-terminal; instead, it uses a C-
terminal lipid-binding domain to facilitate membrane localisation (Pitcher et al. 1992; 
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Stoffel et al. 1994). The GRK4 and GRK6 isoforms rely on palmitoylation sites on 





Figure 1.6 General structure of GRKs 
General structure of the three GRK subfamilies. GRK structure is composed of the regulator of 
G protein signalling homology (RH) (pink) and catalytic domains (grey). The αN-helix (green) 
bridges the N- and C-lobes of the catalytic domain of the kinase. The C-terminal plays a role in 
membrane localisation and it varies between subfamilies. GRK1 subfamily has prenylated C-
terminal where GRK2 subfamily has pleckstrin C-terminal. GRK4 and GRK6 C-termini are 
palmitoylated where GRK5 has polybasic regions in the C-terminus that help in interaction with 






Figure 1.7 Crystal structure of GRK2 
The main features of GRK2 structure are the kinase domain (green), the regulator of G protein 
signalling homology (RH) domain (purple), and pleckstrin homology (PH) domain (red). The ATP 
binding site is shown within the kinase domain, where most of small GRK inhibitors bind. Taken 
from Thal et al. (2011). 
 
1.4.3 Regulation of GRK2 Activation and Function 
The mechanism of GRK activation is complex and not fully understood. The 
interactions between αN-helix and the RH and PH domains keep the kinase in an 
open, nonactive state (Murga et al. 2019; Pack et al. 2018; Penela et al. 2006). 
Disruption of this binding and reorder of αN-helix and RH domain leads to activation 
of the kinase allosterically by agonist-activated GPCR (Yao et al. 2017).  
 
Moreover, posttranslational modifications of GRKs influence kinase functionality. 
For example, c-Src and EGFR phosphorylate GRK2 on tyrosine residues in the α-
N-helix and the RH region, which enhances the function of GRK2 (Murga et al. 
2019). Also, GRK2 can be phosphorylated by PKC and PKA on Ser685, which 
enhances the binding ability of GRK2 to Gβγ and the activated receptor (Murga et al. 
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2019). Other kinases, such as ERK1/2 and MAPK, can also phosphorylate GRK2 
(Penela et al. 2006). 
 
GRK2 undergoes rapid degradation by the proteasome, which is enhanced upon 
agonist-stimulation of GPCR (Penela et al. 2006; Penela et al. 1998). The 
degradation of GRK2 requires arrestin to act as a scaffold for kinases such as c-Src 
and tyrosine kinase (Penela et al. 2006).  
 
1.4.4 Physiological and Pathological Roles of GRK2 and GRK5 
GRKs are not only involved in GPCR phosphorylation, but they also phosphorylate 
non-GPCR substrates (Gurevich, EV et al. 2012). Particularly, the ubiquitous and 
the most studied GRK2 isoform has been shown to be able to interact (mostly 
phosphorylate) with non-GPCR substrates. GRK2, the main GRK, which involves in 
the phosphorylation of MOPr, and GRK5 are the main focus of this section.  
 
GRK2 and GRK5 phosphorylate synucleins, which consist of α-, β- and γ-synuclein, 
GRK2 phosphorylates α- and β-synuclein where GRK5 phosphorylates α-synuclein 
(Gurevich, EV et al. 2012). α-synuclein, the major component of Lewy bodies in the 
presynaptic terminals of the nervous system, plays a major role in sporadic 
Parkinson’s disease (Gurevich, V. V. & Gurevich 2019).  
As mentioned earlier, GRK2 is ubiquitously expressed in human tissues; it is highly 
expressed in the immune system. GRK2 phosphorylates chemokine receptors 
which induce leukocyte accumulation during inflammation. On the other hand, in 
rheumatoid arthritis, patients showed a reduction in the GRK2 expression and 
function (Vroon, Heijnen & Kavelaars 2006; Vroon et al. 2004). 
 
GRK2/5 are associated with a failing heart; therefore, the role of GRKs in major 
disease area like heart failure is of importance. GRK2 has been shown to play an 
essential role in the development of embryo and heart function (Jaber et al. 1996; 
Metaye et al. 2005). GRK2 knockout is lethal in mice due to impairment in cardiac 
development (Matkovich et al. 2006), while cardiac GRK2-deleted mice showed 
unaffected heart structure and viable mice (Matkovich et al. 2006). GRK2-deficient 
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embryos displayed hypoplasia of the ventricular myocardium and dysplasia of the 
interventricular septum, which leads to heart failure (Jaber et al. 1996).  
 
βARs represent about 90% of the adrenoceptors in the heart (O'Connell et al. 2014). 
Three βARs subtypes are expressed in the heart: β1AR, β2AR and β3AR (Cannavo, 
Liccardo & Koch 2013), where the β1AR represents around 80% (Siryk-Bathgate, 
Dabul & Lymperopoulos 2013). βARs are activated by endogenous catecholamines, 
adrenaline and noradrenaline (Wang, Gareri & Rockman 2018). Upon 
catecholamines stimulation, β1AR and β2AR couple to Gs which leads to stimulation 
of AC that results in increasing cAMP in cardiac myocyte and activation of protein 
kinase A (PKA) (Cannavo, Liccardo & Koch 2013). PKA phosphorylates many 
targets that regulate intracellular Ca+2 binding (Bristow et al. 1990; Woo & Xiao 
2012). Also, activation of β2AR leads to coupling with Gi, which inhibits AC and other 
β2AR-independent pathways such as mitogen-activated protein kinase (MAPK) and 
PI3-kinase and Akt pathways (Cannavo, Liccardo & Koch 2013; Xiao 2001).  
 
Continuous stimulation of βARs leads to desensitisation and loss of response to 
catecholamines, which can be contributed to the development of heart failure. 
Studies have shown that overexpression of GRKs in the heart leads to a decrease 
in isoproterenol, βARs agonist, -stimulated contractility and decreased cAMP 
production (Koch, WJ et al. 1995). Also, overexpression of GRK2 leads to impaired 
cardiac function and increased apoptosis (Brinks et al. 2010; Chen, EP et al. 1998). 
Among the expressed GRKs in the heart (Cannavo, Liccardo & Koch 2013), only 
GRK2 and GRK5 have been shown to involve in heart failure (Belmonte & Blaxall 
2011). 
 
GRK2 overexpression has been linked to reduced myocardial contractility and 
reduced βAR responsiveness (Anderson et al. 1999; Koch, WJ et al. 1995). 
Upregulation of GRK2 preceded the reduction in βAR number in spontaneously 
hypertensive heart failure rats (Anderson et al. 1999). Also, samples taken from 
human patients have shown an increase in GRK2 expression and activity with 
reduced βAR numbers and function (Ungerer et al. 1993; Ungerer et al. 1994). In 
animal studies, overexpression of GRK5 reduced βARs response to isoproterenol 
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(Rockman et al. 1996) and impaired cardiac function (Chen, EP et al. 2001). These 
findings suggest that GRK5 involves in the development of heart failure.  
 
The ability of GRK5 to translocate was first shown in the cardiomyocytes of 
spontaneously hypertensive rats (Johnson, LR, Scott & Pitcher 2004; Yi et al. 2005). 
This was supported by the discovery of the nuclear localisation sequence (NLS) 
within GRK5 catalytic domain (Johnson, LR, Scott & Pitcher 2004; Sato et al. 2015; 
Yi et al. 2005). Cardiac hypertrophic stimulation causes activation of calcium-
calmodulin, thereby translocating GRK5 to the nucleus where it targets class II 
histone deacetylase 5 (HDAC5). HDAC5 induces hypertrophic gene transcription 
and derepresses myocyte enhancer factor 2 (MEF2) (Galasinski et al. 2002; Sato 
et al. 2015). 
 
The involvement of GRK2 in heart failure has led to the use of inhibition of GRK2 
strategy to modulate heart failure. Inhibition of GRK2, but not GRK5 because it does 
not use Gβγ to anchor to the plasma membrane, has been achieved through using 
a peptide from the C-terminal domain of GRK2 (βARKct), which competes with 
endogenous GRK2 for Gβγ and blocks its translocation to the plasma membrane 
(Koch, WJ et al. 1993; Koch, WJ et al. 1995). The βARKct prevented and reversed 
the development of heart failure in mice and pig (Raake et al. 2013; Rockman et al. 
1996). Recently, pharmacological inhibition of GRK2 by paroxetine, a GRK2 
inhibitor, has shown an improvement in heart failure (Schumacher et al. 2015; Thal 
et al. 2012). Mice treated with paroxetine showed an increase in left ventricular 
inotropic reserve (Thal et al. 2012). Moreover, paroxetine treatment of heart failure 
mice model reversed cardiac dysfunction and completely restored the βAR system 
(Schumacher et al. 2015). 
 
Studies have shown that the expression of GRK2 is altered in many pathological 
diseases, such as diabetes, Alzheimer’s diseases (Gurevich, EV et al. 2012), and 
cancer (Penela et al. 2010). GRK2 plays a role in regulating insulin signalling, where 
upregulation level of GRK2 and increased activity leads to inhibition of insulin-
induced glucose transport (Ciccarelli et al. 2011; Gurevich, EV et al. 2012). 
Overexpression of GRK2 impairs the translocation of glucose transporter protein 
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type-4 (GLUT4), while the injection of GRK2 antibody leads to increasing the GLUT4 
translocation to the plasma membrane after insulin stimulation (Usui et al. 2004).  
 
Moreover, the levels of GRK2 increase  in the early stages of Alzheimer’s disease 
(Steury, McCabe & Parameswaran 2017), which may lead to enhance the 
interaction of α- and β-synuclein, which  has been linked to Alzheimer’s and 
Parkinson’s  (Steury, McCabe & Parameswaran 2017). GRK2 also has been shown 
to play a role in controlling cell proliferation (Guccione et al. 2016). For example, 
GRK2 is upregulated in thyroid cancer and, hence, reduces cell proliferation 
(Metaye et al. 2008). In addition, overexpression of GRK2 inhibits the growth of 
human hepatocellular carcinoma cells (Wei et al. 2012). In summary, GRK2 
regulates many signalling pathways, thus selectively targeting GRK2 is a critical 
strategy to develop therapeutic agents (Evron, Daigle & Caron 2012). 
 
1.4.5 Small Molecule GRK Inhibitors 
Studies have been conducted to develop potent and selective GRK inhibitors. 
However, all current GRK inhibitors lack selectivity among GRKs. The cumulating 
research on the role of GRK in GPCR signalling pathways, particularly GRK2, has 
elucidated that targeting GRK2 could be a promising strategy to treat many diseases 
and also use the inhibitors as research tools to understand cell physiology. A 
considerable effort has been made to develop potential GRK2 inhibitors, and the 
following are the most promising developed inhibitors of GRK2 and other GRKs:  
Polyanions and Polycations 
Polyanions and polycationic compounds were the first compounds to be examined 
for inhibition of GRK2 in the rhodopsin receptor. Heparin and dextran sulfate, 
examples of polyanions and polycations compounds, were most potent among 
tested compounds with an IC50 of 0.15 µM. However, heparin targeted other kinases 
such as casein kinase II and low-density lipoprotein receptor kinase (Hathaway, 
Lubben & Traugh 1980; Kishimoto et al. 1987). The other effective inhibitors are 
polyaspartic acid (1.3 µM), polyglutamic acid (2.0 µM) and inositol hexasulfate (13.5 
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µM) (Benovic et al. 1989; Guccione et al. 2016). However, these compounds are 
highly charged, which hinders cell penetration, thus limiting their usefulness.  
 
Balanol 
Balanol is a natural product synthesised by the fungus Verticillium balaniodes 
(Setyawan et al. 1999). It is a competitive inhibitor of ATP at the GRK kinase domain 
(Setyawan et al. 1999). It has an advantage over polyanions in that it is a cell 
permeable. Its structure is composed of four rings named A-D. Ring A is a 4-
hydroxybenzoyl moiety and ring B is a hexahydroazepine ring connected to a 
benzophenone moiety (Figure 1.8A).  
 
The crystal structure of balanol with GRK2 has revealed that the A ring occupies the 
hydrophobic adenine subsite of the GRK2 (Figure 1.8B). The B ring occupies the 
ribose subsite, the C ring binds to the polyphosphate subsite while the D ring binds 
to the hydrophobic subsite (Homan & Tesmer 2015). 
Using a phosphorylation assay with biotinylated tubulin dimers to test the inhibitory 
capacity of balanol against GRK isoforms GRK1-7, balanol inhibited the isoforms 
with respective IC50 values of 340 nM, 42 nM, 47 nM, 260 nM, 160, 490 nM and 180 






Figure 1.8 Chemical structure and GRK2 interaction of Balanol 
Chemical structure of balanol (A), and an illustration of the binding of balanol moieties (red) in 
the GRK2 binding site (blue) (B). Adapted and modified from Guccione et al. (2016). 
 
RNA Aptamers 
Another approach of targeting GRK2 is the development of RNA aptamers. 
Aptamers are oligonucleotides that can be identified for many targets, such as small 
molecules, peptides, and proteins (Mayer et al. 2008). Aptamers are identified using 
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the SELEX process (systematic evolution of ligands by exponential enrichment) and 
have been used to target various protein targets. They can be prototype models for 
developing drug-like molecules that can be used in vivo (Mayer et al. 2008).  
 
RNA aptamer C13 has been identified as selective for GRK2 with an IC50 of 4.1 nM 
in a rhodopsin phosphorylation assay (Mayer et al. 2008), and is less potent for 
inhibition of GRK5 with an IC50 of 79.4 nM (Mayer et al. 2008). The problem with 
RNA aptamers is that they are heavy molecules and cannot cross the cell 
membrane (Mayer et al. 2008). 
 
Paroxetine 
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) approved by the FDA 
to treat depression-related disorders (Figure 1.9A). Paroxetine has been shown to 
inhibit GRK2-mediated phosphorylation of rhodopsin in the outer rod segment, with 
an IC50 for inhibition of GRK2 of 19.9 µM, and with lower potency against 
GRK1(316.2 µM) and GRK5 (25.2 µM) (Thal et al. 2012). Paroxetine restored the 
GRK2 expression in ipsilateral superior cervical ganglion (SCG) neurons using rat 
model (Tang et al. 2015).  
 
The crystal structure of paroxetine in combination with GRK2 revealed that the 
dioxole moiety of paroxetine binds to the adenine subsite of GRK2 (Figure 1.9B) 
(Homan et al. 2014; Thal et al. 2012). Also, the methylene moiety interacts with the 
adenine subsite through van der Waal’s interactions. The pyridine moiety binds in 
the ribose subsite of the GRK2 catalytic domain. The fluorophenyl ring formed a 
nonpolar interaction in the P-loop to stabilise GRK2 binding.  
 
Paroxetine has shown modest inhibition of GRK2; however, it is not selective as it 
naturally selectively inhibits serotonin transporters (SERT). Paroxetine is already in 
the clinic and has good pharmacokinetic properties, so it was thought that 
paroxetine analogues would also have good pharmacokinetics parameters 
(Waldschmidt et al. 2017). Tesmer’s group developed a benzolactam derivative of 
paroxetine, CCG206584, in order to obtain a more selective inhibitor (Homan et al. 
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2014). The crystal structure of CCG206584 with GRK2-Gβγ showed less selectivity 
than paroxetine. It also displayed potent inhibition of PKA and PKC compared to 
paroxetine (Homan et al. 2014). 
 
The same group developed other paroxetine derivatives as GRK inhibitors 
(Waldschmidt et al. 2017). The compound 14as was developed by ligation of amide 
moiety to the C-ring of paroxetine (Figure 1.10) (Waldschmidt et al. 2017). The 
compound 14as shows higher potency and better selectivity than paroxetine (IC50 
of 1.38 µM) with an IC50 of 0.03 µM for GRK2 and more than 200-fold selectivity 
over other GRK isoforms as well as ROCK1 and PKA (Waldschmidt et al. 2017). 
 
However, the stability of 14as in mouse liver microsomes was poor with a half-life 






Figure 1.9 Paroxetine structure 
 
Chemical structure of paroxetine (A), and an illustration of the binding of paroxetine moieties in 





Figure 1.10 Chemical structure of 14as 
Substitutions on paroxetine are coloured red. 
 
Another attempt to increase the potency of GRK inhibitor was carried out by 
exchanging the benzodioxole moiety of paroxetine with indazole (Figure 1.11A) 
(Bouley, R et al. 2017). The resulting compounds showed improve potency in GRK2 
inhibition compared to paroxetine; however, they lost the selectivity among other 
kinases (Bouley, R et al. 2017). Very recently, a compound derived from paroxetine 
(CCG258747) was developed which displayed very potent and selective inhibition 
of GRK2 (IC50= 0.018 µM) over other GRK isoforms and other kinases, such as PKA 
and ROCK1 (Figure 1.11B) (Bouley, RA et al. 2020). In addition, CCG258747 has 
good stability in mouse liver microsomes with a half-life of 40 min compared to 23 
min of paroxetine (Bouley, RA et al. 2020).  
 
Screening of a collection of kinase inhibitors known as the structural genomics 
consortium at the University of Oxford resulted in identifying potential GRK inhibitors 
(Homan et al. 2015). Using a differential scanning fluorimetry (DFS) method to 
screen compounds that increase the melting point (Tm) of the GRK2 or GRK5 
(Homan et al. 2015), this screening resulted in the identification of GSK180736A, 
which was initially developed as a ROCK1 inhibitor (Homan et al. 2015). In a tubulin 
phosphorylation assay, GSK180736A had an IC50 of 0.25 µM for GRK2 and was 
4,000- and 400-fold more potent over GRK1 and GRK5, respectively (Guccione et 
al. 2016; Homan et al. 2015). Also, GSK180736A showed potent inhibition of 
ROCK1 and weak inhibition of PKA (Waldschmidt et al. 2018). Thus, GSK180736A 
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is not an ideal GRK inhibitor, which is in addition to its poor bioavailability 
(Waldschmidt et al. 2018). Compound 12n was a derivative of GSK180736A and 
showed to be both potent and selective (Waldschmidt et al. 2016). Using a different 
strategy to develop potent and selective GRK5/6 subfamily inhibitors enabled 
researchers to produce very potent and selective inhibitors over the GRK2/3 
subfamily (Rowlands et al. 2019). Compounds CCG258903 and CCG265328 were 
developed that covalently interact with Cys474, which is unique to the GRK4 
subfamily;   GRK5/6. CCG258903 and CCG265328 showed inhibition of GRK5 and 
GRK6 with IC50 of 0.22, 0.41 and 1.1 and 1.8 µM, respectively (Rowlands et al. 
2019). They showed IC50 values of >100 µM for GRK1 and GRK2 (Rowlands et al. 
2019). However, the IC50 of CCG258903 and CCG265328 was determined using 
purified GRK enzyme, which does not reflect the cell-based assay values. It is 
important to note that the covalent inhibitors are not favoured as drugs due to their 





Figure 1.11 Chemical structures of paroxetine derivatives 





In 2007, the Takeda Pharmaceutical Company developed compound101 
(cmpd101) and compound103A (cmpd103A) as GRK2/3 inhibitors (Ikeda, S, 
Keneko & Fujiwara 2007). Their structures are composed of four rings named A-D 
(Figure 1.12A). When these compounds crystallised with GRK2-Gβγ, they showed a 
slightly different interaction with the catalytic site of GRK2 from that of balanol 
(Figures 1.9B and 1.12B) (Thal et al. 2011). The A rings of cmpd101 and cmpd103 
bind to the adenine subsite whereas the B rings bind to the ribose subsite. The C 
rings bind in the triphosphate subsite of the kinase catalytic domain whilst the D 
rings bind to the hydrophobic subsite, making nonpolar interactions with Gly201, 
Phe202, Leu235, Glu239, Gly337  and Leu338 (Thal et al. 2011). 
 
Cmpd101 and cmpd103 bind to an open, noncatalytic conformation of GRK2 with a 
slight closure of the kinase domain towards the small lobe by 2.4 A° and 3.6 A°, 
respectively (Thal et al. 2011). Both compounds show inhibition of GRK2 with an 
IC50 of 290 and 54 nM, respectively. They show no inhibition against GRK1 and 
GRK5 up to a concentration of 125 µM (Thal et al. 2011).  
Recently, Professor Steve Husbands at the University of Bath has developed a 
series of novel cmpd101 analogues. They were designed based on the idea that the 
selectivity of cmpd101 is due to forming van der Waals interaction (Homan & 
Tesmer 2015) through the A-ring and more hydrogen bonds can lead to a loss in 
the selectivity. To explore the idea, the A/B rings of cmpd101 were replaced by 
naphthyl rings as in compounds BU16007 and BU16006 or quinolone ring as in 
compound BU16005 (Figure 1.13). Also, the amide and CH2NH groups were 
replaced by double bonds, as in compounds BU14013 and BU14014, respectively 
(Figure 1.13). These compounds will be the subject of this thesis.  
 
Finally, at the time of starting my research, most of the potent and selective GRK2 
inhibitors are paroxetine derivatives have not been developed. The only GRK2/3 
inhibitors being used are paroxetine, balalnol, cmpd101 in most of the studies. 
Cmpd101 is a promising inhibitor and can be a scaffold for developing new potent 





Figure 1.12 Chemical structures of cmpd101 and cmpd103A 
Chemical structures of cmpd101 and cmpd103A (A), and an illustration of the binding of 






Figure 1.13 Chemical structures of novel inhibitors 




1.4.6 Application of GRK Inhibitors in GPCR Signalling 
While RNAi and animal gene knockout studies have increased our understanding 
of GRKs (Fan et al. 2013; Matkovich et al. 2006; Mundell, S. J., Benovic & Kelly 
1997), the introduction of small GRKs inhibitors  (Bouley, RA et al. 2020; Ikeda, S, 
Keneko & Fujiwara 2007; Rowlands et al. 2019) has brought further insight into the 
role of GRKs in modulating GPCR signalling. Using GRK inhibitors to study GPCRs 
has identified role of GRKs, in particular GRK2, in regulating various signalling 
pathways. In this section, I will give some examples of utilising GRK inhibitors in 
studying the role of GRK in GPCR signalling.  
 
Paroxetine has been used in investigating the role of GRK2 in GPCR signalling. 
Recently, a study used most potential GRK2 inhibitors, including paroxetine, 
cmpd101, and two paroxetine derivatives, CCG215022 and CCG224063, to 
investigate GRK2-mediated desensitisation of uridine triphosphate (UTP) and 
angiotensin II (AngII)-stimulated cells. These GRK2 inhibitors attenuated UTP- and 
AngII-induced desensitisation in isolated smooth muscle cells (Rainbow et al. 
2018).Using these inhibitors confirmed that GRK2 plays a central role in regulating 
vasoconstrictor-mediated arterial contraction (Rainbow et al. 2018). 
 
In MOPr, Lowe et al. (2015) investigated the role of GRK2 in desensitisation of MOPr 
using GIRK current in LC neurons. LC slices were pretreated with cmpd101 (30 µM), 
a selective GRK2/3 inhibitor, and then stimulated with methionine-enkephalin (Met-
Enk), DAMGO, endomorphin-2, and morphine to induce MOPr desensitisation. 
Cmpd101 inhibited the Met-Enk-, DAMGO-, endomorphin-2- and morphine-induced 
desensitisation of the G protein–activated inwardly-rectifying potassium (GIRK) 
current. The authors concluded that GRK2/3 played a role in MOPr desensitisation 
in LC neurons. 
 
Another study looked at the role of GRK2 in insulin and βAR signalling pathways in 
fibroblasts (Cannavo et al. 2019). Aldosterone blocks insulin signalling in vascular 
smooth muscle cells (Cannavo et al. 2019). The authors wanted to study whether 
GRK2 has a role in this pathway. Fibroblast cells (3T3) were pretreated with 
cmpd101 (3 µM) in the presence or absence of aldosterone. Then cells were 
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stimulated with insulin. They looked at the phosphorylation of insulin receptor 
substrate 1 (IRS1) at Ser307, which is the GRK2 phosphorylation site resulting in 
blocking insulin signalling. They found that cmpd101 blocked the effect of 
aldosterone on the insulin signalling. These results indicate the role of GRK2 in 
aldosterone signalling pathway. 
 
In a mouse myocardial infarction model, treatment with paroxetine after 2 weeks of 
myocardial infarction improved left ventricular function and structure when 
compared to fluoxetine, an analogue of paroxetine with no effect of GRK activity 
(Schumacher et al. 2015). The use of genetically engineered mice further suggested 
that paroxetine was working through inhibition of GRK2 (Schumacher et al. 2015).    
 
In summary, these and other functional studies are revealing interesting insights into 
the role of GRKs in GPCR signalling pathways and the possibility of using GRK 
inhibitors as potential therapeutic agents.  
 
1.5 Bioluminescence Resonance Energy Transfer (BRET)  
Over the years, many methods have been developed to study protein interaction 
with GPCRs, including bioluminescence resonance energy transfer (BRET), 
fluorescence resonance energy transfer (FRET), and other biochemical methods. 
GPCRs are well known to function in dimer/oligomer forms and to interact with 
various effectors in a ligand-driven manner or constitutively. Therefore, studying 
protein-protein interaction is essential in finding and developing targeted therapy. In 
this thesis, I will use the BRET technique, in particular BRET2, to study arrestin-3 
recruitment to MOPr and DOPr. 
 
1.5.1 Principle of BRET 
BRET was initially adapted from marine animals (sea pansy Renilla reniformis and 
jellyfish Aequoria victoria) and has subsequently been used to study protein-protein 
interaction in living cells (El Khamlichi et al. 2019). It generates non-radiating energy 
so that it can avoid the complication of radiation when using a radiolabelled agent 
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(Pfleger, Seeber & Eidne 2006). The energy is transferred from the donor, usually 
Renilla Luciferase, to the acceptor protein, such as Yellow Fluorescent Protein 
(YFP) (Figure 1.14) (El Khamlichi et al. 2019). A protein of interest can be generated 
by fusing donor protein to one protein and the acceptor protein to the other protein 
of interest. Then, both proteins are cotransfected into suitable cell lines (e.g., 
HEK293, CHO). Once the proteins of interest are coexpressed in the chosen cell 
line, the substrate coelenterazine, a cell-permeable substrate that is oxidised, is 
added (Figure 1.14). When the two proteins of interest come in close proximity (<10 
nm) (Pfleger & Eidne 2006), the energy resulting from the catalytic degradation of 
the coelenterazine substrate from the donor (luciferase) to the acceptor (e.g., YFP) 
generates light emission at 530 nm (El Khamlichi et al. 2019). The intensity of BRET 
is influenced by many factors, such as 1) the distance between the two BRET 
proteins; 2) the overlap of the emission of the donor with excitation of the acceptor; 
3) the orientation of the BRET proteins; and 4) the ratio of a donor to an acceptor 
(Ayoub & Pfleger 2010; Pfleger & Eidne 2006). Specific interaction between the two 
proteins shows a hyperbolic relationship and reaches a plateau once all donors bind 
to the acceptor (Ayoub & Pfleger 2010). In nonspecific interaction, the relationship 
is dictated by increasing linearly upon increasing the donor concentration (Ayoub & 
Pfleger 2010). In the last few years, a growing number of BRET systems have been 
developed to increase the BRET signal or the stability of BRET partners.  
 
More systems have been developed to overcome the drawbacks of BRET1, such as 
the high spectral ratio of a donor to the acceptor and high signal/noise ratio. BRET2 
using a coelenterazine derivative, DeepBlue C or coelenterazine 400a has improved 
the RLuc emission, but its luminescence signal last for only a few seconds making 
it less sensitive than BRET1 (El Khamlichi et al. 2019). Also, it requires the 
increasing of the protein expression level, which may detect nonspecific protein-





Figure 1.14 BRET principle 
A schematic representation of the principle of BRET. BRET technology involves the fusion of 
donor (e.g., RLuc) and acceptor (e.g., GFP) to proteins of interest (Protein A and Protein B). Co-
transfection of the donor and the acceptor into cell lines enables to study their interaction. A) 
When the distance between a donor and an acceptor is more than 10 nm i.e., no interaction, 
there is no transfer of energy and no emission from the acceptor. B) the donor comes in close 
proximity to the acceptor (<10 nm), and the energy transfers from the donor to the acceptor result 
in light emission from the acceptor at a specific wavelength. The energy emitted by the acceptor 
relative to the energy emitted by the donor is the BRET ratio. 
 
1.5.2 BRET Application in Cellular Signalling  
BRET technology has been used extensively in studying protein-protein interaction. 
One area that has been applied to is studying the GPCR signalling and identifying 
new mechanisms. Also, it helps in elucidating downstream signalling of GPCRs. 
BRET is of help in studying dimerisation of GPCR and oligomerisation (Issad & 
Jockers 2006; Massoud et al. 2007). It has also been applied in studying GPCR and 
G protein interaction. For example, our lab has used BRET to study the interaction 
of MOPr and G protein, which helps in understanding the morphine and MOPr 




GPCR interactions with G protein have been studied in living cells by using 
BRET. BRET has allowed the determination of full agonists, partial agonist and 
antagonists. Also, BRET has been utilised in the characterisation of different 
receptor conformations induced by distinct ligands by means of agonist biased. 
Moreover, BRET is used to monitor the dissociation of G proteins subunits after 
receptor activation. 
 
Expanding the application of BRET to be used in determining the interactions 
between GPCR and GRK, which a direct way to study the recruitment of GRK to the 
activated receptor (Miess et al. 2018). Agonist-induced arrestin recruitment to the 
phosphorylated GPCR is one common BRET assay. One of the first studies used 
arrestin BRET assay where the receptor was fused with Venus and arrestin-3 with 
RLuc in HEK293 cells. This screening resulted in finding compounds that inhibit 
agonist-induced arrestin-3 recruitment to C-C chemokine receptor type 5 (CCR5) 
(Hamdan et al. 2006). Hill et al. (2018) used BRET to determine the functionality of 
PZM21 in arrestin and G protein activation assay in HEK293 cell expressing MOPr. 
This showed that PZM21 is low efficacy MOPr agonist in both assays. 
 
1.6 Thesis Aims 
The growing body of research on GRKs shows their importance in regulating the 
signalling and trafficking of GPCRs. In addition, GRKs regulate GPCR-independent 
signalling pathways that play a key role in important cellular functions, such as 
platelet-derived growth factor receptor β (PDGFRβ) and EGFR (Gurevich, EV et al. 
2012). There is a need for a better understanding of the role of GRKs in regulating 
phosphorylation of GPCRs and the functional consequences this produces in the 
cell and organism. Until recently, there have been few if any selective inhibitors for 
GRKs. The recent development of Takeda compounds and the promising findings 
make it possible to study the function of individual GRKs.  
 
There has been some progress on the development of potent and selective GRK 
inhibitors. However, the selectivity, in particular, has not been resolved. 
Understanding the structure and functions of GRKs will facilitate the development 
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of potent and selective inhibitors. In this thesis, I aim to study the ability of cmpd101 
and some novel structural analogues to inhibit GRKs, principally by assessing their 
ability to inhibit agonist-induced arrestin-3 recruitment to µ and δ opioid receptors. 
Inhibitors of GRK phosphorylation of opioid receptors could represent drugs that 
suppress tolerance, a common problem observed with the use of opioid receptor 
agonists. The long-term goal of our research is to investigate the role of GRK 
phosphorylation in the function of µ opioid receptor and other GPCRs. Particularly, 
the specific aims of this thesis are: 
1. To use the mu-opioid receptor (MOPr) and an arrestin-3 recruitment assay as a 
readout of GRK phosphorylation to identify and characterise potential novel 
inhibitors of GRK function. 
2. To investigate whether inhibition of arrestin-3 recruitment to MOPr by potential 
GRK inhibitors is agonist-dependent. 
3. To investigate whether inhibition of agonist-dependent arrestin-3 recruitment by 
potential GRK inhibitors is receptor-dependent (MOPr versus DOPr). 
4. To investigate the selectivity of potential GRK inhibitors of different GRKs by 
assessing their ability to inhibit arrestin-3 recruitment to MOPr following cellular 
overexpression of individual GRK isoforms.  
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2.1.1  Compounds and Reagents 
Cmpd101 was purchased from Hello Bio (Bristol, UK) and all other analogues were 
synthesised by Professor Steve Husbands at the University of Bath (Bath, UK). 
DAMGO ([d-Ala2-MePhe4-Gly-ol] enkephalin) was purchased from Bachem 
(Bubendorf, Switzerland); SNC80 ((+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-
piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide), DADLE ([D-Ala2, D-Leu5]-
Enkephalin), GF109203X, PD98059, KN-93 and SP600125 were from Tocris 
Bioscience (Bristol, UK). Morphine hydrochloride was purchased from MacFarlan 
Smith (Edinburgh, UK). Lipofectamine 2000 was purchased from Invitrogen and 
coelenterazine 400a (DeepBlueC) was from Insight Biotechnology (Wembley, UK). 
All other reagents were purchased from Sigma-Aldrich (Dorset, UK). 
 
2.1.2  Antibodies 
The primary and secondary antibodies used in this thesis are listed in Table 2.1. 
The primary antibodies, anti-GRK2, anti-GRK3, anti-GRK5 and anti-GRK6, were 
purchased from Santa Cruz Biotechnology (Insight Biotechnology, Wembley, UK); 
anti-α-tubulin was from Sigma-Aldrich (Dorset, UK), and anti-HA.11 was from 
BioLegend (London, UK). The secondary antibodies: anti-mouse IgG horse-radish 
peroxidase linked antibody was from GE Healthcare (Buckinghamshire, UK), anti-
mouse IgG-alkaline phosphatase was from Sigma-Aldrich (Dorset, UK). All the 
concentrations of the antibodies (Table 2.1) were determined based on a 





Table 2.1 Primary and secondary antibodies 
Antibody Assay Species Dilution Supplier Catalogue number 
Primary antibodies      
Anti-α-tubulin WB Mouse 1:10,000 Sigma T6074 
Anti-GRK2 (C-15) WB Rabbit 1:200 Santa Cruz Sc-562 
Anti-GRK3 (C-14) WB Rabbit 1:300 Santa Cruz Sc-563 
Anti-GRK5 (C-20) WB Rabbit 1:500 Santa Cruz Sc-565 
Anti-GRK6 (C-20) WB Rabbit 1:300 Santa Cruz Sc-566 
Anti-HA.11 ELISA Mouse 1:1,000 Biolegend 901514 
Secondary antibodies      
Rabbit-HRP WB Sheep 1:7,500 GE Healthcare NA934V 
Mouse-HRP WB Sheep 1:10,000 GE Healthcare NXA931 
Mouse-IgG AP ELISA Goat 1:1,000 Sigma A5153 
All primary and secondary antibodies were used for western blotting (WB) or enzyme-linked immunosorbent assay (ELISA). Horse-radish peroxidase 






2.2.1 Preparation of the Plasmids 
The hMOPr-RLuc2 (MOPr-RLuc2) in the pQCXIN vector and DOPr-RLuc2 in the 
pQCXIN vector and arrestin-3-GFP10 (Arr3-GFP) in the pQCXIH vector 
constructs were a gift from Dr Tomasso Costa, Institute Superiore di Sanita, Italy. 
The Gαi-RLuc2 and Gγ-GFP plasmids in the pcDNA3.1 vector were a gift from Dr 
Michel Bouvier, University of Montreal, Canada. The HA-tagged rMOPr construct 
in the pcDNA3 vector was from Dr Helen Sanderson, University of Bristol. GRK2, 
GRK3, GRK5, GRK6 in the pcDNA3.1 vector and pcDNA3.1 constructs were from 
Dr Michael Bouvier, University of Montreal, Canada. The purified DNAs were 
obtained as follows: the subcloning efficiency DH5α competent cells (Invitrogen) 
were divided into 20 µl aliquots and stored in -80°C when required the aliquot of 
DH5α competent cells was thawed on ice. The plasmid DNA (1 µg) was added to 
the 20 µl DH5α competent aliquot and incubated on ice for 30 min. Then, the 
mixture was heat shocked in a water bath at 42°C for 45 seconds and then 
incubated on ice for 2 min. Next, 200 µl of SOC (super optimal broth with catabolite 
repression) medium was added to the mixture and incubated in a shaking 
incubator at 180 rpm and 37°C for 1 h. The transformed cells were then plated on 
LB agar (Luria-Bertani) plates containing an appropriate antibiotic (e.g., Ampicillin 
100 µg/ml or kanamycin 50 µg /ml). The LB agar plate was then placed in an 
incubator at 37°C overnight. The next morning, well separated bacterial colonies 
were picked up by a sterile glass hook and added into 3 ml tubes containing an 
appropriate antibiotic (Ampicillin 100 µg/ml or kanamycin 50 µg /ml) and incubated 
in a shaker incubator at 37°C overnight. The following day, the bacteria cultures 
were expanded into 200 ml LB agar flasks containing the appropriate antibiotic 
(Ampicillin 100 µg/ml or kanamycin 50 µg /ml) and incubated in the shaking 
incubator at 37°C overnight.  
 
The next day, the bacterial cells were pelleted by centrifugation at 6,000 x g for 
15 min at 4ºC. We used the HighSpeed Plasmid Preparation Kit (Qiagen®), which 
is based on modified alkaline lysis, to prepare high-quality DNA for transfection. 
The steps of the protocol were given by the manufacturer as follows: the pellet 
was resuspended in Buffer P1 (10 ml) and then added to Buffer P2 (10 ml). Next, 
the DNA was precipitated with chilled Buffer P3 (10 ml) and incubated on ice for 
20 min and then centrifuged at 20,000 x g for 30 min at 4ºC. The supernatant was 
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then filtered using QIAGEN-tip that had been equilibrated with Buffer QBT (10 ml). 
Following this, the DNA was eluted using Buffer QF (15 ml) and then the DNA 
precipitated by adding 10.5 ml 100% isopropranolol and centrifuged for 30 min. 
The DNA pellet was then washed with 2 ml 70% ethanol and centrifuged for 10 
min. Finally, the DNA pellet was resuspended in a suitable volume of TE buffer. 
The DNA concentration was measured by NanoDropTM 2000 Spectrophotometer 
at 260 nm (Thermo Scientific). The DNA constructs were store at -20ºC. All DNA 
constructs were sequenced by Source BioScience, Nottingham, UK. 
 
2.2.2 Cell Culture  
Human Embryonic Kidney 293 (HEK293) cells were cultured at 37°C in 5% CO2 
in Dulbecco's Modified Eagle's Medium (DMEM, Gibco) supplemented with 10% 
fetal bovine serum (FBS, Corning), 10 U/ml penicillin and 10 mg/ml streptomycin 
(Invitrogen/Life Technologies, Paisley, UK). Cells were seeded onto 100 mm 
dishes and grown to 80-90% confluence, then subjected to splitting. To do this, 
media was removed, and cells were washed with phosphate-buffered saline (PBS, 
Oxoid Limited, Basingstoke, UK). Cells were then detached by adding 0.25% 
trypsin (Gibco). Cells were then collected by adding 5 ml media and transferred to 
centrifuge tubes. Cells were centrifuged at 300 x g for 3 min. The pelleted were 
resuspended in DMEM and transferred to new sterilised dishes or plates and 
cultured in the incubator until required for further splitting or experimentation. All 
cell culture procedures were undertaken in an aseptic cell culture hood. 
 
2.2.3  cDNA Transfection  
For the arrestin-3 recruitment assay, we used two BRET configurations. The 
required DNA constructs were diluted in Opti-MEM media (Gibco) to a total volume 
of 500 ml. We used BRET2 where HEK293 cells cotransfected with MOPr-Rluc2 
(5 µg) and Arr3-GFP (5 µg). Another set of cells was only transfected with MOPr-
Rluc2 to correct for the basal luciferase signal in cells (Borroto-Escuela et al. 
2013). For the Gi activation assay, HEK293 cells were transfected with  HA-MOPr 
(3 µg), Gαi-RLuc2 (3 µg) and Gγ-GFP (3 µg). 
 
The ratio of donor to acceptor was determined previously in our laboratory 
(Gasiunaite G 2017). cDNA construct transfections were carried out using 
Lipofectamine® 2000 according to the manufacturer’s instructions. The DNA of 
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interest was diluted with Opti-MEM media (Gibco) to a final concentration of 5 
µg/ml in a total volume of 500 ml and mixed gently. Also, lipofectamine® 2000 was 
diluted with Opti-MEM media in a total volume of 500 ml and mixed gently. The 
ratio of DNA (µg) to lipofectamine® 2000 (µl) was 1:2.7; this ratio was determined 
previously by Dr Gerda Gausinuaite in our laboratory through a saturation assay, 
where a fixed amount of DNA was coexpressed with an increasing concentration 
of lipofectamine® 2000. The DNA dilution and lipofectamine dilution were 
incubated for 5 min at room temperature. During the incubation, the culture media 
of the dishes that were intended for transfection was removed and replaced with 
9 ml Opti-MEM media. After 5 min incubation, the diluted lipofectamine was added 
slowly to the diluted DNA and mixed gently and incubated for a further 10 min at 
room temperature. After, the complex was added to cells and the cells incubated 
at 37°C in a CO2 incubator for 24 h. Following this, the Opti-MEM media was 
removed and fresh DMEM media (10 ml) was added. All assays were performed 
48 h after transfection. 
 
2.2.4  Bioluminescence Resonance Energy Transfer (BRET) 
Measurements 
BRET assays were used to measure agonist-induced arrestin-3 recruitment to 
MOPr or DOPr and also to measure the dissociation (activation) of G-protein 
subunits (Gαi and Gγ). HEK293 cells were transfected with MOPr-RLuc2 (a BRET 
donor) along with Arr3-GFP (a BRET acceptor), as described in Section 2.2.3. On 
the day of the BRET experiment, the cell media was aspirated and the cells 
washed with sterile 5 ml PBS. Then, the PBS was removed and 1 ml 0.25% trypsin 
was added to help detach the cells. Then, 5 ml of medium was added to each dish 
and the cells and medium transferred into 10 ml centrifuge tubes and the cells 
pelleted by centrifugation at 300 x g for 3 min. The pellet was resuspended in 5 
ml clear media and re-seeded onto white 96-well plates. Cmpd101 and its 
analogues were dissolved in DMSO and the final concentration of DMSO was 
0.3% in all BRET assays.  
 
To construct agonist concentration-response curves (Figures 3.3 and 3.4), cells 
were stimulated with MOPr agonists DAMGO (0.001-30 µM), morphine (0.01-100 
µM), or DOPr agonists SNC80 (0.001-100 µM), or DADLE (0.001-100 µM) for 10 
min. For DAMGO or morphine time courses, the BRET measurements were taken 
every 2 min up to 20 min (Figure 3.5). Three minutes after starting the 
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measurements, DAMGO (10 µM) or morphine (30 µM) was added. In the time 
course experiments, naloxone (10 µM) was added 4 min after the addition of 
DAMGO or morphine.  
To investigate the effect of compounds on the agonist-induced arrestin-3 
recruitment, HEK293 cells were preincubated with cmpd101 or test compounds 
for 30 min (Figures 3.7A, 3.8 and 4.6) and then DAMGO (10 µM), morphine (30 
µM), SNC80 (10 µM), or DADLE (10 µM) was added. For time course 
experiments, BRET measurements were taken at every 2 min up to 16 min 
(Figures 3.7A, 3.8,) or 18 min (Figure 4.6). To investigate the cmpd101-induced 
inhibition of established DAMGO- or morphine-induced arrestin-3 recruitment, 
BRET measurements were taken at every 2 min up to 16 min up to 20 min (Figure 
3.7B) or 18 min (Figure 3.11), cmpd101 was added 4 min after the agonist 
stimulation (Figures 3.7B and 3.11).  
 
For concentration-dependent inhibition of agonist-stimulated arrestin-3 
recruitment by cmpd101 and test compounds, cells were preincubated with 
various concentrations of cmpd101 or test compound (0.01-100 µM) for 30 min at 
37ºC. Then, cells were stimulated with the addition of DAMGO (10 µM), morphine 
(30 µM) or SNC80 (10 µM) for 10 min before BRET measurement.  
 
To measure the effect of different kinase inhibitors on the DAMGO-induced 
arrestin-3 recruitment, cells were preincubated with GF109203X (1 µM), a PKC 
inhibitor; SP600125 (30 µM), a JNK inhibitor; PD998059 (10 µM), an ERK1/2 
inhibitor; KN-93 (1 µM), a CaMKII inhibitor or cmpd101 (30 µM) as a positive 
control and cells then stimulated with DAMGO (10 µM) for a further 10 min.  
 
To measure Gi activation, cells were transfected with HA-MOPr, Gαi-RLuc2 and 
Gγ-GFP, as described in Section 2.2.3. For experimentation, cells were 
preincubated with cmpd101 (30 µM) or test compounds for 30 min. Then, cells 
were stimulated with DAMGO (0.001- 30 µM) for a further 2 min. Coelenterazine 
400a (final concentration of 5 µM) was prepared 10 min before BRET 
measurements. All the BRET measurements were performed using a FLUOstar 
Omega (BMG LABTECH, Germany) microplate reader with a filter set of 410/80 
nm (donor) and 515/30 nm (acceptor). The BRET ratio was determined by 
(dividing the intensity of acceptor luminescence emission at 515 nm by the 
intensity of donor luminescence emission at 410 nm) times 1000. 
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2.2.5 Western Blotting 
Sample Preparation 
HEK293 cells were transfected (as described in Section 2.2.3) with MOPr-RLuc2, 
Arr3-GFP and GRK2, GRK3, GRK5 or GRK6, and another 100 mm cell dish was 
transfected with MOPr-RLuc2, Arr3-GFP, and pcDNA3.1 as a control. After 48 h 
of the transfection, cell dishes were placed on ice and the media was aspirated. 
Cells were washed two times with ice-cold PBS. Then, 400 µl RIPA buffer (150 
mM NaCl, 5 mM EDTA, 50 mM Tris, 1% Triton-X100, 0.5% Sodium deoxycholate, 
0.1% SDS, pH 7.5) was added to the dishes to lyse cells and the cells were then 
scraped into and transferred to sterile Eppendorf tubes. Tubes were placed in a 
slow rotator for 30 min in a cold room. Next, cells were centrifuged at 2,000 x g for 
10 min at 4ºC. The pellets were discarded and the clear solution was transferred 
to new sterile Eppendorf tubes and stored at -20 ºC. The protein concentration in 
each sample was then determined as below. 
 
Measurement of Protein Concentration by DC Assay 
Protein concertation was determined by DC (detergent compatible) protein assay 
using a DC™ Protein assay kit (Bio-Rad, cat# 500-d114). A range of BSA 
concentrations (0-2 mg/ml) was prepared in RIPA buffer as a standard curve.  For 
this, 5 µl of the standards and the samples were added to a 96-well plate. Then, 
25 µl of reagent A and then 200 µl of reagent B was added to each well. The plate 
was incubated at room temperature for 15 min and the absorbances in each well 
were read at 595 nm in a microplate reader (Tecan infinite M200Pro, Tecan 
Austria GmbH). The unknown protein concentrations of the samples were 
determined by interpolation of the BSA standard curve. The curves were 
constructed using GraphPad Prism v8. All curves were carried out in triplicate.    
 
Immunoblotting 
Equal amounts of proteins (50 µg) were resolved by running buffer [25 mM Tris, 
200 mM glycine and containing 0.1% (w/v) sodium dodecyl sulphate (SDS)] on 
10% SDS-polyacrylamide gel at 120V for 90 min. Prestained markers 
(PageRuler™ Plus, Thermo Scientific) (7 µl) were added to estimate the molecular 
weights of the proteins. Proteins were then transferred onto polyvinylidene fluoride 
(PDVF) membranes (Millipore) at 100V for 90 min. Membranes were then blocked 
with 5% (w/v) non-fat dried milk in TBST buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 
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containing 0.1% (v/v) Tween 20) and placed on a rocker for 1 h. Following that, 
membranes were incubated with primary antibodies in 5% (w/v) non-fat dried milk 
in TBST buffer in sealed bags overnight at 4°C on shaking rocker. The next 
morning, membranes were washed three times with TBST, first time 15 min the 
next two 5 min each at room temperature. Membranes were then incubated with 
horseradish-peroxidase (HRP)-conjugated secondary antibody prepared in 5% 
(w/v) non-fat dried milk in 10 ml TBST buffer on shaking rocker at room 
temperature for 1 hr. Then, membranes were washed three times with TBST. After 
that, the protein on membranes was subjected to detection using western blotting 
detection reagents (ELC™, GE Healthcare) for 2 min. Membranes were exposed 
to Hyperfillm ECL (GE Healthcare) for about 1 min in a dark room and the films 
were processed by an SRX-101A developer (Konika Minolta). Pictures were finally 
processed by ImageJ software (NIH). 
 
2.2.6  Enzyme-linked Immunosorbent Assay (ELISA) 
The surface expression of MOPr was determined by ELISA, according to Mundell, 
Stuart J., Nisar and Kelly (2010) with minor modifications. HEK293 cells were 
transfected with HA-MOPr, as described in Section 2.2.3. After 24 h of 
transfection, cells were plated in a 24-well plate precoated with 400 µl poly-L-
lysine. Cells transfected with pcDNA3.1 were plated in parallel and used as 
background controls. Plates were kept at 37°C in a CO2 incubator overnight. The 
following morning, the DMEM medium was replaced by serum-free DMEM and 
incubated at 37°C in a CO2 incubator for 10 min. Cmpd101 or test compound (30 
µM) were added to the plates and incubated at 37°C in a CO2 incubator for 30 
min. Then, DAMGO (10 µM), morphine (30 µM) or vehicle was added for a further 
30 min; this time point was chosen based on Figure 3.14A, which indicates that 
peak agonist-induced surface receptor loss was reached by this time point. Cells 
were then fixed with 3.9% paraformaldehyde (PFA) (VWR) for 5 min. Cells were 
washed three times with TBS (20 mM Tris, 100 mM NaCl, pH 7.5) at room 
temperature in a cell culture hood. After this, cells were blocked with 1% BSA 
prepared in TBS for 45 min at room temperature on a rocker. Following this, cells 
were further incubated with primary antibody (mouse anti-HA monoclonal 
antibody, Biolegend) at a dilution of 1:1,000 (250 µl/well) for 1 hr. Cells were then 
washed a further three times with TBS and then were incubated with 1% BSA at 
room temperature for 15 min. After that, they were incubated with secondary 
antibody (goat anti-mouse IgG alkaline phosphatase conjugate, Sigma) at 1:1,000 
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dilution for 1 hr. After that, cells were again washed three times with TBS. Cells 
were finally incubated at 37°C with 250 µl/well alkaline phosphatase substrate 
(Thermo scientific) until the colour changed to yellow. The reaction was stopped 
by transferring the substrate to 96-well plates containing 2N NaOH. The 
absorbance was then measured at 405 nm using Tecan Infinite plate reader 
(Tecan). All experiments were performed four times in triplicate.  
 
2.2.7  Fluorescence-activated Cell Sorting (FACS) 
Flow cytometry was used to determine the percentage of GFP positive cells in 
HEK293 cells transfected with MOPr-RLuc2 and Arr3-GFP, as described in 
Section 2.2.3 and cultured for 48 hr. Following this, the DMEM media was 
removed and cells were washed with 5 ml PBS. Then, cells were detached by 
adding 1 ml 0.25% trypsin. Cells were then collected by adding 5 ml of medium 
and transferred to centrifuge tubes. Cells were then centrifuged at 300 x g at room 
temperature for 3 min. The pelleted cells were then resuspended in FACS buffer 
(Ca+2 and Mg+2 free PBS, 25 mM HEPES pH 7.0, 2.5 mM EDTA and 0.5% BSA), 
which is designed to prevent cell clumping. Following this, the cells were 
transferred to new sterile Eppendorf tubes at a density of 1x105 cells/ml and kept 
on ice until analysis. The actual FACS analysis was carried out by the Faculty of 
Life Science, the Flow Cytometry Facility, University of Bristol led by Dr Andrew 
Herman. The fluorescence was analysed by Novocyte 3000 Flow Cytometer 
(Acea Biosciences, San Diego, CA, USA). 
 
2.2.8  Data Analysis 
The BRET ratio was determined by dividing the intensity of acceptor luminescence 
emission at 515 nm by the intensity of donor luminescence emission at 410 nm 
times 1000. These values were then subtracted from the no agonist-treated cells 
and normalised to the agonist-induced stimulation and fitted to a curve by 
nonlinear regression using GraphPad Prism v8.0 software (San Diego, CA, USA). 
A snapshot of the raw data obtained from the machine is shown in Figure 2.1. For 
the Gi activation assay, the data were plotted as a percentage decrease from 
vehicle-treated wells. ELISA data were measured in triplicate and the values were 
averaged. The averaged values were then subtracted from the empty vector 
(pcDNA3.1) value. Then, the subtracted values were divided by the control 
(untreated cells) to obtain the percentage of the cell surface receptor loss. A 
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snapshot of the raw data obtained from the machine is shown in Figure 2.2. The 
EC50, maximum response and IC50 values were obtained by averaging the values 
of individual experiment and were fitted to three or four parameters nonlinear 
regression model based on which gave the best r2 and narrow 95% confidence 
interval (Cl). All inhibition curves were fitted to a three parameters model with a 
fixed slope of -1. Standard curves of the DC protein assay were fitted by linear 
regression analysis. Figures 1.1- 6 and 5.16 were created with BioRender.com. 
All data are presented as mean ± SEM from at least three independent 
experiments performed in duplicate for the BRET assay and in triplicate for the 
ELISA assay. The logP values were calculated using ChemDraw Professional 16 
software. It estimates logP of a compound based on its chemical structure. The 
software calculates the logP value using specific logarithms based on the formula: 





Statistical analysis was carried out with one-sample Student's t-test, one-way 
ANOVA, or two-way ANOVA followed by Tukey's or Dunnett's post-hoc test. Post-
hoc tests were chosen based on the type of analysis required. For instance, 
Tukey's test was used to compare between all means of the groups while 
Dunnett's was used to compare selected group mean, such as control or vehicle 







Figure 2.1 Representative example of raw data of BRET readout 
 
The snapshot represents the plate layout. Each row represents one run. The upper box is 
the donor emission readouts and the below box is the acceptor readout. During data 
analysis, donor emission (highlighted in red) is divided by the acceptor emission (highlighted 




Figure 2.2 Representative example of ELISA raw data 
 
 
The snapshot represents a 24-well plate layout for ELISA assay. The first row which marked 
in red is the control samples, the green cells are the samples, the blue cells are the non-




CHAPTER 3 Inhibition of Agonist-stimulated 
Arrestin-3 Recruitment to MOPr and DOPr by 






There has been great interest in developing selective GRK inhibitors due to the 
significant role played by GRKs in the regulation of GPCR signalling. Particularly, 
GRK2 and GRK5 have been shown to be upregulated in heart failure (Dzimiri et al. 
2004; Monto et al. 2012). A number of GRK inhibitors have been developed (Mayer 
et al. 2008; Setyawan et al. 1999; Tesmer, JJ et al. 2010); however, many of them 
are either nonselective between kinases or have weak potency (Thal et al. 2012). 
On the other hand, the Takeda Pharmaceuticals Company developed compound 
101 (cmpd101; (Ikeda, S, Keneko & Fujiwara 2007), which was reported to be a 
selective GRK2/3 inhibitor (Thal et al. 2011). Recently, a new compound, 
CCG258747, has been developed which is potent and selective GRK inhibitor over 
other kinases (Bouley, RA et al. 2020).  
 
Cmpd101 has been used as GRK2/3 inhibitor in a number of in vitro and in vivo 
studies (Abraham et al. 2018; Li, H et al. 2016; Lowe et al. 2015; Pack et al. 2018). 
For example, Lowe et al. (2015) reported that cmpd101 inhibited DAMGO-induced 
MOPr desensitisation in locus coeruleus (LC) neurons, implying that the 
desensitisation is mediated by GRK2/3. Moreover, cmpd101 partially blocked the 
agonist-induced internalisation of galanin receptor 2 (Reyes-Alcaraz et al. 2018) and 
did not block GPCR-mediated 14-3-3 signalling, a multifunctional signal adaptor 
protein (Li, H et al. 2016). The latter signalling pathway is not thought to involve 
GRK/arrestins. 
 
A fundamental step towards determining the role of GRKs in GPCR signalling is to 
establish selective inhibitors for GRKs to be used in standard assays. Thus, the 
main goal of this chapter is to characterise the ability of cmpd101 to inhibit arrestin-
3 recruitment upon addition of different agonists using HEK293 cells expressing 
MOPr or DOPr. We used two MOPr agonists, DAMGO, a full agonist, and morphine, 
a partial agonist, in the arrestin assay as well as DOPr agonists, SNC80 and 
DADLE. We used arrestin-3 recruitment as a proxy assay for GRK phosphorylation 
of the receptor. Also, we utilised a Gi activation BRET assay to examine the 




MOPrs, like most GPCRs, are significantly regulated following agonist activation, 
particularly prolonged agonist activation. For example, MOPr gets phosphorylated 
by GRKs leading to receptor desensitisation. This process is called homologous 
desensitisation and is a GRK-dependent mechanism. Subsequently, the 
phosphorylated MOPr recruits arrestins which leads to receptor internalisation. 
Another desensitisation pathway for MOPr is heterologous desensitisation, which 
can be mediated by second messenger-dependent protein kinases such as PKC 
(Illing, Mann & Schulz 2014). It has been known for some time that the MOPr 
internalisation and desensitisation mechanisms are determined partially by the 
agonist (Johnson, EA et al. 2006). For example, DAMGO and etorphine, which are 
high efficacy MOPr agonists, induce significant receptor desensitisation mediated 
by a GRK-arrestin mechanism (Groer et al. 2011). Thus, they induce extensive 
receptor internalisation. However, morphine, a partial MOPr agonist, induces 
desensitisation, which is mediated in part by PKC and induces little internalisation, 
at least in HEK293 cells (McPherson et al. 2010). Therefore, the activity of GRKs 
plays a pivotal role in determining the GPCR desensitisation and internalisation. 
Thus, we also explored the effect of cmpd101 on the internalisation of MOPr upon 
stimulation with MOPr agonist, using an ELISA technique.  
 
Another important opioid receptor is the δ opioid receptor (DOPr), whose sequence 
is closely related to MOPr, but has distinct physiological and pharmacological 
properties (Al-Hasani & Bruchas 2011; Gendron et al. 2015). We focused on MOPr 
and DOPr as examples of GPCRs and because they are important targets for the 
treatment of moderate to severe pain (Evans 2004; Williams et al. 2013). 
Accordingly, we thought it useful to study the effect of cmpd101 on agonist-induced 
arrestin-3 recruitment to both MOPr and DOPr. This chapter will address a number 
of basic background experiments to provide data for comparison with that in later 
chapters, for example, the actions of cmpd101 to compare to the novel GRK 
inhibitors to be tested later.  The experiments would also provide information on the 




3.2 Results  
3.2.1 Agonist-induced Arrestin-3 Recruitment to MOPr and DOPr 
Firstly, the expression of the GFP construct Arr3-GFP was assessed to get some 
idea of the efficiency of the transient transfection. Accordingly, the expression of 
Arr3-GFP in transfected HEK293 cells was determined using fluorescence 
activating cell sorting (FACS, the actual analysis was undertaken by Faculty of Life 
Science flow cytometry facility, University of Bristol led by Dr. Andy Herman); the 
results are shown in Figure 3.1. This FACS analysis indicated that GFP- positive 
cells represented about 22% of the whole cells compared to the untransfected cells 
(Figure 3.1, A & C). For BRET experiments, the recruitment of arrestin-3 to the MOPr 
or DOPr was assessed in HEK293 cells expressing human MOPr-RLuc2 or DOPr-
RLuc2 and Arr3-GFP. An increase in the BRET ratio is an indication of the arrestin 
coming into close proximity to the receptor, i.e., being recruited. As a control, we 
transfected HEK293 cells with MOPr-RLuc2 only and compared it to HEK293 cells 
expressing human MOPr-RLuc2 and Arr3-GFP, as shown in Figure 3.2. DMSO was 
the vehicle and was used at a final concentration of 0.3% for all BRET assays. This 
concentration of DMSO had no effect on DAMGO-induced arrestin-3 recruitment, 
as shown in Figure 3.2A. Concentration-response curves for agonist-induced 
arrestin-3 recruitment to MOPr or DOPr are shown in Figures 3.3 and 3.4.  
 
DAMGO appeared to be a full agonist in the arrestin-3 assay with an EC50 of 0.84 ± 
0.35 µM and Emax of 2,085 ±163 (BRET ratio; no units), as shown in Figure 3.3B. 
However, this response to DAMGO was completely absent in HEK293 cells 
expressing MOPr-RLuc2 without arrestin-3 (Figure 3.2B). Morphine was a partial 
agonist compared to DAMGO with an EC50 of 1.30 ± 0.36 µM and Emax of 603 ± 50 
(BRET ratio) (Figure 3.3B). We next investigated the activity of SNC80 and DADLE, 
DOPr agonists, using HEK293 cells cotransfected with DOPr. The results showed 
that SNC80 induced a high maximal level of arrestin-3 recruitment with an EC50 of 
0.52 ± 0.10 µM and Emax of 5,112 ± 475 (BRET ratio) as compared to DADLE with 




To further investigate the responses to DAMGO and morphine at MOPr, we 
undertook time-course experiments for both agonists. The responses were 
measured by BRET and, after 3 min of the beginning of the recording, the cells were 
stimulated with maximal concentrations (for arrestin-3 recruitment) of DAMGO (10 
µM) or morphine (30 µM). Each agonist stimulated the peak arrestin-3 recruitment 
after around 1 min of stimulation and the response then remained level over the 
following 16 min, the duration of the experiment (Figure 3.5). In some experiments, 
naloxone (10 µM), a MOPr antagonist, was added after 4 min of the agonist 
stimulation. The responses of DAMGO and morphine were rapidly and completely 
blocked by naloxone (Figure 3.5).  
 
GRKs play a crucial role in GPCR desensitisation and are involved in other 
downstream signal pathways. Whilst we do not have the tool for measuring GRK 
phosphorylation, we used an arrestin-3 recruitment assay instead. We next studied 
the effect of cmpd101 on arrestin-3 recruitment using the BRET arrestin-3 assay. 
Cmpd101 concentration-dependently reduced DAMGO-induced (10 µM) arrestin-3 
recruitment to MOPr, as well as SNC80-induced (10 µM) arrestin-3 recruitment to 
DOPr by a maximum of around 60% and 50% with an IC50 8.0 ± 3.5 µM and 5.8 ± 
0.9 µM, respectively (Figure 3.6, A and B). To further study the kinetics of cmpd101 
inhibition of arrestin-3 recruitment to MOPr, we undertook a time-course experiment. 
HEK293 cells were incubated with cmpd101 (100 µM) for 30 min and then 
stimulated with DAMGO (10 µM) for 10 min. Figure 3.7A shows that preincubation 
with cmpd101 strongly inhibited DAMGO-induced arrestin-3 recruitment for the 
period of the experiment. In addition, we investigated the rate at which cmpd101 is 
able to inhibit established DAMGO-induced arrestin-3 recruitment. Cells were 
stimulated with DAMGO (10 µM) and responses measured by BRET; 4 min later, 
cmpd101 (30 µM) was added. The results (Figure 3.7B) showed that cmpd101 
inhibited DAMGO-induced arrestin-3 recruitment relatively rapidly following the 
addition of cmpd101 and reached the maximum inhibition (~60%) after around 10 
min (Figure 3.7B). We also undertook a time-course experiment to investigate the 
kinetics of cmpd101 inhibition of arrestin-3 recruitment to DOPr. HEK293 cells were 
incubated with cmpd101 (30 µM) for 30 min and then stimulated with SNC80 (10 
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µM) for 10 min. Figure 3.8 shows that preincubation of cmpd101 inhibited SNC80-
induced arrestin-3 recruitment by around 50% for the period of the experiment. 
 
We further investigated whether the inhibition of arrestin-3 recruitment to MOPr or 
DOPr would be different when employing different MOPr or DOPr agonists. To 
determine this, HEK293 cells expressing MOPr or DOPr were preincubated with 
cmpd101 at 30 or 100 µM and were then stimulated with the MOPr agonists; 
DAMGO (10 µM) or morphine (30 µM), or the DOPr agonists; SNC80 (10 µM) or 
DADLE (10 µM), designed to produce maximal arrestin-3 recruitment for that 
agonist. As expected, the maximum arrestin-3 recruitment induced by morphine was 
significantly lower than that of DAMGO (Figure 3.9A). Cmpd101 at 30 and 100 µM 
showed similar maximal inhibition (approximately 65%) of DAMGO-induced 
arrestin-3 recruitment to MOPr (Figure 3.9, A and B). SNC80-induced arrestin-3 
recruitment to DOPr was also inhibited by cmpd101 (maximum approximately 50%) 
(Figure 3.10, A, B and C). On the other hand, cmpd101 inhibited DADLE-induced 
arrestin-3 recruitment by only about 33% (Figure 3.10D). Surprisingly, cmpd101 at 
30 or 100 µM did not significantly inhibit morphine-induced arrestin-3 recruitment, 





Figure 3.1  Detection of GFP by flow cytometry. 
HEK293 cells were transiently transfected with Arr3-GFP (C, D) whilst untransfected (GFPˉ) cells 
(A, B) were used as control. They gated based on forward scatter (FSC-H) and FITC 
fluorescence. Wild type HEK293 cells showed no signal for GFP+ cells (A and B) whilst GFP 
transfected cells showed 22% of the total cells (C and D). The FACS analysis was carried out 






Figure 3.2  Log concentration-response curve for DAMGO-induced arrestin-3 recruitment 
to MOPr. 
A) The effect of (or lack of) different concentrations of DMSO on DAMGO-induced arrestin-3 
recruitment to MOPr. HEK293 cells were transiently transfected with MOPr-RLuc2 and Arr3-
GFP, cells were then pretreated with 0.1, 0.3, or 1% DMSO for 30 min. Cells were then stimulated 
with DAMGO (10 µM) for a further 10 min. B) HEK293 cells were transiently transfected with 
MOPr-RLuc2 and Arr3-GFP (●) or MOPr-RLuc2 alone (○). Cells were then stimulated with 
DAMGO (0.01- 30 µM) for 10 min.  DAMGO-induced arrestin-3 recruitment to MOPr was 
measured by BRET assay. ns, not statistically different, one-way ANOVA. Data were fitted to a 
four-parameter non-linear regression model for a sigmoidal curve with variable slope (slope = 





Figure 3.3  Log concentration-response curves of DAMGO- and morphine-induced 
arrestin-3 recruitment to MOPr. 
HEK293 cells were transfected with MOPr-RLuc2 and Arr3-GFP and incubated with DAMGO 
(10 µM, ●) or morphine (30 µM, ○) for 10 min and Arr3-GFP recruitment and subsequent BRET 
measurements taken. Data were plotted with the basal values included (A) or following 
subtraction of the basal value (B) and fitted to a four-parameter non-linear regression model for 
a sigmoidal curve with variable slope (slope = 0.95 ± 0.6 for DAMGO and 1.2 ± 0.3 for morphine). 





Figure 3.4  Log concentration-response curves of SNC80- and DADLE-induced arrestin-3 
recruitment to DOPr. 
HEK293 cells were transfected with DOPr-RLuc2 and Arr3-GFP and incubated with SNC80 (10 
µM, ●) or DADLE (10 µM, ■) for 10 min and Arr3-GFP recruitment and subsequent BRET 
measurements taken. Data were plotted with the basal value included (A) or (B) following 
subtraction of the basal value and fitted to a four-parameter non-linear regression model for a 
sigmoidal curve with variable slope (slope = 1.2 ± 0.3 for SNC80 and 1.1 ± 0.1 for DADLE). Data 






Figure 3.5  Time course of DAMGO- and morphine-induced arrestin-3 recruitment to MOPr 
and effects of naloxone. 
HEK293 cells were transiently transfected with MOPr-RLuc2 and Arr3-GFP and stimulated with 
DAMGO (10 µM) or morphine (30 µM) and Arr3 recruitment to MOPr measured by BRET assay. 
Kinetic traces after DAMGO or morphine stimulation at 3 min (●) and followed by the addition of 
10 µM naloxone at 7 min (○). The BRET ratio of vehicle-treated cells was subtracted from 
agonist-stimulated values and the data are presented as mean ± SEM of non-normalised results 
from four independent experiments. * P < 0.05 DAMGO compared to no naloxone treatment at 
the same time point, # P < 0.05 morphine compared to no naloxone treatment at the same time 
point; two-way ANOVA followed by Tukey post hoc test for multiple comparisons. 
 
To further investigate morphine-induced arrestin-3 recruitment to MOPr, we 
undertook a time-course experiment. Cmpd101 (100 µM) was added at 4 min after 
stimulation of the cells with morphine (30 µM) (Figure 3.11). As above, the results 
indicated that cmpd101 does not inhibit morphine-induced arrestin-3 recruitment 




We observed an increase in arrestin-3 recruitment in the presence of 100 µM 
cmpd101 when applied on its own. Therefore, we used cmpd101 at 30 µM in the 
majority of further experiments. We also used 10 µM DAMGO and 30 µM morphine 
as these concentrations produce maximum BRET readings for these agonists. 
Furthermore, we measured arrestin-3 recruitment at 10 min after agonist stimulation 
for all BRET assays as this provided a stable signal at this point. 
 
To rule out the possible involvement of various cell kinases associated with 
signalling (e.g., PKC, JNK, ERK1/2 and CaMKII) in agonist-induced arrestin-3 
recruitment to MOPr, we pretreated HEK293 cells with kinase inhibitors. These 
kinase inhibitors were GF109203X (1 µM, a PKC inhibitor), SP600125 (30 µM, a 
JNK inhibitor), PD998059 (10 µM, an ERK1/2 inhibitor), or KN-93 (1 µM, a CaMKII 
inhibitor) as well as cmpd101 (30 µM) as a positive control, and then cells were 
stimulated with DAMGO (10 µM) (Lowe et al. 2015; Rezazadeh, Claydon & Fedida 
2006). We did not observe any significant inhibitory effect on DAMGO-induced 
arrestin-3 recruitment in the presence of the PKC, JNK, ERK1/2 and CaMKII 
inhibitors (Figure 3.12). In addition, none of the kinase inhibitors applied on their 






Figure 3.6 Concentration-dependent inhibition of DAMGO- and SNC80-induced arrestin-3 
recruitment to MOPr and DOPr by cmpd101. 
HEK293 cells were transiently transfected with MOPr-RLuc2 (A) or DOPr-RLuc2 (B) and Arr3-
GFP. Cells were preincubated with cmpd101 (0.1-100 µM) for 30 min and then stimulated with 
(A) DAMGO (10 µM) or (B) SNC80 (10 µM) for 10 min and Arr3-GFP recruitment was measured 
by BRET assay. Data were fitted to a non-linear regression model with three parameters. Data 






Figure 3.7 Inhibition of DAMGO-induced arrestin-3 recruitment by addition of cmpd101. 
A) Time course of DAMGO-induced arrestin-3 recruitment in the absence (●) or presence of   
cmpd101 (100 µM, ○). HEK293 cells expressing MOPr-RLuc2 and Arr3-GFP were preincubated 
with cmpd101 (100 µM) for 30 min and then stimulated with DAMGO (10 µM) for 10 min and the 
BRET measurements were taken every 2 minutes for up to 16 min. (B) HEK293 cells expressing 
MOPr-RLuc2 and Arr3-GFP were stimulated with DAMGO (10 µM) for 4 min before the addition 
of cmpd101 (30 µM) and then BRET measurements were taken every 2 minutes for up to 16 
min. The BRET ratio of nontreated cells at time zero was subtracted. Data are presented as 
mean ± SEM from four independent experiments performed in duplicate. (A) * P < 0.05 vs 
DAMGO at the same time point, two-way ANOVA followed by Bonferroni post hoc test; (B) * P < 







Figure 3.8 Inhibition of SNC80-induced arrestin-3 recruitment by addition of cmpd101. 
Time course of SNC80-induced arrestin-3 recruitment in the absence (●) and in the presence of 
cmpd101 (30 µM, ○). HEK293 cells expressing DOPr-RLuc2 and Arr3-GFP were preincubated 
with cmpd101 (30 µM) for 30 min and then stimulated with SNC80 (10 µM) for 10 min in the 
continued presence of vehicle or cmpd101, and the BRET measurements were taken every 2 
minutes for up to 16 min. The BRET ratio of nontreated cells at time zero was subtracted. Data 
are presented as mean ± SEM from three independent experiments performed in duplicate. * P 





Figure 3.9 Effect of different concentrations of cmpd101 on DAMGO- and morphine-
induced arrestin-3 recruitment to MOPr. 
HEK293 cells expressing MOPr-RLuc2 and Arr3-GFP were preincubated with cmpd101 (30 µM) 
(A) or (100 µM) (B) for 30 min and cells then stimulated with DAMGO (10 µM) or morphine (30 
µM) for 10 min and the BRET signals recorded.  The BRET ratio of nontreated cells was 
subtracted. Data are presented as mean ± SEM from four independent experiments performed 
in duplicate. * P < 0.05, one-way ANOVA followed by Tukey post hoc test for multiple 





Figure 3.10  Effect of cmpd101 on SNC80- and DADLE-induced arrestin-3 recruitment to 
DOPr. 
HEK293 cells expressing DOPr-RLuc2 and Arr3-GFP were preincubated with cmpd101 (30 µM) 
(A) or (100 µM) (B) for 30 min and cells were then stimulated with SNC80 (10 µM) or DADLE (10 
µM) for 10 min and the BRET signal recorded.  The BRET ratio of nontreated cells was 
subtracted. Data are presented as mean ± SEM from four independent experiments performed 
in duplicate. * P < 0.05, one-way ANOVA followed by Tukey post hoc test for multiple 





Figure 3.11 Effect of cmpd101 on morphine-induced arrestin-3 recruitment to MOPr 
 
HEK293 cells expressing MOPr-RLuc2 and Arr3-GFP were stimulated with morphine (30 µM) 
for four minutes before the addition of cmpd101 (100 µM), and the BRET measurements taken 
every 2 minutes for a further 16 min. The BRET ratio of nontreated cells was subtracted. Data 
are presented as mean ± SEM from four independent experiments performed in duplicate. ns, 





Figure 3.12 Lack of effect of various kinase inhibitors on DAMGO-induced arrestin-3 
recruitment to MOPr 
HEK293 cells expressing MOPr-RLuc2 and Arr3-GFP were preincubated with a PKC inhibitor 
(GF109203X, 1 µM), a JNK inhibitor (SP600125, 30 µM), an ERK1/2 inhibitor (PD998059, 10 
µM), or a CaMKII inhibitor (KN-93, 1 µM), for 30 min before the addition of DAMGO (10 µM) or 
media for a further 10 min.  The BRET ratio of no agonist-treated cells was subtracted. Data are 
presented as mean ± SEM of non-normalised results from four independent experiments 
performed in duplicate.  * P < 0.05 compared to DAMGO or DAMGO + DMSO; cmpd101 
statistically significant inhibits DAMGO-induced arrestin-3 recruitment; ns, not statistically 
significant compared to DAMGO + DMSO or DAMGO alone, one-way ANOVA followed by Tukey 
post hoc test for multiple comparisons; NS, not statistically significant vs DMSO, one-way 





3.2.2 Effect of cmpd101 on DAMGO-induced G Protein Activation at MOPr 
To investigate the effect of cmpd101 on the Gi activation and to determine the 
selectivity of cmpd101 towards arrestin/G protein pathway, agonist-induced Gi 
protein activation was measured in HEK293 cells expressing HA-MOPr using a 
BRET assay. DAMGO concentration-response curves were constructed in cells 
expressing MOPr in order to determine its potency and to determine whether 
cmpd101 had any effect on DAMGO-induced G protein signalling (Figure 3.13). The 
results showed that DAMGO induced Gi activation, with an EC50 of 0.40 ± 0.01 µM 
(Figure 3.13). In HEK293 cells pretreated with 30 µM cmpd101, the maximum 
response was not significantly changed from DAMGO-treated cells without 
cmpd101 (Figure 3.13). However, cmpd101 pretreated cells displayed a three-fold 
right shift of the curve (Figure 3.13), the DAMGO EC50 value was significantly 
different (P < 0.05) between cells with DAMGO and cmpd101 (1.20 ± 0.26 μM) and 
DAMGO-only treated cells (0.40 ± 0.01 µM) (Figure 3.13).  
 
3.2.3 Effect of cmpd101 on Agonist-induced Cell Surface Loss of MOPr 
Agonist-induced MOPr internalisation was measured by ELISA as described in 
Chapter 2, Section 2.2.6. HEK293 cells were treated with DAMGO (10 µM), a full 
MOPr agonist, or morphine (30 µM), a partial MOPr agonist, to induce surface 
receptor loss, which was measured by ELISA. The time course of internalisation 
induced by DAMGO (10 µM) is shown in Figure 3.14A. DAMGO produced a time-
dependent loss of surface receptor, with a 22% loss of surface receptor at 30 min 
(Figure 3.14A). DAMGO induced surface receptor loss with an EC50 of 3.3 ± 1.0 µM 
and Emax of 35.2 ± 1.5 % (Figure 3.14B). Morphine induced negligible internalisation 
(Figure 3.15). We assumed that DAMGO reached the maximum of receptor 
internalisation at 30 min, which was not statistically significantly different from 
receptor loss at 60 min; thus, we used this time point (30 min) to construct a DAMGO 
concentration-response curve for MOPr surface receptor loss (Figure 3.14B). 
 
To investigate the effect of cmpd101 on DAMGO-induced surface receptor loss, 
HEK293 cells expressing HA-MOPr were pretreated with cmpd101 (30 µM) for 30 
min and then stimulated with DAMGO (10 µM) for a further 30 min. The addition of 
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cmpd101 on its own did not affect MOPr internalisation, as shown in Figure 3.15. 
However, cmpd101 significantly reduced DAMGO-induced MOPr internalisation by 





Figure 3.13 Effect of cmpd101 on Gi activation induced by DAMGO at MOPr. 
HEK293 cells were transiently transfected with HA-MOPr, Gαi-RLuc2 and Gγ-GFP. Cmpd101 (30 
µM) (○) was added 30 min before the addition of DAMGO (10 µM) for two minutes. DAMGO-
induced BRET ratios were expressed as the percentage decrease from nontreated cells. Data 
were fitted to a non-linear regression model with three parameters. ns; not statistically significant, 
one-sample Student’s t-test. Data are presented as mean ± SEM from four independent 





Figure 3.14 DAMGO-induced MOPr cell surface loss. 
HEK293 cells were transiently transfected with HA-MOPr and were stimulated with DAMGO (10 
µM) for up to 60 min at 37°C. The cell surface receptor expression was measured by ELISA. (A) 
Time course of DAMGO-induced internalisation of MOPr. (B) Concentration-response of 
DAMGO-induced internalisation of MOPr at 30 min. Data were fitted to a non-linear regression 
model with four parameters using GraphPad Prism software. The minimum response was 
constrained to zero. Data are presented as mean ± SEM of four independent experiments 
performed in triplicate. * P < 0.05 vs time zero, one-way ANOVA followed by Tukey post hoc test 





Figure 3.15 Inhibition of DAMGO-induced MOPr internalisation by cmpd101. 
HEK293 cells were transiently transfected with HA-MOPr and were pretreated with cmpd101 
(30 µM) or DMSO (where is indicated in the graph) for 30 min and then were stimulated with 
DAMGO (10 µM) or morphine (30 µM) for 30 min in the continued presence of cmpd101 or 
vehicle at 37°C. The cell surface receptor expression was measured by ELISA. Data are 
presented as mean ± SEM of four independent experiments performed in triplicate. Statistical 
analysis was performed by one-way ANOVA followed by Tukey post hoc test for multiple 
comparisons (* P < 0.05, compared to control; # P < 0.05, compared to DAMGO; ns, not 






In this chapter, HEK293 cells expressing MOPr-RLuc2 or DOPr- RLuc2 and Arr3-
GFP were used to study arrestin-3 recruitment to the receptor, measured by BRET 
assay. The ratio of MOPr-RLuc2 or DOPr-RLuc2 to Arr3-GFP (1:1) was determined 
previously in our laboratory where a fixed amount of MOPr-RLuc2 or DOPr-RLuc2 
(a donor) was coexpressed with an increasing amount of Arr3-GFP (an acceptor) to 
determine the plateau of the donor saturation. The FACS results (Figure 3.1) 
showed that the GFP positive cells represented 22% of the transfected cells, which 
was somewhat less than expected, but was more than adequate to perform the 
BRET experiments in this thesis. We investigated two MOPr agonists, DAMGO, a 
full agonist, and morphine, a partial agonist and how they affect arrestin-3 
recruitment to MOPr. We used another important opioid receptor, DOPr, to compare 
it with MOPr data and to widen our understanding of the effect of cmpd101 on the 
function of a different receptor. Also, we determined the ability of cmpd101, a 
GRK2/3 inhibitor, to inhibit agonist-induced arrestin-3 recruitment. We also 
measured agonist-induced Gi activation and the effects of cmpd101 on this, and 
finally, the agonist-induced internalisation of MOPr was measured in HEK293 cells 
using ELISA.  
 
HEK293 cells are widely used in biomedical research because they are easy to 
grow, maintain and to transfect (Gharagozlou et al. 2003; Hill et al. 2018; Manglik et 
al. 2016). The BRET assay was chosen to measure the arrestin-3 recruitment to 
MOPr and DOPr in HEK293 cells because it is sensitive and is a relatively high 
throughput assay (El Khamlichi et al. 2019).  
 
The results of BRET assay for arrestin-3 recruitment confirmed that DAMGO is likely 
to be a full agonist at MOPr compared to morphine which is a partial agonist. 
Similarly, SNC80 appeared to be a full agonist at DOPr and DADLE is a partial 
agonist. These findings align with previously published studies (Groer et al. 2011; 
Miess et al. 2018), as well as previous results from this laboratory (Conibear et al. 
2020; Hill et al. 2018; McPherson et al. 2010; Sutcliffe et al. 2017). The addition of 
naloxone completely reversed the DAMGO-induced arrestin-3 recruitment to MOPr. 
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This indicates that arrestin-3 recruitment requires ongoing receptor activation, which 
is blocked by naloxone.  
 
Cmpd101 at 30 and 100 µM similarly inhibited DAMGO-induced arrestin-3 
recruitment to MOPr or SNC80-induced arrestin-3 recruitment to DOPr. However, 
we did not observe full inhibition of DAMGO or SNC80-induced arrestin-3 
recruitment, being around 60% and 50%, respectively. One possibility that another 
GRK isoform/s involved in the receptor phosphorylation (e.g., GRK5/6) (Li, J et al. 
2003) is not inhibited by cmpd101 and, thus, some phosphorylation and arrestin 
recruitment can take place.  Another possible explanation is that arrestin-3 
recruitment may depend on the active conformation of the receptor as well as on 
the GRK-mediated phosphorylation of the receptor. There are also studies 
suggesting that PKC activation is involved in morphine desensitisation and 
tolerance (Levitt & Williams 2012; Yousuf et al. 2015). These possibilities could 
explain why cmpd101 at 30 and 100 µM did not affect morphine-induced arrestin-3 
recruitment. Also, it can be explained that proportion of morphine-induced arrestin-
3 recruitment to MOPr is due to interaction with the active state of the receptor, as 
opposed to the GRK phosphorylation of the receptor. Under these conditions, 
cmpd101 might be less effective. Also, morphine may recruit a different GRK (e.g., 
GRK5) which is not inhibited by cmpd101 (Doll et al. 2012). 
 
Cmpd101 at 1 µM in a cell-free system has been reported to inhibit a small number 
of non-GRK kinases by more than 50%, including protein kinase C-related protein 
kinase (PRK2), mitogen- and stress-activated kinases (MSK1), serum and 
glucocorticoid-related kinase (SGK1), ribosomal S6 kinase 1 (S6K1), and p90 
ribosomal protein S6 kinase (RSK1) (Lowe et al. 2015). Additionally, the same study 
reported that cmpd101 at 1 µM inhibited PKC, ERK1/2, JNK and CaMKII by less 
than 20% (Lowe et al. 2015). While these kinase inhibitors are widely used, we 
observed that these kinases, often associated with receptor cell signalling, did not 
affect DAMGO-induced arrestin-3 recruitment to MOPr in HEK293 cells (Figure 
3.12), which indicates that arrestin-3 recruitment is independent of PKC, ERK1/2, 
JNK or CaMKII activity in our BRET assay. It should however be acknowledged that 
we did not provide positive controls for the effects of these kinase inhibitors, 
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however the effectiveness of such inhibitors has previously been widely 
demonstrated. 
 
DAMGO-induced Gi activation in HEK293 cells was measured by BRET assay, with 
DAMGO-induced Gi activation indicated by a decrease in the BRET signal. A 
decrease in the BRET signal indicates the dissociation of Gα and Gβγ. Pretreatment 
of the cells with cmpd101 (30 µM) led to a three-fold rightward shift of the curve, 
indicating a reduction in the potency of DAMGO. However, the maximum response 
of DAMGO upon addition of cmpd101 was not reduced. The crystallisation of GRK2 
with Gβγ revealed that the pleckstrin homology (PH) domain of GRK2 binds to the 
Gβγ subunit (Lodowski et al. 2003). This binding contributes to the recruitment of 
GRK2 to the plasma membrane where GRK2 can phosphorylate the agonist-
activated receptor and recruit arrestins. Ultimately, arrestin binding blocks G 
proteins signalling (Gurevich, V. V. & Gurevich 2019; Li, J et al. 2003). It is possible 
that cmpd101 could affect the fucnction of the Gβγ subunits of the heterotrimeric G 
protein. GRK2 could facilitate the orientation of G protein with the receptor and when 
GRK2 is inhibited it partly disrupt the ability of GRK2  to facilitate the interaction of 
the G protein with the receptor. Hence, a small inhibition of Gi activation could be 
observed. Apart from an indirect effect of cmpd101 via GRK2, a direct inhibitory 
effect of cmpd101 or the other inhibitors on G protein function cannot be excluded. 
 
Cmpd101 is a commercially available selective small molecule inhibitor of GRK2 
and GRK3 (Thal et al. 2011). It has been reported to be selective for GRK2 and 
GRK3 with an IC50 of 35 nM (Ikeda, S, Keneko & Fujiwara 2007) and 290 nM (Thal 
et al. 2011) in different in vitro assays. Also, cmpd101 has no significant inhibitory 
activity at  GRK1 or GRK5 at concentrations up to 125 µM in a purified enzyme 
assay (Thal et al. 2011). In HEK293 cells, cmpd101 inhibits DAMGO-induced 
arrestin-3 recruitment to MOPr with an IC50 value of 8 ± 3.5 µM. Cmpd101 has been 
used since then as a selective GRK2/3 inhibitor in different biochemical assays 
(Abraham et al. 2018; Jung et al. 2016; Lowe et al. 2015). To the best of our 
knowledge, no study has conducted a thorough investigation of the selectivity of 
cmpd101 in different assay conditions apart from that of Thal et al. (2011). The 
finding that cmpd101 affected the DAMGO-induced Gi activation in our study (Figure 
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3.13) raised questions regarding the selectivity of cmpd101. This finding supports 
the previous results that cmpd101 partially inhibits agonist-induced desensitisation 
in LC neurons (Lowe et al. 2015). Moreover, a recent study conducted on prostate 
smooth muscle has shown that cmpd101 (50 µM) failed to inhibit the agonist-
induced phosphorylation state of β2AR, which is phosphorylated and desensitised 
by GRK2 (Yu et al. 2018). In the same study, the author concluded that cmpd101 
inhibited agonist-induced contraction in prostate smooth muscle by a GRK-
independent mechanism (Yu et al. 2018). However, in human uterine smooth 
muscle cells (ULTR), Rainbow et al. (2018) reported that cmpd101 (30 µM) partially 
inhibited GRK2-medited histamine H1 receptor desensitisation. This discrepancy 
could be attributed to the different cell types used. Collectively, these studies 
suggested that cmpd101 (and presumably the other experimental compounds used) 
may have off-target effects and the results should be interpreted with caution when 
using different cell lines and conditions.  
 
The internalisation of HA-MOPr was assessed by ELISA using an anti-HA antibody 
to label surface receptors. DAMGO (10 µM) induced time-dependent loss of 
receptor surface, whereas morphine did not induce significant MOPr internalisation. 
These results are consistent with previously published data from this laboratory 
(Johnson, EA et al. 2006; McPherson et al. 2010). DAMGO-induced MOPr 
internalisation reaches a steady state at 30 min, which is not different from that at 
60 min (22% and 25%, respectively). Previous studies have reported that agonist-
induced MOPr internalisation reaches the maximum at 30 min which is thought to 
involve recycling MOPr back to the plasma membrane (Alvarez et al. 2002; Minnis 
et al. 2003). Cmpd101 significantly reduced DAMGO-induced MOPr internalisation. 
This result may be explained by the ability of cmpd101 to inhibit GRK function (Lowe 
et al. 2015; Thal et al. 2011). DAMGO has been shown to induce phosphorylation 
at both Thr370 and Ser375 on the C-terminus of MOPr while morphine induces 
relatively weak phosphorylation at  Ser375 only (Doll et al. 2011; Gluck et al. 2014; 
Just et al. 2013).  DAMGO-induced phosphorylation at Ser375 is mediated by GRK2 
and GRK3; however, morphine-induced phosphorylation at Ser375 appears to be 
mediated at least in part by GRK5 (Doll et al. 2012). A prior study showed that 
cmpd101 inhibited DAMGO-induced phosphorylation at Ser375 and, thus, inhibited 
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receptor internalisation in HEK293 cells (Lowe et al. 2015). Furthermore, the Ser375 
residue is believed to be the initial site on the C-terminus of MOPr for agonist-
induced phosphorylation and then phosphorylation of the flanking residues, Thr370, 
Thr376 and Thr379 ((Lau et al. 2011; Lowe et al. 2015; Miess et al. 2018). This also 
accords with other observations, which showed that isoproterenol, a full agonist at 
β2 adrenoreceptor (β2AR), has been shown to increase phosphorylation levels of 
the established multiple 13 β2AR phosphorylation sites (Nobles et al. 2011). On the 
other hand, carvedilol increased the phosphorylation levels of only Ser355 and Ser356 
(Nobles et al. 2011). These findings support the notion that different agonists induce 
different phosphorylation patterns of GPCRs. Thus, cmpd101 was able to inhibit 
DAMGO-induced internalisation of MOPr due to inhibition of GRK isoforms that 
involved in the phosphorylation of Ser375 (Miess et al. 2018). 
 
3.4 Conclusion 
In this chapter, we have described the effect of cmpd101 on agonist-induced 
arrestin-3 recruitment to MOPr and DOPr. In HEK293 cells, DAMGO, a full MOPr 
agonist, and SNC80, a full DOPr agonist, induce high levels of arrestin-3 recruitment 
while morphine, a partial MOPr agonist, and DADLE, a partial DOPr agonist, show 
less arrestin-3 recruitment. In addition, we have investigated the effect of cmpd101, 
a proposed GRK2/3 inhibitor, on arrestin-3 recruitment to MOPr and DOPr upon 
addition of MOPr agonists (DAMGO or morphine) or DOPr agonists (SNC80 or 
DADLE). Cmpd101 inhibits DAMGO- or SNC80-induced arrestin-3 recruitment by 
about 60% and 50%, respectively, while it inhibits DADLE-induced arrestin-3 
recruitment by 33%. However, it failed to inhibit morphine-induced arrestin-3 
recruitment. The ability of the cmpd101 to inhibit arrestin-3 recruitment appears to 
be governed by the agonist employed.  
 
I also have determined the effect of cmpd101 on Gi activation. I have demonstrated 
that cmpd101 can inhibit DAMGO-induced Gi activation. Finally, the internalisation 
of MOPr in response to DAMGO and morphine has been investigated. It is well-
established that morphine induces much less MOPr internalisation in comparison 
with DAMGO, which induces robust internalisation. Cmpd101 greatly inhibits 
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DAMGO-induced MOPr internalisation in HEK293 cells. Our data, therefore, confirm 
the role of GRKs in mediating agonist-induced MOPr internalisation.  
 
These findings contribute to the existing knowledge of GRK inhibitor, cmpd101, by 
providing new evidence of the use of cmpd101 in the cell-based settings. The results 
demonstrate that cmpd101 gives the opportunity to study the roles of GRKs in opioid 
receptors (MOPr and DOPr) and other GPCRs signalling. 
 
In the next chapter, I will examine the utility of novel GRK inhibitors to determine 
their effects on the arrestin-3 recruitment to MOPr and DOPr and to compare their 




CHAPTER 4 Effect of Novel Compound101 







Several small molecule inhibitors for GRKs, particularly GRK2, have been reported. 
Polyanionic and polycationic compounds, such as heparin, were the first to be 
reported to have inhibitory activity on GRK2 (Benovic et al. 1989). Since the 
crystallisation of human GRK2 with the natural product balanol (Tesmer, JJ et al. 
2010), the search for selective GRK2 inhibitors has been focused on the ATP 
binding site in the GRK (Murga et al. 2019). Balanol inhibits GRK2 with an IC50 of 
50 nM, but it also inhibits PKA with an IC50 of 110 nM (Tesmer, JJ et al. 2010). 
Paroxetine (Figure 4.1), an FDA-approved serotonin selective reuptake inhibitor 
(SSRI), has modest inhibitory activity against GRK2 (IC50 =1.1 µM) and is more than 
6-fold selective over other GRK isoforms (Thal et al. 2012). The Takeda compounds, 
cmpd101 (Table 4.1) and cmpd103 were reported to be somewhat selective for the 
GRK2/3 subfamily, although they did not proceed to clinical trials because of their 
limited bioavailability (Ikeda, S, Keneko & Fujiwara 2007; Okawa et al. 2017). 
Recently, a compound derived from paroxetine (CCG258747) (Figure 4.1) was 
developed that showed potent inhibition of GRK2 (IC50= 0.018 µM) and modest 
inhibition of GRK1 and GRK5 with IC50 values of 9.3 and 1.5 µM, respectively 
(Bouley, RA et al. 2020).   CCG258747 also inhibited ROCK1 with an IC50 of 27 µM 
(Bouley, RA et al. 2020). 
 
Understanding the structure and functions of GRKs will facilitate the development 
of potent and selective GRK inhibitors. Also, developing a selective inhibitor for 
individual GRKs/ or subfamilies is a critical step that could be used in advancing the 
therapy of diseases where GRKs may play a role. Furthermore, inhibitors of GRK 
phosphorylation of opioid receptors could represent drugs that suppress tolerance, 
a common problem observed with the use of opioid receptor agonists. Finally, 
selective GRK inhibitors will be important to explore the physiological function of 
these kinases in living systems. 
 
In this chapter, I will study the ability of the novel compounds (Table 4.1), analogues 
of cmpd101, to inhibit GRK/s, principally by assessing their ability to inhibit agonist-
induced arrestin-3 recruitment to µ and δ opioid receptors. In addition, to further 
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explore the selectivity of theses analogues in cell signalling, I will investigate their 
effect on both agonist-induced Gi activation and MOPr internalisation. In these 
experiments, cmpd101 will serve as a standard GRK inhibitor, in order to compare 
its activity with that of the novel compounds. 
 
 
Figure 4.1 Structures of paroxetine and CCG258747 





Table 4.1  Chemical structures of cmpd101 and novel analogues 
 
 






4.2.1 Effect of the Novel Compounds on Agonist-induced Arrestin-3 
Recruitment to MOPr and DOPr 
The novel compounds were screened as well as cmpd101 (a standard GRK 
inhibitor) at 30 and 100 µM using the BRET arrestin-3 recruitment assay. The novel 
compounds were initially tested at 100 µM, to observe as maximum an effect if 
possible. I compared the ability of these novel compounds to inhibit both DAMGO- 
and morphine-induced arrestin-3 recruitment to MOPr. DAMGO is a high efficacy 
peptide agonist at MOPr, whilst morphine is a lower efficacy non-peptide agonist 
and is, of course, widely used clinically. In further experiments, their effects on 
agonist-induced arrestin-3 recruitment to another opioid GPCR receptor, the δ 
receptor (DOPr), was investigated. For these experiments, the high efficacy 
agonists: SNC80 and DADLE were employed, with both being high efficacy 
agonists, but SNC80 being a synthetic agonist and DADLE a peptide (Conibear et 
al. 2020).  
 
At a concentration of 100 µM, most of the inhibitors reduced DAMGO-induced (10 
µM) arrestin-3 recruitment to MOPr (Figure 4.2). Compounds BU14016, BU16005 
and BU16007 showed slightly higher inhibition (82%, 71% and 71%, respectively) 
than cmpd101 (58%), while compounds BU16006, BU14017 and BU16009 showed 
similar inhibition (61%, 56% and 52%, respectively) to cmpd101. The other 
compounds, BU14013 and BU14014, showed less inhibition (26%) (Figure 4.2). 
Likewise, when these novel compounds were applied at a lower concentration of 30 
µM, most of them, including cmpd101, showed a similar level of inhibition as they 
did at 100 µM (Figure 4.3). 
 
I also investigated whether the novel compounds might have an effect on basal 
arrestin-3 recruitment to MOPr (Figure 4.4). They induced an apparent increase in 
the basal arrestin-3 recruitment at both 30 µM and 100 µM, while 100 µM showed a 
higher apparent increase than at 30 µM; however, one-way ANOVA found no 




To further investigate the effect of other MOPr agonists on arrestin-3 recruitment in 
the presence of these novel compounds, HEK293 cells expressing MOPr were 
pretreated with cmpd101 or novel compounds (100 µM), and then the cells were 
stimulated with the lower efficacy agonist morphine (30 µM) for 10 min (Figure 4.5). 
Morphine-induced recruitment of arrestin-3 to MOPr was assessed using BRET and 
was significantly less than that seen with DAMGO (about 50%). Surprisingly, at 100 
µM most of the compounds showed little or no inhibition of arrestin-3 recruitment 
induced by morphine (Figure 4.5). In addition, cmpd101 did not inhibit morphine-
induced arrestin-3 recruitment whilst BU14016, BU16005 and BU16007, which 
showed the highest inhibition of DAMGO-induced arrestin-3 recruitment, also 
showed negligible inhibition (Figure 4.5). Unexpectedly, BU14017 significantly 
enhanced morphine-induced arrestin-3 recruitment (Figure 4.5). Interestingly, when 
compounds were screened at 30 µM, most compounds did not show inhibition of 
morphine-induced arrestin-3 recruitment, although, there is a trend towards 
inhibition, except for BU14013 which remained an activator rather than an inhibitor 
(Figure 4.6). 
 
To explore these findings further, a time course was performed for morphine-
induced arrestin-3 recruitment with BU14017 and BU14014 because these two 
compounds exerted an apparent enhancing effect on arrestin-3 recruitment induced 
by morphine when applied at 100 µM (that by BU14017 was statistically significant; 
Figure 4.5).  The responses over time are shown in Figure 4.7, indicating that 
BU14017 and BU14014 appeared to enhance morphine-induced arrestin-3 
recruitment throughout the time course of morphine activation (Figure 4.7). In 
contrast, it should be noted that I had previously found that 100 µM BU14017 
inhibited DAMGO-induced arrestin-3 recruitment by about 60% (see Figures 4.2 and 
4.3 above). Also, when cells were stimulated by DAMGO, 100 µM BU14014 
inhibited arrestin-3 recruitment by about 20% (Figures 4.2 and 4.3). 
I next investigated the ability of cmpd101 and the novel compounds to inhibit 
agonist-induced arrestin-3 recruitment to the closely related δ receptor (DOPr). The 
agonists used were SNC80 and DADLE (each 10 µM), using HEK293 cells 
cotransfected this time with DOPr. The results showed that SNC80 (10 µM) induced 
a high maximal level of arrestin-3 recruitment as compared to DADLE (10 µM) 
94 
 
(Figures 4.8 and 4.10). In addition, SNC80-induced arrestin-3 recruitment to DOPr 
signal was about 2-fold higher than that generally obtained for DAMGO-induced 








Figure 4.2 Cmpd101 and novel compounds at 100 µM inhibit DAMGO-induced arrestin-3 
recruitment to MOPr. 
HEK293 cells were cotransfected with MOPr-RLuc2 and Arr3-GFP. A) Cells were preincubated 
with cmpd101 or novel compounds (all at 100 µM) or DMSO as a vehicle for 30 min and then 
stimulated with DAMGO (10 µM) for a further 10 min. B) Data from A were normalised to the 
response induced by 10 µM DAMGO, to give % inhibition of the agonist-induced response. BRET 
ratio of no agonist-treated cells was subtracted from agonist-treated cells. * P < 0.05 compared 
to DAMGO alone; # P < 0.05 compared to cmpd101; ns, not statistically significant compared to 
DAMGO alone, NS, not statistically significant compared to cmpd101, one-way ANOVA followed 







Figure 4.3 Cmpd101 and novel Compounds at 30 µM inhibit DAMGO-induced arrestin-3 
recruitment to MOPr. 
HEK293 cells were cotransfected with MOPr-RLuc2 and Arr3-GFP. A) Cells were preincubated 
with cmpd101 or novel compounds (all at 30 µM) for 30 min and then stimulated with DAMGO 
(10 µM) for a further 10 min. B) Data from A were normalised to the response induced by 10 µM 
DAMGO, to give % inhibition of the agonist-induced response.  BRET ratio of no agonist-treated 
cells was subtracted from agonist-treated cells. * P < 0.05 compared to DAMGO or 
DAMGO+DMSO; # P < 0.05 compared to cmpd101; one-way ANOVA followed by Tukey’s 







Figure 4.4 Effect of 30 or 100 µM cmpd101 and novel compounds on the basal level of 
arrestin-3 recruitment to MOPr. 
HEK293 cells were transiently cotransfected with MOPr-RLuc2 and Arr3-GFP. Cells were 
preincubated with cmpd101 or novel compounds at A) 30 µM or B) 100 µM for 30 min. ns, not 
statistically significant compared to basal, one-way ANOVA. Data represented as mean ± SEM 





Figure 4.5 Effect of 100 µM cmpd101 and novel compounds on morphine-induced arrestin-
3 recruitment to MOPr. 
HEK293 cells were transiently transfected with MOPr-RLuc2 and Arr3-GFP. A) Cells were 
preincubated with cmpd101 (100 µM), novel compounds (100 µM) or DMSO as a vehicle for 30 
min and then stimulated with morphine (30 µM) for a further 10 min.  BRET ratio of no agonist-
treated cells was subtracted from agonist-treated cells. B) Data were normalised to the response 
induced by 30 µM morphine, to give % of the morphine-induced response. Arrow indicates an 
increase in morphine-induced arrestin-3 recruitment. * P < 0.05 compared to morphine; ns, not 
statistically significant compared to morphine; NS, not statistically significant compared to 
cmpd101, one-way ANOVA followed by Dunnett’s multiple comparison test. Data represented 






Figure 4.6 Effect of 30 µM of cmpd101 and novel compounds on morphine-induced 
arrestin-3 recruitment to MOPr. 
HEK293 cells were transiently transfected with MOPr-RLuc2 and Arr3-GFP. A) Cells were 
preincubated with 30 µM cmpd101 or novel compounds for 30 min and then stimulated with 
morphine (30 µM) for a further 10 min.  BRET ratio of no agonist-treated cells was subtracted 
from agonist-treated cells. B) Data from A were normalised to the response induced by 30 µM 
morphine, to give % of the morphine-induced response. # P < 0.05 compared to cmpd101; ns, 
not statistically significant compared to morphine, one-way ANOVA followed by Dunnett’s 






Figure 4.7 Effect of BU14017 and BU14014 on 30 µM morphine-induced arrestin-3 
recruitment to MOPr. 
HEK293 cells were transiently transfected with MOPr-RLuc2 and Arr3-GFP and preincubated 
with BU14017 (100 µM, ○) or BU14014 (100 µM, □) for 30 min. Cells were then stimulated with 
morphine (30 µM) and BRET measurements were taken every 2 min up to 18 min. The BRET 
ratio of vehicle-treated cells was subtracted from morphine-stimulated values. Data are 
represented as mean ± SEM of four independent experiments. * P < 0.05 BU14014 compared 
to respective morphine value; # P < 0.05 BU14017 compared to morphine, two-way ANOVA 






Figure 4.8 Effect of 100 µM cmpd101 or novel compounds on SNC80-induced arrestin-3 
recruitment to DOPr. 
HEK293 cells were transiently transfected with DOPr-RLuc2 and Arr3-GFP. A) Cells were 
preincubated with 100 µM cmpd101 or novel compounds for 30 min and then stimulated with 
SNC80 (10 µM) for a further 10 min. B) Data from A were normalised to the response induced 
by 10 µM SNC80, with the BRET ratio of no agonist-treated cells was subtracted from agonist-
treated cells. * P < 0.05 compared to SNC80; # P < 0.05 compared to cmpd101, one-way ANOVA 





Interestingly, whereas at 100 µM cmpd101 inhibited SNC80-induced arrestin-3 
recruitment to DOPr by about 50%, of the novel compounds only BU14017 was able 
to significantly inhibit (~ 40%) the SNC80 signal (Figure 4.8). Furthermore, using the 
inhibitors at 30 µM, only cmpd101 was able to inhibit the SNC80 response (Figure 
4.9). Using DADLE as the agonist, cmpd101, BU16007 and BU14017 at 100 µM 
each inhibited arrestin-3 recruitment by 30, 30 and 40%, respectively; however, the 
overall general pattern of inhibition did resemble that obtained with SNC80 
(compare Figure 4.8 and 4.10). These results with DOPr are different from those for 
DAMGO-induced arrestin-3 recruitment to MOPr. For example, BU14016 at 100 µM 
inhibited DAMGO-induced arrestin-3 recruitment to MOPr by 80%, but was unable 
to inhibit SNC80- or DADLE-induced arrestin-3 recruitment to DOPr (Figures 4.2, 
4.8 and 4.10). 
 
 Next, the novel compounds were applied at 100 µM on their own to determine their 
effect on basal arrestin-3 recruitment to DOPr. The results indicated that adding 
most of these novel inhibitors at 100 µM produced around a 1.5-fold increase in 
basal arrestin-3 recruitment to DOPr (Figure 4.11). In contrast, BU14016 showed 
no effect on basal arrestin-3 recruitment to MOPr or DOPr when added at either 30 
or 100 µM (Figures 4.4 and 4.11). 
 
To further investigate the effect of these novel inhibitors on the agonist-induced 
arrestin-3 recruitment to MOPr or DOPr, full concentration inhibition curves were 
constructed for BU14016, BU16005 and BU16007; these compounds showed the 
greatest inhibition of DAMGO-induced arrestin-3 recruitment to MOPr (Figures 4.2 
and 4.3). The inhibition curves are shown in Figures 4.12 and 4.13. The IC50 and 
maximum inhibition values are summarised in Table 4.2. The results confirmed our 
previous findings (Figure 4.3 and 4.9). Interestingly, BU16007, which showed higher 
inhibition of DAMGO-induced arrestin-3 recruitment to MOPr at a concentration of 
30 µM than of cmpd101 (Figure 4.3), showed a higher potency with an IC50 of 0.7 ± 
0.4 µM and maximum inhibition of 90% compared to cmpd101 IC50 9.3 ± 0.9 µM and 
maximum inhibition of 50% (Figure 4.12). The other compounds, BU14016 and 
BU16005, showed an IC50 of 2.9 ± 2.3 µM and 7.6 ± 2.0 µM and maximum inhibition 
of 90 and 60%, respectively (Figure 4.12). Conversely and intriguingly, BU14016, 
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BU16005 and BU16007 failed to inhibit SNC80-induced arrestin-3 recruitment to 
DOPr (Figure 4.13). However, cmpd101 showed a maximum 50% inhibition of 
SNC80-induced arrestin-3 recruitment to DOPr (Figure 4.13), which is similar to the 







Figure 4.9  Effect of 30 µM cmpd101 and novel compounds on SNC80-induced arrestin-3 
recruitment to DOPr 
HEK293 cells were transiently transfected with DOPr-RLuc2 and Arr3-GFP. A) Cells were 
preincubated with 30 µM cmpd101 or novel compounds for 30 min and then stimulated with 
SNC80 (10 µM) for a further 10 min.  The BRET ratio of no agonist-treated cells was subtracted 
from agonist-treated cells. B) Data were normalised to the response induced by 10 µM SNC80. 
* P < 0.05 compared to SNC80; # P < 0.05 compared to cmpd101; ns, not statistically significant 
compared to SNC80, one-way ANOVA followed by Dunnett’s multiple comparison test. Data 






Figure 4.10  Effect of cmpd101 or novel compounds on DADLE-induced arrestin-3 
recruitment to DOPr 
HEK293 cells were transiently transfected with DOPr-RLuc2 and Arr3-GFP. A) Cells were 
preincubated with 100 µM cmpd101 or novel compounds for 30 min and then stimulated with 
DADLE (10 µM) for further 10 min.  The BRET ratio of no agonist-treated cells was subtracted 
from agonist-treated cells. B) Data were normalised to the response induced by 10 µM DADLE. 
* P < 0.05 compared to DADLE; # P < 0.05 compared to cmpd101; ns, not statistically significant 
compared to DADLE; NS, not statistically significant compared to cmpd101, one-way ANOVA 






Figure 4.11  Effect of cmpd101 and novel compounds on basal arrestin-3 recruitment to 
DOPr 
HEK293 cells were transiently cotransfected with DOPr-RLuc2 and Arr3-GFP. Cells were 
preincubated with cmpd101 or novel compounds (30 µM) for 30 min and BRET measurements 
made. * P < 0.05 compared to DMSO or basal; ns, not statistically significant compared to DMSO 
or basal, one-way ANOVA followed by Tukey’s multiple comparison test. Data represented as 





Figure 4.12  Concentration-dependent inhibition of 10 µM DAMGO-induced arrestin-3 
recruitment to MOPr by cmpd101 and selected novel compounds. 
HEK293 cells were cotransfected with MOPr-RLuc2 and Arr3-GFP. Cells were preincubated with 
cmpd101 (0.1 - 100 µM) or novel compounds (0.01 - 100 µM) for 30 min and then stimulated 
with DAMGO (10 µM) for further 10 min.  The BRET ratio of no agonist-treated cells was 
subtracted from agonist-treated cells. Data were fitted to a non-linear regression model with three 
parameters using GraphPad Prism v8 software. Data are represented as mean ± SEM of results 






Figure 4.13  Concentration-inhibition curves for the ability of cmpd101 and novel 
compounds to inhibit 10 µM SNC80-induced arrestin-3 recruitment to DOPr. 
HEK293 cells were cotransfected with DOPr-RLuc2 and Arr3-GFP. Cells were preincubated with 
cmpd101 or novel compounds (0.01- 100 µM) for 30 min and then stimulated with SNC80 (10 
µM) for further 10 min.  The BRET ratio of no agonist-treated cells was subtracted from agonist-
treated cells. Where possible, data were fitted to a non-linear regression model with three 
parameters using GraphPad Prism v8 software. Data are represented as mean ± SEM of results 
from four independent experiments each performed in duplicate. 
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Table 4.2 IC50 and maximum inhibition of cmpd101 and novel compounds 
 






recruitment to MOPr 
(10 µM) 
SNC80-induced arrestin-3 













Cmpd101 9.3 ± 0.9 50 5.6 ± 0.8 50 
BU14016 2.9 ± 2.2 90 ND ND 
BU16007 0.7 ± 0.4 90 ND ND 
BU16005 7.5 ± 2.0 60 ND ND 
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4.2.2 Effect of Novel Compounds on DAMGO-induced Gi Activation at MOPr 
Next, I investigated the effect of these inhibitors on Gi activation to determine their 
selectivity in the arrestin/G protein signalling pathways. Some compounds were 
chosen that were either very effective at inhibiting DAMGO-induced arrestin-3 
recruitment to MOPr, or, alternatively, were weak inhibitors. G protein subunit 
dissociation was assessed by BRET assay, which measures the separation of Gα 
and βγ during receptor activation and the BRET signal is reduced (Masuho, 
Martemyanov & Lambert 2015). The agonist concentration-response curves of the 
compounds are shown in Figure 4.14. DAMGO increased G protein dissociation 
(i.e., activated G protein) with an EC50 of 0.4 ± 0.1 µM, which is similar to the EC50 
for DAMGO (0.8 ± 0.4 µM) obtained in the arrestin-3 recruitment assay (see Chapter 
3, Figure 3.2B). These experiments showed that cmpd101 and BU14016 modestly 
inhibited DAMGO-induced Gα/Gβγ dissociation as depicted by a decrease in the 
BRET ratio (Figure 4.14). The EC50 and Emax values are summarised in Table 4.3. 
Cmpd101 and BU14016 shifted the DAMGO curve to the right by 3- and 6- fold, 
respectively (Figure 4.14). On the other hand, compounds BU14014 and BU14013, 
which were weak at inhibiting DAMGO-induced arrestin-3 recruitment to MOPr, did 






Figure 4.14  Effect of cmpd101 and novel compounds on log concentration-response 
curves of DAMGO-induced Gi activation. 
HEK293 cells were transiently transfected with HA-MOPr, Gαi-RLuc2 and Gβγ-GFP. Cmpd101 
(30 µM) or novel compounds (30 µM) was added 30 min before the addition of DAMGO (0.001- 
30 µM) for a further 2 minutes. DAMGO-induced BRET ratios were expressed as the percentage 
decrease compared to nontreated cells. Data were fitted to a non-linear regression model with 
three parameters with the minimum constrained to zero. Data are presented as mean ± SEM 





Table 4.3 EC50 and Emax values of DAMGO in the presence of cmpd101 and the novel 
compounds 
 
Inhibitor DAMGO EC50 (µM) Emax (BRET ratio, no units) 
no inhibitor 0.4 ± 0.1 13.1 ± 0.7 
Cmpd101 1.2 ± 0.3 11.5 ± 0.4 
BU14016 2.4 ± 0.5* 11.7 ± 1.4 
BU14014 0.8 ± 0.4 13.6 ± 2.0 
BU14013 0.3 ± 0.1 11.1 ± 0.8 
EC50 and Emax values are taken from Figure 4.14. * P < 0.05 compared to no inhibitor (DAMGO 





4.2.3 Effect of the Novel Compounds on the Cell Surface Loss of MOPr 
Next, I want to determine the ability of cmpd101 and selected novel compounds to 
inhibit cell surface loss of MOPr as a result of DAMGO-induced internalisation of the 
receptor (Johnson, EA et al. 2006). ELISA was used to determine the effect of 
cmpd101 and some of the novel compounds on cell surface loss of MOPr. The 
results are shown in Figure 4.15. DAMGO at 10 µM clearly increased surface 
receptor loss of the receptor in HEK293 cells expressing HA-MOPr by about 30% 
(Figure 4.15). Applying cmpd101 and the selected novel compounds (all at 30 µM) 
on their own did not affect the basal level of surface MOPr loss (Figure 4.15B). On 
the other hand, compound BU16007 significantly reduced the DAMGO-induced 
surface receptor loss by 87% whilst cmpd101 and BU14016 reduced loss by 77% 
and 47%, respectively (Figure 4.15). In contrast, the compound BU16013, which 
failed to inhibit DAMGO-arrestin-3 recruitment to MOPr, did not reduce the DAMGO- 





Figure 4.15 Inhibition of DAMGO-induced MOPr surface loss by cmpd101 and novel 
compounds 
A) HEK293 cells were transiently transfected with HA-MOPr and were pretreated with cmpd101 
(30 µM) or the novel compounds (30 µM) or DMSO for 30 min and then were stimulated with 
DAMGO (10 µM) (as indicated in the graph) for a further 30 min at 37°C. B) Cells were 
preincubated with cmpd101 (30 µM), novel compounds (30 µM) or DMSO for 30 min, DAMGO 
was added as indicated in the graph. The cell surface receptor expression was measured by 
ELISA. Control (basal) was set to 100%. Data are represented as mean ± SEM of four 
independent experiments performed in triplicate. Statistical analysis was performed by one-way 
ANOVA followed by Tukey post hoc test for multiple comparisons (* P < 0.05, compared to 
DAMGO; # P < 0.05, compared to control; NS, not statistically significant compared to control; 





This thesis sought to identify more potent or more selective GRK inhibitors based 
on the structure of cmpd101. Here, colleagues at the University of Bath synthesised 
some novel cmpd101 analogues (see Table 4.1 for their structures), with the aim of 
determining their abilities to inhibit agonist-induced arrestin-3 recruitment to MOPr 
or DOPr; as a proxy of GRK-induced phosphorylation of the receptor. These novel 
compounds were screened to determine their ability to inhibit arrestin-3 recruitment 
in HEK239 cells transiently expressing MOPr or DOPr. In the initial screening, each 
compound was tested at a single high concentration (100 µM). I found that, at this 
concentration, compounds BU14016, BU16005 and BU16007 showed slightly 
higher inhibition than cmpd101; however, it was not a statistically significant 
difference from cmpd101 (Figure 4.2), while compounds BU16006, BU14017 and 
BU16009 showed similar inhibition to cmpd101 (Figure 4.2). The other compounds, 
BU14013 and BU14014, showed less inhibition (Figure 4.2). Among the 
compounds, BU14016, BU16005 and BU16007 inhibit arrestin-3 recruitment to 
MOPr by more than 60% at 100 μM. Therefore, I report here new potential GRK 
inhibitors, BU14016, BU16005 and BU16007, effective at inhibiting DAMGO-
induced arrestin-3 recruitment to MOPr. I show that these compounds exhibit 
effective inhibition of arrestin-3 recruitment when applied at concentrations of 100 
µM as well as 30 µM.  
 
Surprisingly, when compounds were applied at 100 µM with regard to morphine-
induced arrestin-3 recruitment, most of the inhibitors appeared to either have no 
effect or to be activators rather than inhibitors, except for BU14016 and BU16005, 
which are weak inhibitors (Figure 4.5). However, at 30 µM, the trend for most of the 
inhibitors reversed, except for BU14013, which remains an activator (Figure 4.6). 
One possibility is that some of the inhibitors bind to GRK/s that involve and stabilise 
an active conformation. I further investigated this observation by undertaking time 
courses of BU14017 and BU14014 (Figure 4.7), which confirms BU14017 and 
BU14014 are modestly enhancing morphine-induced arrestin-3 recruitment.     
The results showed that, at a high concentration (100 µM), compounds BU14016 
and BU16007 achieved almost complete inhibition of arrestin recruitment (both ~ 
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90%) while cmpd101 and BU16005 did not achieve complete inhibition of DAMGO-
induced arrestin-3 recruitment to MOPr. It is possible that these compounds do not 
inhibit another GRK/s involved in MOPr phosphorylation; therefore, some 
phosphorylation and arrestin recruitment takes place. Alternatively, the unexpected 
modest increase in arrestin recruitment that high concetration of some of these 
compounds produced could oppose the expected inhibition of recruitmetnt. 
 
The results also show that cmpd101 and the novel compounds have distinct effect 
on of inhibition of arrestin-3 recruitment to MOPr depending upon the agonist used. 
Studies have found that Ser375 is the primary phosphorylation site in MOPr (Doll et 
al. 2011). In addition, it was reported that DAMGO stimulates the phosphorylation 
of multiple sites in MOPr, including Thr370 and Ser375, while morphine stimulates the 
significant phosphorylation of Ser375 only (Doll et al. 2012). It has been reported that 
DAMGO phosphorylates Thr370 and Ser375 with GRK2 and GRK3 while morphine 
phosphorylates Ser375 with GRK5 (Doll et al. 2012). In addition, DAMGO 
phosphorylates the receptor more efficiently than morphine; thus, the level of 
DAMGO-arrestin-3 recruitment is higher (> 2-fold) than of morphine-induced as 
measured by BRET assay. Morphine-induced arrestin-3 recruitment to MOPr may 
not just depend upon phosphorylation, but instead on morphine-induced changes in 
receptor activation. This may in part explain why the inhibitors have no effect on 
arrestin-3 recruitment induced by morphine.  
 
In the present study, I also investigated the activity of SNC80 and DADLE using 
HEK293 cells cotransfected with DOPr. The findings showed that cmpd101, 
BU16007, and BU14017 displayed a similar pattern in the inhibition of arrestin-3 
recruitment induced by each agonist (see Figures 4.8 and 4.10). The compounds 
cmpd101, BU16007, and BU14017 exhibited comparable ability to inhibition of 
arrestin-3 recruitment to DOPr induced by either SNC80 or DADLE. However, the 
rest of the compounds did not show any inhibition of arrestin-3 recruitment to DOPr 
induced by SNC80 or DADLE. The reasons for this are presently unclear, but could 
be attributed to the possibility that SNC80- and DADLE-induced phosphorylation of 
DOPr involve the GRK/s that are not inhibited by the other experimental inhibitors. 
In HEK293 cells stably expressing HA-DOPr, both SNC80 and DADLE induced 
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robust phosphorylation of Thr361 and Ser363, which are the major phosphorylation 
sites of DOPr (Mann et al. 2020).  
 
One unanticipated finding was that the novel compounds showed relatively little 
inhibition of arrestin-3 recruitment to DOPr. Studies have shown that MOPr and 
DOPr are phosphorylated at different sites (Doll et al. 2011; Doll et al. 2012; Guo et 
al. 2000). It has been shown that DOPr is hierarchically phosphorylated by GRK2 at 
Ser363 and then at Thr358 (Guo et al. 2000). Using phosphosite-specific antibodies 
for the carboxy-terminal residues of the MOPr, it has been revealed that MOPr is 
phosphorylated at Ser363, Thr370 and Ser375 (Doll et al. 2011). Based on these 
findings, the differences between MOPr and DOPr in terms of phosphorylation sites 
and different GRKs involved may explain why these analogues showed little 
inhibition. Further studies are needed to determine their selectivity and potency for 
GRK subtypes and explore their action on the downstream signalling.  
 
It was observed that, at high concentration (100 μM), the novel compounds slightly 
increased basal (i.e., agonist-independent) arrestin-3 recruitment to MOPr, while at 
30 μM the increase is much less; however, these changes were not statistically 
significant. Likewise, the novel compounds significantly increase basal arrestin-3 
recruitment to DOPr at 100 μM except for BU14016 and BU16009. This could be 
that these inhibitors induce a receptor conformational change that able to engage 
with the arrestins in an agonist-independent manner.  
 
BU14014 and BU14013 show the least inhibition of DAMGO-induced arrestin-3 
recruitment compared to cmpd101 and other novel compounds. As expected, 
BU14014 and BU14013 did not affect Gi activation, while cmpd101 and BU14016 
make 3- and 6-fold shift to the right of DAMGO-induced Gi activation curve. These 
findings are in line with the reported action of cmpd101 on G protein-coupled 
inwardly potassium channel (GIRK) activation. The previous study from our 
laboratory reported that cmpad101 (30 µM) partially reduced desensitisation of 
opioid-activated GIRK in locus coeruleus neurons. The reason for this is not clear, 





Compounds BU14016 and BU16007, which show more effective or similar inhibition 
to cmpd101 with regard to DAMGO-induced arrestin-3 recruitment to MOPr, also 
significantly reduced DAMGO-induced internalisation, possibly through inhibiting 
GRK/s. On the other hand, compound BU14013, which fails to inhibit DAMGO-
induced arrestin-3 recruitment to MOPr, was not able to block MOPr internalisation. 
A possible explanation for this might be that BU14013 is not able to inhibit GRK/s 
that involved in MOPr internalisation. Alternatively, cell permeability plays a major 
role in determining the efficacy of compounds in cells. For example, the recently 
developed GRK inhibitor compounds CCG224406 and CCG215022, potent GRK2 
inhibitors with IC50 values of 0.13 µM and 0.15 µM respectively, show poor cell 
permeability when tested in a parallel artificial membrane permeation assay; thus, 
they have failed to inhibit DAMGO-induced MOPr internalisation in HEK293 and 
U2OS cell line (Bouley, RA et al. 2020). However, Rainbow et al. (2018) reported 
that CCG215022 strongly inhibited Ang-II induced desensitisation of AT1R. Since 
we do not have the facility to measure the lipophilicity, which is an indicator of cell 
permeability, of the novel compounds, the partition coefficient (LogP) values were 
calculated using ChemDraw professional 16 (PerkinElmer Informatics). The 
summary of the cell permeability parameters of the cmpd101 and the novel 
compounds are shown in Table 4.1. Most novel compounds have estimated logP 
values under 5 (Table 4.1), which are considered cell permeable (Lipinski et al. 
2001). We would not expect BU16005 and BU16007 to penenterate the cell 
particularly well because they have logP values of 5.1 and 6.1, respectively (Table 
4.1). However, BU16005 and BU16007 are the most effective at inhibiting DAMGO-
induced arrestin-3 recruitment to MOPr. Hence, the estimated logP values do not 
correlate with the cellular activity of the novel compounds; nevertheless, the 
influence of cell permeability cannot be ruled out.  
 
This thesis sought to investigate the importance of the pyridinyl-triazole moiety and 
the role of hydrogen bond donor and acceptor groups in their activity. To explore 
this idea, the A/B rings of cmpd101 were replaced by naphthyl rings, as in BU16007 
and BU16006, or quinoline ring, as in BU16005 (see Table 4.1). Also, looking at the 
importance of the hydrogen bond donor and acceptor groups in the middle of the 
119 
 
molecule, the amide group and CH2NH group were replaced by a double bond, as 
in compounds BU14013 and BU14014, respectively (Table 4.1).  
Molecular modelling conducted by Mehrnoosh Ostovar (University of Bath; 
unpublished) of selected analogues (BU14014 and BU16009) with GRK2 (Figure 
4.16) revealed that the lack of an NH group between rings B and C might contribute 
to the lower potency for inhibition of GRK activity and, hence, arrestin-3 recruitment. 
This is supported by our results where BU14014 and BU16009 exhibited reduced 
abilities to inhibit arrestin-3 recruitment. Another example, BU14013, which is 
missing an amide group between ring C and D compared to cmpd101, shows lower 
inhibition of DAMGO-induced arrestin-3 recruitment to MOPr. The low inhibition of 
BU14013 could be explained by the lack of hydrogen bond formation in this region 
with the GRK2.  On the other hand, BU16006, which contains a naphthyl group (A/B 
rings) instead of the pyridyl 1,2,4-triazole (A/B rings) in cmpd101, shows similar 
inhibition of DAMGO-induced arrestin-3 recruitment to MOPr as cmpd101. This 
suggests that the formation of hydrogen bond in this region with GRK2 does not 
seem to give any advantage in enhancing the potency of the inhibitor. 
 
The ATP binding site of the kinase is composed of the adenine, ribose, triphosphate 
and hydrophobic subsites (Thal et al. 2011). The amino group and C ring of 
cmpd101 occupy the triphosphate subsite forming hydrogen bonds with the side 
chain of Asp335 and Lys220 (Homan & Tesmer 2015; Thal et al. 2011). In addition, 
replacing the pyridyl 1,2,4-triazole in cmpd101 with a naphthyl ring did not improve 
the potency towards GRK2. Thal et al. (2011) observed that compounds forming 
fewer hydrogen bonds are more selective for GRK2. Thus, H-bond formation does 
not play a major role in the potency of cmpd101. Our results supported this idea that 
neither BU16007 nor BU16006 displayed significant improvements in the inhibition 
of arrestin-3 recruitment to MOPr compared to cmpd101. 
 
Bouley, RA et al. (2020) developed a new paroxetine derivative (CCG258747) 
(Figure 4.1) that showed potent and selective inhibition of GRK2 (IC50= 18 nM) over 
GRK1, GRK5, PKA and ROCK1. The crystal structure of CCG258747 complexed 
with GRK2-Gβγ showed the interactions of the inhibitor with the GRK2 kinase 
domain. Importantly, the addition of the indazole D-ring of CCG258747 played a role 
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in the potency of the inhibitor while the benzodioxole ring influenced the selectivity 
(Bouley, RA et al. 2020). Previous studies of GRK2 inhibitors have revealed that 
interactions with hydrophobic subsites of the kinase influence the potency of 
inhibition (Homan & Tesmer 2015). The synthesis of a compound that is structurally 
related to GSK180736A, a compound analogue to paroxetine, by mimicking the 
difluoro benzyl amide of compound103 has shown great potency and selectivity for 
GRK2 (Waldschmidt et al. 2016). Thus, modification of the D-ring of cmpd101 plays 
a major role in the potency and selectivity. This can be reflected in our results that 




Figure 4.16 Molecular docking of cmpd101, BU14014 and BU16009  
The molecular docking studies show: A) The docked pose of cmpd101 (purple) in the GRK2 
binding site. The dashed yellow lines indicate hydrogen bonds (lengths are shown in Å). The 
protein secondary structure is shown as an animation coloured red at the C-terminus, through 
orange, yellow and green to blue at the N-terminus. B) Overlay of the crystal structure (PDB 
Code 3V5W) ligand (cyan) with the docked poses of cmpd101 (pink), BU14014 (cis) (yellow), 
and BU16009 (white). This docking study is taken from Ostovar et al. (University of Bath, 
unpublished). 
4.4 Conclusion 
Our colleagues at the University of Bath synthesised a small library of compounds 
based on the GRK inhibitor cmpd101 in which A/B rings, amide group, or D ring of 
cmpd101 were replaced by a variety of functional groups. I have determined in part 
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the ability of these compounds to inhibit GRK/s using arrestin-3 recruitment as a 
proxy assay. I show here that cmpd101 shows similar inhibition of agonist-induced 
arrestin-3 recruitment to MOPr and DOPr. I have found that modification of A/B or 
D rings of cmpd101 lead to a minor improvement in the inhibition of agonist-induced 
arrestin-3 recruitment. Also, I have found that the compounds BU14016, BU16007, 
BU16006 and BU16005 are just as effective as cmpd101 in inhibition of arrestin-3 
recruitment to MOPr. However, the ability of the different test compounds to inhibit 
arrestin-3 recruitment to a GPCR is agonist-dependent (DAMGO versus morphine) 
and receptor-dependent (MOPr versus DOPr). The reasons for such differences are 
not always apparent and will require further study. 
Furthermore, the data presented here suggest that compounds BU16007, BU16005 
and BU14016 are effective inhibitors of GRKs. Based on these findings, it seems 
promising to further investigate the replacement of A/B or D ring of cmpd101 to 
further improve GRKs’ potency. Altogether, these new cmpd101 analogues 
represent a good start to design small molecule inhibitors that can be used to 
explore the roles of the individual GRKs. In the next chapter, studies will be directed 
towards determining the selectivity of cmpd101 and the novel compounds for 




CHAPTER 5 The Selectivity of Compound101 
and Novel Compounds for Inhibition of 





GRKs phosphorylate GPCRs on the C-terminus and/or intracellular loops, which 
plays a vital role in receptor desensitisation and trafficking (Gurevich, Vsevolod V., 
Gurevich & Tesmer 2016). In recent years, research has focused on GRKs due to 
the finding that altered levels or activity of some GRKs, in particular, GRK2 and 
GRK5, may play a role in certain diseases (Murga et al. 2019). Studies have shown 
that GRK2 and GRK5 play a critical role in heart failure (Belmonte & Blaxall 2011). 
Thus, selective GRK inhibitors could be used as therapeutic agents in diseases 
where GRKs play a role. Accumulating studies have confirmed the benefit of 
inhibition of GRK2 in an animal model of heart failure (Cannavo, Liccardo & Koch 
2013). The first studies used β-ARKct, a peptide inhibitor of GRK2, expressed in 
mice which could enhance cardiac function (Koch, WJ et al. 1995). Also, β-ARKct 
expressed in mice has been reported to show beneficial effects in dilated 
cardiomyopathy (Rockman et al. 1998) and hypertrophic cardiomyopathy (Freeman 
et al. 2001; Harding et al. 2001). Recently, paroxetine, an FDA approved selective 
serotonin reuptake inhibitor, has been identified as GRK2 inhibitor (Thal et al. 2011). 
In mouse models, paroxetine has been shown to increase the myocyte contractility 
(Sato et al. 2015; Thal et al. 2012).  
 
Apart from development as therapeutic agents, selective GRK inhibitors would help 
in studying the physiological functions of individual GRK isoform in the body as well 
as in specific tissues and cells. Several developed GRK inhibitors have already been 
used to study the role of GRKs in regulating GPCR signal (Birdsong & Williams 
2020; Lowe et al. 2015; Rainbow et al. 2018; Thal et al. 2011). Using selective and 
potent individual GRK isoforms inhibitors would lead to a better understanding of 
the significance of the role of GRKs in regulating GPCR signalling and in modulating 
physiological processes. For example, there is increasing evidence of the beneficial 
effect of inhibition of GRK2 and probably GRK5 in heart failure patients has led to 
the search for the development of selective inhibitors of GRK2 and GRK5. However, 
studies on the role of other GRK isoforms (GRK1, GRK4 and GRK7) are limited 
because of their tissue-limited expression and lack of selective inhibitors. Despite 
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all efforts to find a small molecule GRK inhibitor, the selective inhibitor of particular 
GRKs has, however, yet to be developed. 
 
In this chapter, I aim to determine the selectivity of the cmpd101 and novel inhibitors 
towards GRK isoforms. The arrestin-3 recruitment assay, with cellular 
overexpression of GRK isoforms (GRK2, GRK3, GRK5 and GRK6) will be employed 
to explore the kinase selectivity towards our inhibitors. The inhibitors to be used in 
this part of the study have been chosen because, in earlier chapters, they show 
either extensive inhibition of arrestin-3 recruitment compared to cmpd101, or 






5.2.1 GRK Overexpression Increases Agonist-induced Arrestin-3 
Recruitment 
An investigation of the selectivity of cmpd101 and its analogues towards arrestin-3 
recruitment mediated by different GRK isoforms (GRK2, GRK3, GRK5 and GRK6) 
in HEK293 cells was first undertaken. HEK293 cells were transiently transfected 
with MOPr-RLuc2 or DOPr-RLuc2 and Arr3-GFP in the presence of overexpressed 
GRK isoforms. Again, the BRET assay was used to measure the interaction 
between the MOPr or DOPr and Arr3 in the presence of the overexpressed GRKs. 
 
GRK isoform protein overexpression was assessed by Western blot. The GRK2 (80 
kDa), GRK3 (80 kDa), GRK5 (66 kDa), and GRK6 (68 kDa) bands were detected at 
the expected molecular weights (Figure 5.1) in agreement with previously published 
reports (Doll et al. 2012). The results showed a marked increase of GRK2 
expression compared to the endogenous GRK2 (Figure 5.1). The results also 
showed the overexpression of the GRK3, GRK5 and GRK6; however, the antibodies 
used were not able to detect endogenous GRK3, GRK5 or GRK6 (Figure 5.1).  
 
The influence of overexpression of GRK isoforms on arrestin-3 recruitment was then 
investigated using the BRET assay. Compared to previous results reported in this 
thesis (Chapter 4, Figures 4.3 and 4.6), transfection with pcDNA3.1 had no effect 
on DAMGO- or morphine-induced arrestin-3 recruitment to MOPr. In pcDNA3.1-
contransfected cells, DAMGO and morphine-induced arrestin recruitment similar to 
that induced in non-pcDNA3.1 transfected cells (compare Figures 5.4 and 5.7 with 
Figures 4.3 and 4.6). The overexpression of GRK isoforms resulted in an increase 
in both DAMGO- and morphine-induced arrestin-3 recruitment to MOPr (Figures 5.2, 
5.3 and Table 5.1). It was observed that, although the overexpression of GRK 
isoforms increased the efficacy of DAMGO and morphine, it did not significantly 
change the basal levels of arrestin-3 recruitment (Figures 5.2, 5.3 and Table 5.1).  
 
I then investigated arrestin-3 recruitment in HEK293 transfected with MOPr and 
different GRK isoforms (overexpression of GRK2, GRK3, GRK5 or GRK6). This 
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represented an attempt to investigate the selectivity of the novel compounds for 
different GRK subtypes, although, of course, any endogenous GRKs would 
presumably still be active. As a control, some cells were transfected with pcDNA3.1 
alone (Figure 5.4). Cells were pretreated with cmpd101 or the novel compounds (30 
µM) and then stimulated with DAMGO (10 µM). The results showed that 
cotransfection with pcDNA3.1 generally did not affect the ability of the novel 
inhibitors to inhibit arrestin-3 recruitment to MOPr as compared with previous results 
in this thesis (Chapter 4, Figure 4.3). Figures 5.5 and 5.6 show that cmpd101 at 30 
µM seems to be a more effective inhibitor in cells where GRK2 (95%) and GRK3 
(95%) are overexpressed, and less so in cells where GRK5 (70%) and GRK6 (70%) 
are overexpressed compared to pcDNA3.1-treated cells (Figure 5.10). These 
results also show that BU14016, BU16005 and BU16007 were effective inhibitors 
of arrestin-3 recruitment in the presence of overexpression of all four GRKs tested. 
Of these, BU14016 at 30 µM was in each case a somewhat weaker inhibitor than 
the other three compounds. Although BU16006 and BU14017 did not significantly 
inhibit DAMGO-stimulated arrestin-3 recruitment in vector-treated cells (Figure 5.4), 
they did significantly inhibit arrestin-3 recruitment in the presence of overexpression 
of all four of the GRKs tested (Figures 5.5 and 5.6). However, in the previous chapter 
BU14017 (30 µM) significantly inhibited DAMGO-stimulated arrestin-3 recruitment 
(Figure 4.3). Furthermore, in the presence of overexpression of GRK isoforms, 
BU16009, BU14013 and BU14914 remained unable to significantly inhibit DAMGO-
induced arrestin-3 recruitment (apart from BU14013 versus GRK6) (Figures 5.5 and 
5.6). The results also demonstrated an apparent lack of selectivity of the compounds 
for inhibition of the different GRKs, as the effective inhibitors displayed the same 
pattern of inhibition irrespective of the GRK subtype overexpressed. In summary, 
overexpression of GRK isoforms marginally changed the inhibition pattern of novel 
inhibitors of DAMGO-induced arrestin-3 recruitment (see summary in Figure 5.10).  
 
In pcDNA3.1 cotransfected cells, only BU116007 showed significant inhibition of 
morphine-induced arrestin-3 recruitment while cmpd101 and other compounds were 
ineffective (Figure 5.7), which is similar to the results obtained in the previous 
chapter with no pcDNA3.1 transfected (Figure 4.5). In morphine-stimulated cells, 
cmpd101 significantly inhibited arrestin-3 recruitment in the presence of 
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overexpressed GRK2, GRK3, or GRK5 (Figures 5.8 and 5.9A). On the other hand, 
overexpression of GRK6 did not affect the ability of cmpd101 to inhibit morphine-
induced arrestin-3 recruitment compared to pcDNA3.1-treated cells (Figure 5.9B). 
Compared to pcDNA3.1-treated cells (Figure 5.7), compounds BU16005 and 
BU16007 showed an increase in the inhibition of arrestin-3 recruitment in the 
presence of overexpressed GRK2 or GRK5 (Figures 5.8A and 5.9A). In contrast, 
overexpression of GRK3 or GRK6 did not affect the inhibitory ability of BU116005 
compared to pcDNA3.1-treated cells. Overexpression of GRK3 or GRK6 also led to 
a decrease in the ability of BU116007 to inhibit arrestin-3 recruitment compared to 
vector-transfected cells (Figures 5.7, 5.8B and 5.9B).  Overall, cmpd101, BU16005 
and BU16007 only show an enhanced inhibition of morphine-induced arrestin-3 
recruitment in overexpressed GRK cells compared to pcDNA3.1-treated cells 
(Figure 5.11). 
 
5.2.2 Effect of GRK2 Overexpression on the Ability of cmpd101 or BU14016 
to Inhibit concentration-dependent Arrestin-3 Recruitment to MOPr and 
DOPr 
Next, I investigated the effect of GRK2 overexpression on the ability of cmpd101 
and BU14016 to inhibit the concentration-dependent recruitment of arrestin-3 to 
MOPr and DOPr with DAMGO or SNC80 as agonists, respectively. The EC50, Emax 
and Hill slope values from these experiments are summarised in Table 5.2. As 
expected, overexpression of GRK2 resulted in a marked increase in the potency of 
DAMGO, as well as the maximum response of this agonist (Figure 5.12). However, 
in marked contrast, in DOPr expressing cells, GRK2 overexpression did not lead to 
an increase in the potency of SNC80, or an increase in maximum response (Figure 
5.13). As shown previously in this thesis, both cmpd101 and BU14016 (each 30 µM) 
effectively inhibited DAMGO-induced arrestin-3 recruitment to MOPr (see Figure 
4.3). In the presence of overexpressed GRK2, cmpd101 remained a highly effective 
inhibitor of arrestin-3 recruitment to MOPr; however, BU14016 was less effective 
(Figure 5.12A). The EC50, Emax and Hill slope values of DAMGO in the presence and 
absence of GRK2 overexpression are summarised in Table 5.3. For DOPr, whilst 
SNC80-induced arrestin-3 recruitment was inhibited by cmpd101 both in the 
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presence and absence of overexpressed GRK2, BU14016 was ineffective as an 
inhibitor in each case (Figure 5.13B and C). This latter reflected earlier findings in 
this thesis (see Figure 4.9). Moreover, overexpression of GRK2 significantly 
increased the basal level of arrestin-3 recruitment to DOPr (Figure 5.13A). 
 
5.2.3 The Selectivity of cmpd101 and BU16007 for Inhibition of Arrestin-3 
Recruitment Driven by Different GRK Isoforms  
Next, the ability of cmpd101 and BU16007 (which in most cases appears to be a 
more potent inhibitor of DAMGO-induced arrestin-3 to MOPr than cmpd101) to 
inhibit DAMGO-induced arrestin-3 to MOPr in the presence of overexpressed GRKs 
was investigated. HEK293 cells were cotransfected with MOPr and GRK isoforms 
(GRK2, GRK3, GRK5, or GRK6). Cells were pretreated with cmpd101(0.001- 100 
µM) or BU16007 (0.001- 100 µM) for 30 min and then stimulated with DAMGO (10 
µM) for a further 10 min. Perhaps surprisingly, cmpd101 and BU16007 showed 
similar IC50 values irrespective of the GRK isoform tested (Figure 5.14). The IC50 
values are summarised in Table 5.4. Moreover, the results also showed that 
BU16007 was more potent than cmpd101 in the presence of all GRK isoforms 






Figure 5.1 Analysis of GRK isoforms expression in HEK293 cells 
Immunoblotting for GRK isoforms expressed endogenously (WT) in HEK293 cells, or transfected 
with A) GRK2, B) GRK3, C) GRK5 or D) GRK6. After 48h of transfection, cells were lysed and 
immunoblotted with antibodies to GRK2, GRK3, GRK5 or GRK6. Blots were then stripped and 
probed with anti-α-tubulin antibody to ensure equal loading. Representative blots of two 





Figure 5.2  DAMGO-induced arrestin-3 recruitment to MOPr in the presence of 
overexpressed GRKs 
HEK293 cells were transiently transfected with MOPr-RLuc2, Arr3-GFP and either pcDNA3.1, 
GRK2, GRK3, GRK5 or GRK6. Cells were stimulated with a saturating concentration of DAMGO 
(10 µM, where indicated in the graph legend) for 10 min and BRET measurements were then 
taken. * P < 0.05; ns, not statistically significant, two-way ANOVA followed by Tukey’s multiple 
comparison test. Data are represented as mean ± SEM from four independent experiments, 





Figure 5.3  Morphine-induced arrestin-3 recruitment to MOPr in the presence of 
overexpressed GRKs 
HEK293 cells were transiently transfected with MOPr-RLuc2, Arr3-GFP and either pcDNA3.1, 
GRK2, GRK3, GRK5 or GRK6. Cells were stimulated with morphine (30 µM, where indicated in 
the graph legend) for 10 min and BRET measurements were then taken. * P < 0.05; ns, not 
statistically significant, two-way ANOVA followed by Tukey’s multiple comparison test. Data are 




Table 5.1 Fold change of agonist-induced arrestin recruitment in the presence of 
overexpressed GRK isoforms 
 
DAMGO 
 Basal DAMGO 
GRK2 1.1 2.3 
GRK3 1.7 2.9 
GRK5 1.5 3.7 
GRK6 1.2 5.4 
Morphine 
 Basal Morphine 
GRK2 1.0 9.0 
GRK3 1.4 10.3 
GRK5 1.4 7.3 
GRK6 1.5 2.6 
 





Figure 5.4 Effect of cmpd101 and novel compounds on DAMGO-induced arrestin-3 
recruitment to MOPr in HEK293 cells transfected with pcDNA3.1 
HEK293 cells were cotransfected with MOPr-RLuc2, Arr3-GFP and pcDNA3.1. Cells were 
preincubated with cmpd101 or novel compounds (all 30 µM) for 30 min and then stimulated with 
DAMGO (10 µM) for a further 10 min. The BRET ratio of no agonist-treated cells was subtracted 
from vehicle- or DAMGO-treated cells. * P < 0.05, compared to DAMGO; # P < 0.05 compared 
to cmpd101; ns, not statistically significant compared to DAMGO, one-way ANOVA followed by 
Tukey’s multiple comparison test. Data are represented as mean ± SEM from four independent 





Figure 5.5 Effect of cmpd101 and novel compounds on DAMGO-induced arrestin-3 
recruitment to MOPr in HEK293 cells transfected with GRK2 or GRK3 
HEK293 cells were cotransfected with MOPr-RLuc2, Arr3-GFP and A) GRK2 or B) GRK3.  Cells 
were preincubated with cmpd101 or novel compounds (all 30 µM) for 30 min and then stimulated 
with DAMGO (10 µM) for a further 10 min. The BRET ratio of no agonist-treated cells was 
subtracted from vehicle- or DAMGO-treated cells. * P < 0.05 compared to respective DAMGO; # 
P < 0.05 compared to cmpd101; ns, not statistically significant compared to DAMGO; NS, not 
statistically significant compared to DMSO, one-way ANOVA followed by Tukey’s multiple 
comparison test. Data are represented as mean ± SEM from four independent experiments, 





Figure 5.6 Effect of cmpd101 and novel compounds on DAMGO-induced arrestin-3 
recruitment to MOPr in HEK293 cells transfected with GRK5 or GRK6 
HEK293 cells were cotransfected with MOPr-RLuc2, Arr3-GFP and A) GRK5 or B) GRK6.  Cells 
were preincubated with cmpd101 or novel compounds (all 30 µM) for 30 min and then stimulated 
with DAMGO (10 µM) for a further 10 min. The BRET ratio of no agonist-treated cells was 
subtracted from vehicle- or DAMGO-treated cells. * P < 0.05, compared to DAMGO, # P < 0.05 
compared to cmpd101; ns, not statistically significant compared to DAMGO, one-way ANOVA 
followed by Tukey’s multiple comparison test. Data are represented as mean ± SEM from four 




Figure 5.7 Effect of cmpd101 and novel compounds on morphine-induced arrestin-3 
recruitment to MOPr in HEK293 cells transfected with pcDNA3.1 
HEK293 cells were cotransfected with MOPr-RLuc2, Arr3-GFP and pcDNA3.1. Cells were 
preincubated with cmpd101 or novel compounds (all 30 µM) for 30 min and then stimulated with 
morphine (30 µM) for a further 10 min. The BRET ratio of no agonist-treated cells was subtracted 
from vehicle- or morphine-treated cells. * P < 0.05 compared to morphine; # P < 0.05 compared 
to cmpd101; ns, not statistically significant compared to morphine, one-way ANOVA followed by 
Tukey’s multiple comparison test. Data are represented as mean ± SEM from four independent 






Figure 5.8 Effect of cmpd101 and novel compounds on morphine-induced arrestin-3 
recruitment to MOPr in HEK293 cells transfected with GRK2 or GRK3 
HEK293 cells were cotransfected with MOPr-RLuc2, Arr3-GFP and A) GRK2 or B) GRK3.  Cells 
were preincubated with cmpd101 or novel compounds (each 30 µM) for 30 min and then 
stimulated with morphine (30 µM) for a further 10 min. The BRET ratio of no agonist-treated cells 
was subtracted from vehicle- or morphine-treated cells. * P < 0.05 compared to respective 
morphine alone; # P < 0.05 compared to cmpd101; ns, not statistically significant compared to 
respective morphine, NS, not statistically significant compared to DMSO, one-way ANOVA 
followed by Tukey’s multiple comparison test. Data are represented as mean ± SEM from four 





Figure 5.9 Effect of cmpd101 and novel compounds on morphine-induced arrestin-3 
recruitment to MOPr in HEK293 cells transfected with GRK5 or GRK6 
HEK293 cells were cotransfected with MOPr-RLuc2, Arr3-GFP and A) GRK5 or B) GRK6.  Cells 
were preincubated with cmpd101 or novel compounds (each 30 µM) for 30 min and then 
stimulated with morphine (30 µM) for a further 10 min. The BRET ratio of no agonist-treated cells 
was subtracted from vehicle- or morphine-treated cells. * P < 0.05 compared to morphine alone, 
# P < 0.05 compared to cmpd101; ns, not statistically significant compared to morphine, one-way 
ANOVA followed by Tukey’s multiple comparison test. Data are represented as mean ± SEM 




Figure 5.10 Percentage inhibition of DAMGO-induced arrestin-3 recruitment by cmpd101 and the novel compounds  
This is a summary of Figures 5.4, 5.5 and 5.6. Data were normalised to the response induced by 10 µM DAMGO to give percentage inhibition of 
DAMGO-induced response. * P < 0.05 compared to pcDNA3.1, # P < 0.05 compared to GRK2; one-way ANOVA followed by Tukey’s multiple 




Figure 5.11 Percentage inhibition of morphine-induced arrestin-3 recruitment by cmpd101 and the novel compounds 
This is a summary of Figures 5.7, 5.8 and 5.9. Data were normalised to the response induced by 30 µM morphine to give a percentage of morphine-
induced response. * P < 0.05 compared to pcDNA3.1, # P < 0.05 compared to GRK2; one-way ANOVA followed by Tukey’s multiple comparison 




Figure 5.12 Inhibition of DAMGO-induced arrestin-3 recruitment to MOPr by 30 µM 
cmpd101 or BU14016 in absence or presence of GRK2 overexpression 
HEK293 cells were transiently transfected with MOPr-RLuc2, Arr3-GFP and A) pcDNA3.1 or B) 
GRK2. Following this, Cmpd101 (30 µM), BU14016 (30 µM) or vehicle (0.3% DMSO) was added 
30 min before the addition of DAMGO (0.001- 30 µM) for a further 10 min. The BRET ratio of 
non-agonist-treated cells was subtracted from that of DAMGO-treated cells. A and B, data were 
fitted to a non-linear regression model with four-parameters using GraphPad Prism v8 software 
and the bottom values of the curves constrained to zero. The resulting EC50, Emax and Hill slope 
values are summarised in Table 5.1. Data are presented as mean ± SEM from four independent 

















EC50 (µM) 3.9 ± 2.0 2.2 ± 1.3 2.8 ± 1.5 9.1 ± 0.9 
Emax (BRET 
ratio) 
2,165 ± 663 1,779 ±312 163 ± 71 376 ± 43 











EC50 (µM) 0.1± 0.02 0.1 ± 0.06 8.6 ± 1.6 5.08 ± 0.2 
Emax (BRET 
ratio) 
4,406 ± 324 4,554 ± 341 598 ± 170
*
 3,016 ± 411 
Hill slope 0.9 ± 0.08 0.7 ± 0.1 0.6 ± 0.7 0.6 ± 0.1 
 
The values are taken from Figure 5.10. Data are expressed as mean ± SEM of four independent 
experiments, each performed in duplicate. * P < 0.05, compared to the respective DAMGO + 





Figure 5.13 Inhibition of SNC80-induced arrestin-3 recruitment to DOPr by cmpd101 and 
BU14016 in the presence or absence of GRK2 overexpression 
HEK293 cells were transiently transfected with DOPr-RLuc2, Arr3-GFP and A) pcDNA3.1 or B) 
GRK2. Cmpd101 (30 µM), BU14016 (30 µM) or vehicle (0.3% DMSO) was added 30 min before 
the addition of SNC80 (0.001- 30 µM) for a further 10 min. The BRET ratio of no agonist-treated 
cells was subtracted SNC80-treated cells. C) the BRET ratio of untreated cells of A and B. Data 
in A and B were fitted to a non-linear regression model with four-parameters using GraphPad 
Prism v8 software and the bottom values of the curves were constrained to zero. The EC50, Emax 
and Hill slope values are summarised in Table 5.2. Data are presented as mean ± SEM from 

















EC50 (µM) 0.3 ± 0.1 0.3 ± 0.06 1.3 ± 0.7
*
 0.4 ± 0.07 
Emax (BRET 
ratio) 
3,635 ± 107 3,258 ± 371 2,065 ± 197 3,533 ± 404 











EC50 (µM) 0.1 ± 0.02 0.1 ± 0.01 1.0 ±0.2 0.2 ± 0.02 
Emax (BRET 
ratio) 
4,002 ± 62 4,046 ± 229 2,677 ± 149
*
 4,339 ± 115 
Hill slope 1.1 ± 0.1 1.2 ± 0.2 1.2 ± 0.01
*
 1.4 ± 0.1 
 
The values are taken from Figure 5.11. Data are expressed as mean ± SEM of four independent 
experiments, each performed in duplicate. * P < 0.05, compared to respective SNC80 or SNC80 




Table 5.4 IC50 values of cmpd101 and BU16007 for inhibition of arrestin-3 recruitment to 
MOPr in the presence of GRK isoforms 
 
 GRK2 GRK3 GRK5 GRK6 
Cmpd101 (µM) 7.4 ± 1.7 11.5 ± 12.4 16.9 ± 1.8 6.3 ± 6.5 
BU16007 (µM) 2.9 ± 1.3 1.5 ± 1.0 2.3 ± 0.3 2.0 ± 1.1 
 
The IC50 values are taken from Figure 5.14. The IC50 measurements are an average of four 







Figure 5.14 Concentration-dependent inhibition of DAMGO-stimulated arrestin-3 
recruitment to MOPr by cmpd101 and BU16007 in the presence of overexpressed GRK 
isoforms 
HEK293 cells were cotransfected with MOPr-RLuc2, Arr3-GFP and GRK2, GRK3, GRK5, or 
GRK6. Cells were preincubated with A) cmpd101 (0.001- 100 µM) or B) BU16007 (0.001- 100 
µM) for 30 min and then stimulated with DAMGO (10 µM) for a further 10 min. The BRET ratio 
of no agonist-treated cells was subtracted DAMGO-treated cells. Data were fitted to a non-linear 
regression model with three parameters using GraphPad Prism v8 software. Data are 






Cmpd101 has been used as a GRK inhibitor and often assumed to be a selective of 
GRK2/3 in many studies; however, our findings in previous chapters suggest that 
cmpd101 may also affect non-GRK targets. The selectivity of cmpd101 for GRKs 
has only been determined in a cell-free system (Thal et al. 2011). Thus, in this 
chapter, I have determined the selectivity of cmpd101 and novel inhibitors towards 
GRK isoforms (GRK2, GRK3, GRK5 and GRK6) in intact HEK293 cells transfected 
with MOPr or DOPr and overexpressed GRK isoforms, and the arrestin-3 
recruitment was assessed by the BRET technique. Studying the effect of these 
inhibitors in HEK293 cells cotransfected with specific GRKs provides a simple 
means to initially detect differences in the selectivity of the novel compounds for 
GRK subtypes.  
 
The selectivity of GRK inhibitors has previously been determined using different 
assays. For instance, purified GRK isoforms are convenient in studying the 
selectivity of an inhibitor for individual GRK isoform (Thal et al. 2011). However, the 
potency determined in a cell-free assay does not always correlate with that obtained 
in a cell-based assay. Another approach is using GRK knockout cells in order to 
overcome the influence of endogenous GRKs. One way to study inhibitor selectivity 
is using overexpressed GRK in cell-based assay, which is the assay used in this 
thesis because the other methods were not at this time feasible in our laboratory. 
Instead, HEK293 cells were used in the presence of transfected and overexpressed 
GRK isoforms. HEK293 endogenously express GRK2, GRK3, GRK5  and GRK6 
(Violin, Ren & Lefkowitz 2006). Endogenous GRK2 was detectable in HEK293 cells 
using western blot, but it was not possible to detect endogenous GRK3, GRK5, or 
GRK6. This could be attributed to low expression of the GRK in question, or the lack 
of sensitivity of the antibodies used. Whilst it is also possible that endogenously 
expressed GRKs 3, 5 and 6 are absent from these particular HEK293 cells, this 
seems unlikely as other studies report their presence (Doll et al. 2012; Just et al. 
2013). 
Overexpression of GRKs enhanced the maximal efficacy of DAMGO and morphine. 
Also, overexpression of GRK2 enhanced the potency of DAMGO. This is in 
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agreement with the previous report that overexpression of GRK2/3 increased 
potency and efficacy of DAMGO- and morphine-induced arrestin-2 and -3 
recruitment to MOPr (Miess et al. 2018). This can be explained by the efficiency and 
extent of arrestin-3 recruitment being largely dependent on the extent of GRK 
phosphorylation of the receptor (Miess et al. 2018). On the other hand, in the DOPr-
transfected cells, overexpression of GRK2 enhanced neither the potency nor 
efficacy of SNC80 (Figure 5.12). Several reasons can explain these findings. One 
possibility is that DOPr is expressed in these cells at a greater level than MOPr; 
thus, the signal is enhanced. Another possible reason is due to the fact that DOPr 
is more efficient in recruiting arrestin-3 than MOPr (Lowe et al. 2002); therefore, 
DOPr recruits more arrestins that reflected in increasing the signal. Also, it is 
possible that SNC80 is more efficient in inducing DOPr phosphorylation (Mann et 
al. 2020), which is a prerequisite for arrestin recruitment and, thus, the signal is 
enhanced. Alternatively, these findings can be explained by the fact that I used a 
limited system where SNC80 is considered a full agonist and already recruits 
arrestin-3 to the maximum capacity. Thus, overexpression of GRK2 does not affect 
SNC80-induced arrestin-3 recruitment.  
 
Nickolls et al. (2013) and Manglik et al. (2016) reported that the overexpression of 
GRK2 increased the basal arrestin-3 recruitment to MOPr. This differs from the 
findings presented here that overexpression of GRK2 does not cause an increase 
in the basal of DAMGO-induced arrestin-3 recruitment. On the other hand, 
overexpression of GRK2 enhanced the basal arrestin-3 recruitment to DOPr. It 
seems possible that these results are due to the high constitutive activity of DOPr 
(Mann et al. 2020; Neilan et al. 1999). Another possible reason is that arrestin 
recruitment depends on the level of GRK expression (Miess et al. 2018), considering 
both experiments were conducted at different times.  
 
Studies have focused on developing selective inhibitors for GRK2 and GRK5 
(Bouley, RA et al. 2020; Waldschmidt et al. 2018; Waldschmidt et al. 2017; 
Waldschmidt et al. 2016) because such inhibitors could potentially benefit patients 
with heart disease (Cannavo, Liccardo & Koch 2013). All small molecule inhibitors 
of GRK so far work through binding to the active site of the GRK domain, which is 
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conserved in all AGC kinases (Johnson, LN 2009). For instance, cmpd101 exhibits 
its selectivity for GRK2 through binding to the active site of GRK2 (Thal et al. 2011) 
in a way similar to that of balanol, a nonselective GRK inhibitor (Figure 5.15A and 
B) (Murga et al. 2019; Tesmer, JJ et al. 2010). The selectivity of cmpd101 mostly 
depends on the overall conformation of the GRK2 active site as opposed to 
cmpd101 interactions with specific GRK residues (Tesmer, VM et al. 2012; Thal et 
al. 2011). Recently, Bouley, R et al. (2017) have developed indazole and 
benzodioxole compounds derived from paroxetine to improve potency and 
selectivity towards inhibition of GRK2. Compared to paroxetine, the crystal structure 
of these compounds in complex with GRK2-Gβγ shows a stronger interaction with 
the hinge of GRK2 and they also stabilise a different conformation of the kinase 
(Figure 5.15C and D) (Bouley, R et al. 2017; Murga et al. 2019). The compound 
CCG224061, one example of the indazole-paroxetine derivatives, shows a dramatic 
increase in potency for inhibition of GRK2 (20-fold) compared to paroxetine (Bouley, 
R et al. 2017). However, it also retains selectivity for GRK1, GRK5, PKA and ROCK1 
(Bouley, R et al. 2017). Thus, the selectivity towards GRKs is not always easy to 
predict from the chemical structure of the inhibitors. Thus, finding potent and 
selective inhibitors for individual GRK remains a major aim in the field. 
 
Cmpd101 is a commercially available small molecule inhibitor selective for GRK2/3 
with an IC50 of 35 nM (Ikeda, S, Keneko & Fujiwara 2007) and 290 nM (Thal et al. 
2011) determined in different in vitro assays. Also, cmpd101 has no significant 
inhibitory activity at GRK1 or GRK5 at concentrations up to 125 µM in a purified 
enzyme assay (Thal et al. 2011). However, our studies revealed surprisingly that 
cmpd101 does not appear to show any selectivity towards different GRK isoforms 
as assessed in these GRK isoform overexpression studies. These findings lead us 
to two possible conclusions: first, cmpd101 is not GRK2/3 selective, at least in 
HEK293 cells, or second, that, in our experimental system, GRK2 (endogenously 
present) initiates the phosphorylation of MOPr and this is followed by 
phosphorylation by other GRK isoforms leading to greater arrestin-3 recruitment. 
Therefore, this effect of endogenous GRKs cannot be ruled out in our study model.    
Also, it was observed that the pattern of inhibition by the novel compounds was 
similar across all overexpressed GRKs. Again, it seems possible that endogenous 
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GRK2/3 induces phosphorylation of Ser375 followed by multi-phosphorylation of 
flanking residues Thr370, Thr376 and Thr379, possibly by other kinases. This is evident 
when both cmpd101 and BU16007 showed similar IC50 values for inhibition of 
arrestin-3 recruitment regardless of overexpressed GRK isoform.  
 
It is interesting to note that overexpression of GRKs did not affect inhibition of 
cmpd101 or BU14016 of arrestin-3 recruitment to DOPr, whereas it enhanced their 
inhibition in arrestin recruitment to MOPr. There are, however, several possible 
reasons for this inconsistency. First, it could be that DOPrs were expressed at a 
much higher level than MOPr in the cells. Second, it may be receptor-dependent 
where DOPr is more efficient in recruiting arrestin than MOPr upon stimulation with 
agonist, so that enhances the arrestin to the maximum. Third, it is possible that it is 
an agonist-dependent where SNC80 induced robust phosphorylation of the 
receptor, and thus enhanced arrestin affinity.  
 
Cmpd101 has been reported to have an IC50 for GRK2/3 in the nanomolar range 
(Thal et al. 2011) while our studies in intact cells report IC50 values within the 
micromolar range. The likely reason for this is that our data are obtained from intact 
cells so that an inhibitor has to cross the cell membrane before reaching its target 
on the GRK (Rainbow et al. 2018). There is no published experimental 
measurement of the cell permeability parameters for cmpd101, only the predicted 
ones using professional software. The widely used measure of lipophilicity is log of 
the partition coefficient (logP), which is defined as the partition coefficient of a 
molecule between aqueous (water) and lipophilic (octanol) phases. The reported 
logP values of cmpd101 are 5.46 (XLogP; GuidetoPharmacology) and 3.2 (XLogP3-
AA; PubChem). Since the data on the cell permeability parameters of the novel 
compounds are not available, the LogP values were calculated using ChemDraw 
Professional 16.0 software (PerkinElmer Informatics).  The LogP values are 
summarised in Chapter 4, Table 4.1. The calculated LogP of cmpd101 is 3.7, which 
is considered to be a cell-permeable.  Most of the LogP values of the novel 
compounds are under 5 (Table 4.1), which supposed to cross the cell membrane. 
However, some compounds have LogP value of more than 5, such as BU16005, 
BU16007 and BU14013. Surprisingly, BU16007, which is the most potent inhibitor, 
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has a LogP value of 6 (Table 4.1). Therefore, the calculated LogP values do not 
straightforwardly reflect the cellular action of the novel compounds.  
 
Phosphorylation of opioid receptors plays a major role in receptor desensitisation 
and internalisation (Gurevich, Vsevolod V., Gurevich & Tesmer 2016). MOPr and 
DOPr are phosphorylated at different residues mediated mainly by GRK2/3 
(Brackley et al. 2016; Doll et al. 2012; Lemos Duarte & Devi 2020). About 20 
phosphorylatable residues have been identified in the intracellular regions of MOPr, 
including Thr357,(which is within 354TSST357 cassette), Thr370, Ser375, Thr376 and 
Thr379, which are within 370TREHPSTANT379 cassette (Figure 5.16A) (Chen, YJ et 
al. 2013; Gluck et al. 2014; Lau et al. 2011; Miess et al. 2018). It has been reported 
that alanine mutation of 354TSST357 residues does not affect desensitisation or 
internalisation of MOPr (Lau et al. 2011; Yousuf et al. 2015).   On the other hand, 
DOPr has been shown to be phosphorylated at the Thr358 and Ser363 residues in the 
C-terminus of the receptor (Law et al. 2000; Mann et al. 2020; Navratilova et al. 
2005; Zhang et al. 2005). Also, different agonists promote phosphorylation of distinct 
residues on the C-terminal of MOPr. For instance, DAMGO phosphorylates MOPr 
at multiple residues, including Thr370 and Ser375, which appears to be mainly 
mediated by GRK2/3, while morphine weakly phosphorylates MOPr at Ser375 
residue, which appears to be mediated in part by GRK5 (Doll et al. 2012). 
Additionally, MOPr and DOPr are also phosphorylated by agonist-independent 
mechanisms (Mann et al. 2015; Xiang et al. 2001). For example, MOPr and DOPr 
are phosphorylated at Thr370 and Ser344 residues, respectively, which is mainly 
mediated by PKC (Mann et al. 2015; Xiang et al. 2001). 
 
It has been shown that agonist-induced phosphorylation of Ser375 occurs faster than 
at other residues, and this is mainly mediated by GRK2/3 (Just et al. 2013). 
Therefore, phosphorylation of Ser375 is the primary site of phosphorylation followed 
by phosphorylation of the flanking residues, Thr370, Thr376 and Thr379. This could 
explain the observed increase in arrestin recruitment upon overexpression of 
GRK2/3. In the case of overexpression of GRK5/6, the endogenous GRK2/3 could 
phosphorylate Ser375 followed by phosphorylation of the flanking residues by other 
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GRKs, hence increasing arrestin recruitment to the receptor as reflected by an 
increase in the BRET signal.  
 
Also, it was observed that the pattern of inhibition by the novel compounds was 
almost similar across all overexpressed GRK. Again, it seems possible that 
endogenous GRK2/3 phosphorylates Ser375 followed by multi-phosphorylation of 
flanking residues. This is evident when both cmpd101 and BU16007 showed similar 
IC50 values for GRK regardless of overexpressed isoform.  
 
Also, it is noteworthy to note that cmpd101 and BU14016 seem effective in 
pcDNA3.1 cotransfected cells. However, in GRK2 overexpressed cells, BU14016 
was less effective. For example, at 1 µM, BU14016 gave 75% inhibition and at 30 
µM gave only about 20% inhibition. This suggests that the amount of inhibition of 
BU14016 depends on the size of the signal; thereby, BU14016 may be a weak 
inhibitor, depending upon the magnitude of the arrestin-3 induced signal.  
 
5.4 Conclusion 
I have used the arrestin-3 recruitment assay to study the selectivity of cmpd101 and 
a series of novel compounds towards GRK isoforms when overexpressed in 
HEK293 cells. Two opioid receptors, MOPr and DOPr, were used as representative 
of GPCRs in the presence of overexpressed GRKs. In these experiments, cmpd101 
and novel compounds did not appear to show selectivity towards individual GRK 
isoforms. On the one hand, these findings could suggest that cmpd101 and some 
of the novel compounds can be used as pan-GRK inhibitors to study the role of 
GRKs in GPCR signalling and other cellular processes. On the other hand, however, 
the results and apparent lack of selectivity could reflect the complexities of 






Figure 5.15 Crystal structures of inhibitors bound to the active site of GRK2 
The crystal structures of inhibitors bound to GRK2-Gβγ. Cmpd101 (A) is shown as a ball and stick 
model carbons, oxygens, nitrogens, and fluorines are shown in white, red, blue, and yellow, 
respectively. Balanol (B) is drawn with carbons (tan), oxygens (red), and nitrogens (cyan). 
CCG2224061 (C) is shown with carbon atoms in cyan. Hydrogen bonds are shown as black 
dashed lines and backbone nitrogens are shown as blue spheres. Paroxetine (D) is shown as a 
stick model, carbons, oxygens, and nitrogens are shown in cyan, red, and blue, respectively. 
Hydrogen bonds are drawn as black dashed lines. Upon inhibitor binding, small conformational 
changes occur in the large lobe, the P-loop, and the αB-αC-loop. The crystal structure of (A) was 
taken from (Thal et al. 2011); (B) from (Tesmer, JJ et al. 2010); (C) from (Bouley, R et al. 2017); 





Figure 5.16 Phosphorylation sites 
A schematic showing the intracellular regions of A) mouse MOPr, TSST residues are shown in 
blue, Ser375 residue is shown in green which is the primary site of phosphorylation of MOPr. 
Flaking residues Thr370, Thr376 and Thr379 are shown in yellow. B) human DOPr, the primary 
phosphorylation site Ser363 (red) and Thr358 (green). 
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GRKs phosphorylate-activated GPCRs leading to an increase in the affinity of 
arrestin to bind to the receptor and block further G protein activation. Therefore, the 
G protein-dependent signalling of a GPCR is terminated and the receptor undergoes 
desensitisation, often followed by internalisation and recycling. Besides their role in 
regulating GPCR signalling, GRKs also can bind to non-GPCR substrates in a 
phosphorylation-independent manner. Moreover, GRKs have been implicated in the 
progression of many diseases. Particularly, GRK2 and GRK5, which are the most 
studied GRK isoforms, are the main kinases upregulated in heart failure. GRK2 also 
mediates the desensitisation of MOPr, which is the main target of acute pain therapy 
with opioid agonist drugs.  
 
Many studies have attempted to modulate the activity of GRK2 using various 
strategies. For instance, using small interfering RNA (siRNA) (Just et al. 2013), a 
truncated peptide (Raake et al. 2013), and a dominant-negative mutant of GRK2 
(DNM-GRK2) (Celver et al. 2004; Cooke et al. 2015). However, the most promising 
and practical strategy to date is the use of small molecule inhibitors, such as 
cmpd101 (Lowe et al. 2015). The search for selective and potent inhibitors for 
individual GRK isoforms could be beneficial in intervening in heart diseases, in the 
case of GRK2 and GRK5, and serve as research tools for studying the function of 
GRK isoforms in the physiological regulation of GPCRs. However, the development 
of potent and selective GRK inhibitors, with good cell permeability, remains a 
challenge.  
 
The main goal of this thesis was to investigate the ability of cmpd101 and some 
novel compounds, analogues of cmpd101, to inhibit agonist-induced arrestin-3 
recruitment to MOPr, which is an indirect means of assessing GRK phosphorylation 
of receptor, in a cell-based system. The results of this thesis have demonstrated 
that cmpd101 and BU14016, BU14007 and BU16005 were effective at inhibiting 
DAMGO-induced arrestin-3 recruitment to MOPr (Table 6.1). In other words, 
cmpd101 and some of the novel compounds are in all likelihood able to inhibit 




A second aim was to compare the inhibitory effect of the novel compounds on 
agonist-induced arrestin-3 recruitment to MOPr by different agonists. Namely, 
whether the inhibition of arrestin recruitment by potential GRK inhibitors is an 
agonist-dependent phenomenon. For MOPr, the research reported in this thesis has 
demonstrated that the inhibition of arrestin-3 recruitment to MOPr is indeed agonist-
dependent (Table 6.1). As reported, some of the novel compounds inhibited 
DAMGO-induced arrestin-3 recruitment and failed to inhibit morphine-induced 
arrestin-3 recruitment. Possibly, morphine is a partial agonist at MOPr which could 
contribute to the inability of the compounds to inhibit morphine-induced arrestin-3 
recruitment. For DOPr, the novel compounds show a similar pattern of inhibition of 
SNC80- and DADLE-induced arrestin-3 recruitment to DOPr (Table 6.2). A caveat 
of the studies is that both DOPr agonists used are considered full agonists at the 
arrestin-3 recruitment assay in HEK293.  
 
A third aim of the thesis was to investigate whether the inhibition of arrestin 
recruitment by novel compounds is a receptor-dependent phenomenon. The results 
of this thesis show that cmpd101 inhibited agonist-induced arrestin-3 recruitment to 
MOPr and DOPr at similar potency. It is interesting to note that the novel compounds 
showed different inhibition capacity of agonist-induced arrestin-3 recruitment to 
DOPr. These results do not explain whether the inhibition of arrestin-3 recruitment 
is receptor-dependent or not in the case of cmpd101. 
 
This thesis also sought to investigate the selectivity of cmpd101 and the novel 
compounds towards individual GRK isoforms. Our attempts, however, using 
arrestin-3 recruitment assay with HEK293 cells expressing MOPr and 
overexpressing GRK isoforms, failed to detect selectivity of cmpd101 and the novel 
inhibitors towards individual GRK isoforms (see Tables 6.3 and 6.4). 
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Table 6.1 Percent inhibition of DAMGO- and morphine-induced arrestin-3 recruitment to 
MOPr by cmpd101 and novel inhibitors 
 
MOPr 
DAMGO (10µM) Morphine (30µM) 
Compound 30 µM 100 µM 30 µM 100 µM 
Cmpd101 81 58 43 -2 
BU14016 81 82* -15 27 
BU16005 79 71 28 14 
BU16007 88 71 61 -13 
BU16006 37*  61 17 -24 
BU14017 64 56 10 -60 
BU16009 24* 52 36 -16 
BU14013 11* 26* -49* -27 
BU14014 18* 26* -4 -56 
This table is a summary of Figures 4.2-3, 4.5-6. (-) sign indicates activation of agonist-induced 
arrestin-3 recruitment. The table highlights the different effects of cmpd101 and the novel 
inhibitors on arrestin-3 recruitment to MOPr by DAMGO versus morphine. * P < 0.05 compared 





Table 6.2 Percent inhibition of SNC80- and DADLE-induced arrestin-3 recruitment to DOPr 
by cmpd101 and novel inhibitors 
DOPr 
SNC80 (10µM) DADLE (10µM) 
Compound 30 µM (%) 100 µM (%)  100 µM (%) 
Cmpd101 49 50  32 
BU14016 -1* 2*  7 
BU16005 4* -1*  5 
BU16007 6* 21*  31 
BU16006 1* -0.3*  3 
BU14017 10* 37  39 
BU16009 5* 11*  8 
BU14013 4* 16*  15 
BU14014 9* 8*  7 
This table is a summary of Figures 4.8-10. (-) sign indicates activation of agonist-induced 
arrestin-3 recruitment. The table highlights the broadly similar effects of cmpd101 and the novel 
inhibitors on arrestin-3 recruitment to DOPr by the two high efficacy agonists. * P < 0.05 






Table 6.3 Percent inhibition of DAMGO-induced arrestin-3 recruitment to MOPr in the 














Cmpd101 79 95 96 71 74 
BU14016 65 52 45 45 57 
BU16005 68 63 73 69 74 
BU16007 76 85 81 80 84 
BU16006 39 29 36 41 42 
BU14017 41 36 35 45 50 
BU16009 26 6 19 16 28 
BU14013 20 0.7 16 14 31* 
BU14014 2 2.6 8 -5 6 
This table is a summary of Figures 5.4-6. (-) sign indicates activation of agonist-induced arrestin-
3 recruitment. The table highlights that the inhibitors have the same effect irrespective of which 
GRK subtype is overexpressed.  * P < 0.05 compared to respective pcDNA3.1, two-way ANOVA 







Table 6.4 Percent inhibition of morphine-induced arrestin-3 recruitment to MOPr in the 














Cmpd101 28 93* 95* 45 36^ 
BU14016 29 4 -17* 3 -1 
BU16005 23 42 17 53 15 
BU16007 59 53 18 54 57 
BU16006 3 4 -15 12 -15 
BU14017 -30 1 -28 18 -17 
BU16009 2 -4 -26 9 -32 
BU14013 -51 -13 -36 14* -22 
BU14014 -14 11 -27 -3 -28 
 This table is a summary of Figures 5.7-9. (-) sign indicates activation of agonist-induced arrestin-
3 recruitment. * P < 0.05 compared to respective pcDNA3.1, ^ P < 0.05 compared to respective 




6.2 The Selectivity of cmpd101 Against Arrestin/GRK Pathway 
Since the development of cmpd101 (Ikeda, S, Keneko & Fujiwara 2007), it has been 
used as a selective GRK2/3 inhibitor. Thal et al. (2011) determined the selectivity of 
cmpd101 towards GRK isoforms in an isolated enzyme assay. Some published 
reports contain evidence of the non-selective action of cmpd101. Moller et al. (2020) 
reported that cmpd101 at 10 µM did not affect the basal internalisation or arrestin-3 
recruitment to MOPr. However, at 30 µM, cmpd101 decreased both basal 
internalisation and arrestin-3 recruitment to MOPr (Moller et al. 2020). The authors 
concluded that cmpd101 might have off-target effects at a concentration higher than 
30 µM (Moller et al. 2020). There has been no specific attempt within the published 
literature (except of some observations) to explore the selectivity of cmpd101 
towards GRK isoforms in a cell-based system. This thesis builds upon these 
reported findings, showing other sites of action of cmpd101 at the cellular level. 
Using cmpd101 at a concentration of more than 30 µM is not recommended, as 
suggested by the findings of this thesis where cmpd101 inhibit DAMGO-induced 
activation of G protein, and previously reported studies (Moller et al. 2020; Yu et al. 
2018). A caveat of the experiments in this thesis is that the work is limited to HEK293 
cells and opioid receptors. Future studies should extend these studies to involve 
other cell lines and receptors.  
 
6.3 The Novel Inhibitors 
Several potential GRK inhibitors have been developed, such as paroxetine (Thal et 
al. 2012), balanol (Homan & Tesmer 2015), compd101 (Ikeda, S, Keneko & Fujiwara 
2007), GSK180736A (Homan et al. 2015). All these inhibitors either lack the 
selectivity over other GRK isoforms and other kinases such as PKA, ROCK1 or they 
are not good candidates for clinical use due to poor bioavailability. The novel 
inhibitors reported in this thesis are chemically modified versions (analogues) of 
cmpd101, assumed to be a GRK2/3 inhibitor. In our study, most of the compounds 
inhibited arrestin-3 recruitment due to overexpression of GRK isoforms, with no 
apparent selectivity towards individual isoforms. However, a preliminary study 
conducted by our collaborator, Prof. Stefan Schulz at the Friedrich Schiller 
Universität Jena, Germany, has shown that compound BU16007 strongly inhibited 
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the DAMGO-induced phosphorylation of Ser375, Thr370, Thr376, and Thr379 
(unpublished results) (Figure 6.1A). These results align with findings reported in this 
thesis that BU16007 strongly inhibited DAMGO-induced arrestin-3 recruitment to 
MOPr (Chapter 4, Figures 4.3 and 4.12). Cmpd101 inhibited DAMGO-induced 
phosphorylation of Thr370, Thr376, and Thr379 and modest inhibition of Thr375 (Figure 
6.1A) Unexpectedly, compounds BU14016 and BU16005, which show strong 
inhibition of DAMGO-induced arrestin-3 recruitment to MOPr (Figure 4.3), did not 
inhibit DAMGO-induced phosphorylation of Ser375, Thr370, Thr376, or Thr379. In 
morphine stimulated cells, cmpd101 and BU16007 strongly inhibited morphine-
induced phosphorylation at Ser375 (Figure 6.1B). Of note, these results are from one 
experiment. During my thesis research years, new inhibitors have been developed, 
in particular CCG258747 which shows potent and selective inhibition of GRK2 
versus other GRK isoforms as well as other kinases such as PKA and ROCK1 
(Bouley, RA et al. 2020). Our compound BU16007 stands out from the other 
compounds as it shows better selectively inhibition of DAMGO-induced arrestin-3 to 
MOPr over morphine. However, it is not possible to compare the potency of our 
compounds with that of the recently developed inhibitor CCG258747 because they 
were tested under different conditions. Our compounds were tested in cell-based 
assay whilst CCG258747 was tested in isolated GRK enzymes. Studies are needed 
to investigate compound BU16007 in more detail as it can serve as a scaffold for 




Figure 6.1 Effect of cmpd101 and the novel inhibitors on agonist-induced phosphorylation 
of MOPr  
HEK293 cells stably expressing hemagglutinin (HA)–tagged MOPr, were pretreated with 
cmpd101 or the novel inhibitors (each 30 µM) for 30 min, then cells were stimulated with (A) 10 
µM DAMGO or (B) 30 µM morphine for a further 30 min. Cells were lysed and immunoblotted 
with anti-pThr370, anti-pSer375, anti-pThr376, or anti-pThr379 antibodies. This is a representative 
blot of two independent experiments, but the same effects were observed in each experiment. 
These studies were conducted by Nina Cathleen Blum, a PhD student of Prof. Stefan Schulz at 





6.4 The Selectivity of cmpd101 and Novel Inhibitors Towards GRK 
Isoforms 
In this thesis, I have tried to investigate the selectivity of cmpd101 and the novel 
compounds towards individual GRK isoforms, using the arrestin-3 recruitment 
assay. However, cmpd101 and the novel compounds showed no apparent 
selectivity towards individual GRK isoforms in this assay. These findings illustrate 
the likely complexity of the phosphorylation mechanism of MOPr. It has been 
reported that high efficacy agonists, such as DAMGO and fentanyl, induce 
phosphorylation of multiple sites on the C-terminus of MOPr (Just et al. 2013; Miess 
et al. 2018), which occurs in a hierarchal manner. When Ser375 was mutated to 
alanine, there was no apparent phosphorylation of the flanking residues upon 
stimulation of the mutant MOPr with DAMGO (Just et al. 2013). In overexpression 
GRK experiments, the influence of endogenous GRKs cannot be excluded in our 
studies and that could explain in part the findings presented in this thesis.  
 
One caveat of the studies in this thesis is that the effects of the novel inhibitors on 
the activity of the other kinases such as PKA, PKC and others are not known, and 
future studies should explore these effects. Importantly, cmpd101 at 1µM inhibits 
PKA, PKC, CaMKII, ERK1/2 and JNK by less than 20% in purified kinase screening 
assay (Lowe et al. 2015).  
 
Attempts have been made to develop selective inhibitors of GRKs since the 
accumulating findings linked them to many diseases, in particular, heart failure. 
These attempts have had modest success in developing modest inhibitors for 
GRK2. Very recently, Bouley, RA et al. (2020) have developed a promising potent 
and selective GRK2 inhibitor. Preliminary results obtained from GRK2/3 knockout 
cells show that BU16007 could also inhibit GRK5/6. However, with all these efforts, 
selective GRK4/5/6 inhibitors have yet to be developed. 
 
Instead of attempting to completely inhibit the action of a GRK, it could be more 
effective to modulate the GRK activity. It has been established that GRKs can bind 
to Gβγ, and the alpha subunit of Gq, these can be inhibited by using small molecule 
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inhibitors, rather than inhibiting GRK (Gurevich, EV et al. 2012). With the growing 
list of substrates that GRK can bind to, developing another strategy may be possible. 
One way is to target the substrate that binds to GRK, so there would be no need to 
inhibit GRK activity. PKC is also known to regulate GRK2 activity (Bailey, Oldfield, 
et al. 2009). Thus, targeting PKC by selective inhibitors is another way of modulating 
GRKs (Ghanemi 2015). In addition, overexpression of GRK activity has been 
reported in many diseases and decrease in the activity of GRK has also has been 
reported in other illnesses, such as depression (Gurevich, EV et al. 2012). 
Therefore, inhibition of GRK is not an ideal strategy in several diseases. Thus, the 
need to develop other methods to modulate GRK activity.  
 
Another method that is promising is using a gene therapy technique to selectively 
target specific GRKs (Gurevich, EV et al. 2012). In psychiatric diseases, it has been 
reported that GRK activity is reduced so, in some cases, enhancing GRK activity 
could be used to manage psychiatric diseases (Ahmed et al. 2010; Gurevich, EV et 
al. 2012). In practical terms, at present, the only way to enhance GRK activity by 
using gene therapy. Briefly, gene therapy concept is based on using non-infectious 
viral or nonviral vectors to carry the gene of interest (in this context GRK2) into a 
specific cell type in a specific tissue (Kieserman et al. 2019). Most commonly used 
viral vectors are lentiviral and adenoviral vectors, where circular plasmid DNA vectors 
are examples of nonviral vectors (Kieserman et al. 2019). Some viral vectors have 
been successfully used to deliver βARKct, a peptide inhibitor of GRK2, to the heart 
of pig model of heart failure after subjected to left ventricular myocardial infarction 
(Raake et al. 2013). The βARKct expression in heart showed an improvement in 
cardiac function (Raake et al. 2013).  
Many mechanisms of GRK are still unexplored in detail, such as how GRKs are 
synthesised in the cell and how they are degraded. Knowing these processes could 




6.5 Future Experiments 
The search for selective and potent GRK inhibitors is still understudied. Here I will 
include a brief discussion on potential future studies to explore further the results 
presented in this thesis: 
6.5.1 Short-Term Goals: 
Ongoing studies are looking at the ability of the novel compounds to inhibit agonist-
induced phosphorylation of the residues on MOPr. As shown in Figure 6.1, the 
preliminary results are interesting and can explain some of the results presented in 
this thesis, such as the potent inhibitory effect of BU16007. Also, another ongoing 
study in the laboratory is an examination of the effect of these novel inhibitors on 
the potential role of GRKs in desensitisation of the MOPr-activated G protein-
activated inwardly-rectifying potassium (GIRK) current in locus coeruleus (LC) 
neurons. They measure the potassium current (K+) induced by Met-enkephalin by 
using whole-cell patch-clamp recording in LC from rat brain slices. These studies 
will investigate the ability of these compounds to inhibit the acute MOPr 
desensitisation induced by an agonist. 
 
To explore further the results of this thesis, it would be good to investigate the effect 
of cmpd101 and BU16007 on the recruitment of GRK to the receptor, which provides 
a direct measurement of GRK recruitment to the activated receptor and, 
presumably, phosphorylation. The MOPr can be fused with a donor (e.g., RLuc8) 
and GRK isoform can be fused with an acceptor (Venus). The recruitment of GRK 
to the receptor after stimulation by an agonist can be monitored by BRET. This 
method will give a clear picture of the selectivity of the novel compounds.  
 
6.5.2 Medium-Term Goals: 
For MOPr, it is well-documented that GRK2 and probably GRK3 are the main 
phosphorylation kinases. To further study the selectivity of individual GRKs, one 
way is to conduct the experiment by using GRK2/3-knockout cells to rule out the 




6.5.3 Long-Term Goals: 
A complete pharmacokinetic profile is not available for cmpd101 and the novel 
compounds; a further study could be conducted to determine the pharmacokinetic 
parameters of cmpd101 and the novel compounds in vitro and in vivo. These kinds 
of studies give a great idea of the bioavailability of the compounds which can be 
related to their cellular effects.  
 
Compound BU16007 is a promising GRK inhibitor and it can be structurally 
optimised to develop new molecules that are more potent and have better selectivity 
for GRKs. Besides, the nature of the interaction of BU16007 with GRK2 is not 
known; it would be useful to do docking studies to reveal the nature of the 
interactions with GRK2 and possibly with other GRK isoforms.  
 
6.6 Conclusion 
In summary, although much has been done, at present there remains no selective 
and potent inhibitor for individual GRK isoforms. This indicates how complex is 
developing potent and selective GRK inhibitors and it is a long-term process.  
 
The findings of this thesis suggest that cmpd101 might affect off-targets when used 
at or more than 30 µM, so it is recommended to use it at a lower concentration to 
give the intended action as selective GRK2/3 inhibitor. Also, using arrestin-3 
recruitment assay in HEK293 cells, the data in this thesis has shown that cmpd101 
and the novel compounds do not show selectivity for individual GRK isoforms.  
Moreover, the studies of this thesis, along with the preliminary studies of Prof Stefan 
Schulz, have shown that compound BU16007 is a promising GRK inhibitor. Our 
studies have expanded our understanding of the action of cmpd101 in cell-based 
settings. Also, the findings suggest that phosphorylation is a complicated process 
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